All Clinical Trials
Northwestern Scleroderma Program RegistryThe Scleroderma Patient Registry collects clinical information and biological samples for patients seen at the Northwestern Scleroderma Program (NSP). The information collected is used for studies designed to increase our understanding about the course of the disease and the care and outcomes of scleroderma patients. Researchers conduct studies to learn more about scleroderma, understand why the skin and other internal organs become thickened and hardened (fibrotic) in people with scleroderma, and determine what therapies are effective for treating scleroderma. The registry also allows us to identify possible patients for future studies related to scleroderma. There are five optional components of the Registry: completion of health questionnaires, skin biopsies at two different time points, annual blood collection, and participation in NUgene.
Who Can Participate?Patients ≥18 years old with a diagnosis of scleroderma (including all sub-types of disease) as defined by American College of Rheumatology criteria or scleroderma mimic disorder, localized scleroderma, or very early diagnosis of systemic sclerosis (VEDOSS), per physician assessment.Principal Investigator, Study ID, Keywords STU00002669 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 05H6: Acute Leukemias and Map KinaseNormally, white blood cells are produced in a controlled way by the bone marrow. In someone with AML or ALL, this production process is abnormal and immature cells are produced and sent into the blood stream. In this immature state, the cells affect the production of other normal cells and these cannot perform their usual functions. Therefore patients with AML or ALL are vulnerable to infection, anemia, and bleeding. The purpose of this study is to understand what causes the white blood cells to grow abnormally, and to determine if there are novel agents that can be used to stop this abnormal growth. In this research project, a sample of blood and bone marrow will be studied in the laboratory to learn more about the nature of the disease, and to understand what causes the defect in the growth of these cells. Who Can Participate?You may be eligible for this research study if you have been diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), which are cancers of the blood that affect white blood cells. Principal Investigator, Study ID, Keywords STU00004841 Click to Copy URL to Clipboard For questions about this study, contact: |
NCI 02X3: SPORE in Pancreatic Cancer Tissue CoreThe purpose of this research study is to examine many aspects of gastrointestinal disease including pancreatic and colon cancer, including its genetics, its early stages, and the effects of cancer on other tissues such as muscle and adipose (fat) tissue. Tissues from patients (with cancer as well as from those without), who are undergoing pancreatic surgery, will be used in this research. Who Can Participate?You may be eligible for this research study if you are visiting the high risk clinic and/or are undergoing surgery to remove a portion of your pancreas. Principal Investigator, Study ID, Keywords STU00007180 Click to Copy URL to Clipboard For questions about this study, contact: |
HLA-Identical Sibling Renal Transplant Tolerance With Donor Hematopoietic Stem Cells and Campath-1H
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive
therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor
hematopoietic stem cell (DHSC) lineages for pairs to demonstrate immunologic
unresponsiveness, and to investigate the safety and efficacy of the treatment regimen
including withdrawal of immunosuppression after one year post-transplant for those
recipients having received DHSC infusions.
Principal Investigator, Study ID, Keywords |
Chicago Lupus DatabaseEstablishing in 1991 and maintained by Northwestern University, the Chicago Lupus Database (CLD) is a registry of individuals with lupus who are willing to be contacted about future lupus research studies for which they might be eligible. Participants can enroll in any number of research studies designed to help us learn more about lupus.
Who Can Participate?Men and women 18 years or older with either a probable or definite lupus diagnosis can sign up for the Chicago Lupus Database.Principal Investigator, Study ID, Keywords STU00009193 Click to Copy URL to Clipboard For questions about this study, contact: |
Characteristics of the Stretch Reflex Response in Various JointsThe purpose of this research study is to better understand posture control in able-bodied individuals and in individuals who have had a stroke. Participants will be asked to sit in a chair and maintain various muscle contractions while a motor moves their arm. Who Can Participate?Participants must meet the following criteria: 35-70 years old; ability to flex and extend at the elbow; no anti-spastic medication; no botox treatment in the arm; right-handed; right side paretic (if stroke survivor); no secondary neurological impairments; no other musculoskeletal impairments in the upper extremity; available to come to the Shirley Ryan AbilityLab for one 2.5-hour session Principal Investigator, Study ID, Keywords STU00009204 Click to Copy URL to Clipboard For questions about this study, contact: |
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORYThis study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods.
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00009443 Click to Copy URL to Clipboard For questions about this study, contact: |
NUGene: Gene-Disease Associations and Treatment OutcomesShare your health data and a little blood to help with studies on all kinds of diseases— cancer, diabetes, heart disease. A ready pool of samples and treatment histories speeds up research. It’s simple to help. And your info is so important to the search for new ways to prevent and treat illnesses. Want to make an impact in just 20 minutes? Give some blood, answer some questions, and share your health records with your study team’s database. Researchers use it to find disease patterns and search for new ways to prevent and treat illnesses. Who Can Participate?Must be a patient at Northwestern or one of its affiliates.Principal Investigator, Study ID, Keywords STU00010003 Click to Copy URL to Clipboard For questions about this study, contact: |
Eye Donor ProgramThe eye donor program is designed to contribute to our understanding of diseases of the eye. Patients will be asked permission to have their eyes donated for scientific evaluation at the time of the death of the patient. Donated eyes will be studied at the eye pathology lab of the department of ophthalmology. Laboratory findings will be correlated and compared to the clinical findings observed in the same patients prior to their death.
Principal Investigator, Study ID, Keywords STU00017021 Click to Copy URL to Clipboard For questions about this study, contact: |
Genetics of BRCA2-related Prostate CancerRecruiting Research Participants for a New Study on the “Genetics of Prostate Cancer” At the time of conception, fertilization of the egg by the sperm brings together the genetic material (DNA) from both parents, half from the mother and half from the father, producing the embryo. In the very early stages of embryonic development, the embryo is made up of cells that have the potential to develop into all types of cells, like skin, muscle, liver, brain, pancreas, breast, ovary, fallopian tube, or prostate cells. Because of this ability, these cells are called “pluripotent” embryonic stem cells (ESCs). However, about a week after fertilization, the embryonic cells lose their ability to develop into all of the different cells and tissues of the body and gradually “differentiate” into the various tissues and organs that have different specific functions. So, there is a relatively narrow window during which pluripotent ESCs exist in the embryo. At the end of the in vitro fertilization (IVF) process for couples undergoing subfertility treatment, the doctors are usually left with one-week-old embryos. In 1998, using such embryos for research, scientists figured out how to grow pluripotent ESCs in the lab that can stay in their pluripotent state if the right growth conditions are present. Changing the growth conditions in certain ways, scientists learned how to stimulate the ESCs to go through a process called “differentiation,” in which the stem cells can develop into any of the different cell types present in the body. ESCs were used in the early animal cloning experiments that produced the cloned ewe named “Dolly;” however, cloning human cells is illegal. While ESCs offer promising and exciting opportunities, like the possibility of growing organs in the lab, because their production involves technical and ethical problems, efforts were directed to produce pluripotent stem cells from mature cells to avoid the use of embryos. In 2007, Japanese researchers found an amazing way (for which they received a Nobel Prize) to transform mature cells, like regular skin or blood cells, directly into stem cells without using human eggs. They found a combination of proteins that, if injected into mature cells, gradually reprogrammed them into induced pluripotent stem cells, abbreviated iPSCs. Research Project Drs. Dan Theodorescu and Clive Svendsen, the Principal Investigators at the Cedars-Sinai Medical Center in Los Angeles, California in collaboration with Dr. William Catalona, the Principal Investigator at Northwestern University are engaged in research using iPSCs to develop a model of human prostate cancer using iPSCs from men who carry BRCA2 mutations that are related to a higher risk for developing aggressive prostate cancer (the Cedars-Sinai team has already accomplished this for ovarian cancer in women who carry BRCA1 mutations). As study controls, they will also enroll men with non-BRCA2-related prostate cancer and those without prostate cancer. They will not use embryos. In the laboratory, the researchers will take the white blood cells from a blood sample back in time to when they were capable of making any cell type in the body and differentiate them forward into prostate cells carrying (or for non-BRCA2-mutation carriers, not carrying) the BRCA2 mutation in a petri dish. Using these transformed prostate cells, they will use current genetic engineering and molecular biology research methods to study the mechanisms of the transformation of normal prostate cells into aggressive prostate cancer cells. This model also can be used in cell-signaling studies and drug screening studies for designing future therapies. The bank of prostate iPSCs that they will create may be shared with research institutions around the world. These researchers are now recruiting men and their male family members who carry a BRCA2 mutation and other prostate cancer patients and controls without prostate cancer to participate in this study. This research is being performed to discover the causes of prostate cancer and how it is passed down in families using the BRCA2 mutation as a model system and also can be applied to non-BRCA2-related cancers. This study is called “The genetics of prostate cancer” and is approved by the Institutional Review Boards at Northwestern University (STU00018651) and Cedars Sinai, whose function is to protect the rights of research subjects and to oversee ethical issues. Participation in this study will involve having up to 50 ml of your blood drawn (10 teaspoons), and completing family history questionnaires (baseline and follow-ups) and clinical follow-up questionnaires, if applicable. The time involved includes the time required to read the 10-page consent form, and the time required to travel to Northwestern Memorial Hospital, Galter Pavilion, 675 North St. Clair Street, Chicago, IL 60611 for the research blood draw.If it is not convenient for you to come to our clinic you may be able to get blood drawn at a clinic of your choice and we will arrange to have it shipped to Cedars-Sinai in Los Angeles, California. It will take about 20 to 40 minutes to complete the questionnaire. In the case that your family history suggests familial prostate cancer, Dr. Catalona may want your family members to participate in the study as well. You may be asked to contact your relative(s) about the study. We will follow up with a family history follow-up questionnaire annually, which takes 15 to 30 minutes to finish, to update the file. If you develop prostate cancer, we will want you to fill out a clinical follow-up questionnaire about prostate cancer and follow you up with the questionnaire annually as well, which takes 10 minutes to finish. In addition, we may request up one or more additional blood samples of 10 to 20 ml (2-4 teaspoons) from you at a later date, depending on the evolving needs of the study. You may refuse to provide these follow-up blood samples without affecting your participation in this study. The blood sample(s) will be saved for future analysis. Efforts will be made to limit the use and disclosure of your personal information, including research studies and medical records, to people who have a need to review this information. We cannot promise complete secrecy. Organizations that may inspect and copy your information include the IRB and other representatives of this institution. Research results will not be available to you or your physician except under extraordinary circumstances. These are situations in which a life-threatening medical disorder is discovered for which medical treatment is available to prevent or alleviate long-term medical complications. If such a situation should occur, we will contact you via phone, email or mail. Those interested in participating may contact Dr. Catalona at 312 695-4471 or william.catalona@nm.org. Further background information on stem cells is available from the author who created the background information for this article: Meshorer E (2020) What Are Embryonic Stem Cells and How Can They Help Us?. Front. Young Minds. 8:32. doi: 10.3389/frym.2020.00032. Copyright © 2020 Meshorer Who Can Participate?Male carriers of BRCA2 mutations with prostate cancer and men with metastases aged 18 years or older Principal Investigator, Study ID, Keywords STU00018651 Click to Copy URL to Clipboard |
Mediators of Atherosclerosis in South Asians Living in America
South Asian (Indian, Pakistani, Bangladeshi, Nepali, and Sri Lankan) individuals have high
rates of cardiovascular disease that is not explained by traditional cardiovascular risk
factors. Though South Asians represent over one-quarter of the world's population, there are
no longitudinal studies in this high-risk ethnic group. The investigators aim to establish a
longitudinal study of South Asians at two United States centers to identify risk factors
linked to subclinical atherosclerosis and incident cardiovascular disease. The purpose of
this study is to understand the causes of heart disease and stroke in South Asians and
compare these causes to those in other United States ethnic groups.
Principal Investigator, Study ID, Keywords |
NU 00X3: Pathology Core FacilityThe main purpose of this project is to collect samples for research. The samples will be stored at the Pathology Core Facility (PCF) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School (NUMS). PCF serves as the centralized resource that addresses the sample collection needs for the research community. The samples collected can be used by researchers at Northwestern University and third party commercial and non-profit institutions who have approval from their Institutional Review Board (a committee which is responsible for the ethical oversight of the study) for their projects. You will be asked to donate a sample of blood. In addition, any extra tissue or fluid from what has been collected from you for your routine care will be used. Examples of samples include but are not limited to tissue, blood, urine, and bone marrow. Principal Investigator, Study ID, Keywords STU00020989 Click to Copy URL to Clipboard For questions about this study, contact: |
RTOG 0724 - A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterecotmy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
It is not yet known whether chemotherapy and radiation therapy are more effective when given
with or without additional chemotherapy in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation
therapy to see how well they work when given with or without additional chemotherapy in
treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
Who Can Participate?Some of the eligibility criteria include:- Participants must be 18 years old or older. - Participants must have undergone radical hysterectomy prior to entering the study. - Participants cannot be allergic to carboplatin, paclitaxel and/ or cisplatin. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords cervical adenocarcinoma cervical adenosquamous cell carcinoma cervical squamous cell carcinoma stage IA cervical cancer stage IB cervical cancer stage IIA cervical cancer
For questions about this study, contact: |
Asymmetric Neurodegeneration and Language in Primary Progressive AphasiaThe observational primary progressive aphasia (PPA) research program at Northwestern University seeks to study individuals living with PPA over time using neuropsychological testing and advanced imaging techniques. Participants are asked to come to Chicago in order to help: Who Can Participate?You must carry a diagnosis of Primary Progressive Aphasia, established at a thorough evaluation prior to enrollment. If you think you may have dementia, but have not yet been evaluated, you must first undergo a clinical evaluation. This clinical evaluation is not part of the research. Patients must also meet screening criteria which require the patient to be a right-handed, native English speaker and safe to undergo a 3T MRI.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Chemokine mechanisms in chronic pelvic painThe purpose of this study is to investigate the types of biomarkers, which are measurable indicators of a health condition, present in patients who suffer from chronic pelvic pain syndrome. Biomarker levels will be determined from patient samples of blood, urine, and expressed prostatic secretions.
Who Can Participate?Patients with chronic pelvic pain syndrome (CPPS). Pain must be present for 3 out of the past 6 months. Must be 18 years of age or older.Principal Investigator, Study ID, Keywords STU00030121 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 99G8: Northwestern Ovarian Cancer Early Detection and Prevention Program: A Specimen and Data Study
RATIONALE: To improve strategies for detection and prevention of early-stage disease.
PURPOSE: This research study is collecting specimens and data to develop better methods for
early detection and prevention of ovarian cancer among the high risk population and those
who have the disease.
Principal Investigator, Study ID, Keywords |
Alzheimer's Disease Research CenterThe purpose of the Northwestern University Alzheimer’s Disease Research Center (NUADRC) study is to support clinical and basic research on memory and aging by collecting, storing, and disseminating clinical data. These data and samples include memory and thinking tests, brain imaging scans, blood samples, and brain donations. We collect these data and samples from study participants who are experiencing healthy aging and those who suffer from dementia or Mild Cognitive Impairment. This study is a longitudinal, observational trial meaning that research participants will be observed over time, and data will be collected, but there is no attempt to alter the symptoms or course of disease (an intervention). Participants attend annual visits that typically last one to three hours. If participants can no longer attend in-person visits, we will continue to follow them through telephone visits with a designated study partner. This study is a multi-site study meaning Northwestern University is one of 33 sites in the United States. Research data is shared with a national database. There are currently over 15,000 participants in this study nationally with approximately 500 of them enrolled at Northwestern University. Once they enroll, most participants are referred to other research studies being led by investigators within the Mesulam Center or the greater Northwestern University scientific community. Who Can Participate?The Northwestern University Alzheimer’s Disease Research Center (NUADRC) Clinical Core study enrolls individuals with diagnoses of Mild Cognitive Impairment, Alzheimer's disease or other dementia (frontotemporal dementia, primary progressive aphasia, Lewy Body disease and others) as well as healthy individuals with no cognitive impairment. See below for specific eligibility criteria. Patients Diagnosed with Dementia or Mild Cognitive Impairment (MCI)
Healthy Volunteers
All participants are asked to engage in research brain imaging scans, including MRI and PET. Certain surgical implants and/or devices, claustrophobia, or previous high radiation exposure may make you ineligible to participate in brain imaging scans. All in-person visits take place at Northwestern University’s downtown Chicago campus and participants can receive free parking if they park on Northwestern University’s campus. Additional compensation is determined by participation. Please contact the study coordinator for questions. Principal Investigator, Study ID, Keywords STU00023196 Click to Copy URL to Clipboard For questions about this study, contact: |
Neural Mechanisms in Sensory Reception and Processing in the Healthy Adult (VA RR&D Grant # B3302K)The measures of treatment effect in the project include reception and processing of sensory stimulation as measured by functional MRI in the severely injured brain. The neural responses to these sensory stimuli in the healthy brain have never been identified nor mapped. Therefore, the purpose of this new project is to determine the mechanisms of responses to the same sensory stimuli used in the 597-006 except in the healthy brain, which will allow for comparisons between the healthy and severely injured brains mechanistic responses to sensory input. The rationale is that in order to assert that the neural responses in the injured brain are measured reliably with fMRI over time and that they deviate from normal, a comparable fMRI protocol with healthy brains must be completed because this basic knowledge does not exist in the scientific literature.
It is hypothesized that images acquired at rest and contrasted with images acquired during sensory stimulation will identify significant activation in the relevant association areas (i.e., auditory cortex-A1, somatosensory area-S1) as well as the brain stem and thalamus in accordance with receiving and processing sensory stimulation. It is also hypothesized that significant activation will be demonstrated in these areas for each of the 4 imaging sessions (i.e., reliably over time).
Principal Investigator, Study ID, Keywords STU00024134 Click to Copy URL to Clipboard For questions about this study, contact: |
NCI 01X1: Breast Cancer Program: Tissue and Specimen Collection FacilityThe purpose of this research study is to help advance the scientific understanding of breast cancer. A portion of breast or skin tissue and a sample of blood, along with clinical information, will be collected and stored in a database for research purposes only. Only tissue or fluid in excess of that required for clinical diagnosis and/or staging will be collected. Specific clinical data will include: treatment for cancer (surgical procedures, chemo or hormone therapy, radiation), cancer outcome (recurrence, metastases, death due to disease, and death without disease, alive, alive with disease). Who Can Participate?You may be eligible for this research study if you are a woman with breast cancer undergoing biopsy or surgical procedures for the diagnosis, treatment, or prevention of your cancer.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Peripheral Neuropathy Research Registry (PNRR)National Peripheral Neuropathy Research Registry (PNRR), a collection of different types ofinformation, such as patient medical, family, and social histories and blood samples. Theinformation is carefully maintained so that it can be studied repeatedly in the future. The registryaims to help researchers’ access large amounts of information about people with PN. By using thisregistry, researchers will facilitate both basic and clinical research studies that will bring improvedunderstandings of the etiology (origination) and pathogenesis (development) of PN. They willspecifically ask why some patients with peripheral neuropathy develop neuropathic pain and othersdo not, and what the characteristics of patients with painful peripheral neuropathy are in terms oftheir symptoms, examination findings, and blood tests. Ultimately this research may result inimproved diagnosis, more effective treatments, and possibly prevention.
Who Can Participate?Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral NeuropathyPrincipal Investigator, Study ID, Keywords STU00048864 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 04H7: Molecular Mechanisms of Disease Progression in Myeloid MalignancyIn this research project, samples of blood and bone marrow will be studied in the laboratory to learn more about the nature of chronic myelogenous leukemia (CML) cells and how various medications and chemical agents affect them. The purpose of this study is to learn about how CML leukemia cells become resistant to medications or progress to acute leukemia (blast crisis). This may prove to be helpful in the design of new more effective drugs for the treatment of CML in the future. Who Can Participate?You may be eligible to take part in this research study if you have been diagnosed with chronic myelogenous leukemia (CML), a chronic form of leukemia, OR if you are a normal individual without any blood disorders. Principal Investigator, Study ID, Keywords STU00039629 Click to Copy URL to Clipboard For questions about this study, contact: |
A Family Study of Pragmatic LanguageOur project examines pragmatic (social) language skills in families. We enroll both children (ages 12- adult) and their parents. Eligible participants include autistic individuals and their parents, individuals with fragile X syndrome and their mothers, and families who do not have these conditions. Participation includes completing different types of activities, including conversational activities, saying and listening to different sounds, puzzles, and answering questions about yourself. Participation in our research is flexible, as we have several options to choose from depending on the amount of time you would like to spend. There is n virtual only option (~1-2 hours), as well as an additional opportunity to come to our laboratory in Evanston for additional activities (~3-4 hours). Who Can Participate?Participants must be native speakers of English and must not have any problems with hearing Principal Investigator, Study ID, Keywords STU00051863 Click to Copy URL to Clipboard For questions about this study, contact: |
Northwestern University The Department of Psychiatry and Behavioral Sciences, Clinical Research Program (NU CRP) Recruitment PipelineThe recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitmentregistry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies.
Principal Investigator, Study ID, Keywords STU00059328 Click to Copy URL to Clipboard Schizophrenia Schizoaffective Depression Anxiety Bipolar Bipolar Type 1 Bipolar Type 2 Mania Hypomania Major Depressive Disorder Mood Cognition Research Study Adult Adolescent Children Alzheimer's disease Clinical Trial Non Clinical Trial Therapy Investigational Drug Post Traumatic Stress Disorder
For questions about this study, contact: |
A PHASE 3 SINGLE CENTER STUDY OF ISLET TRANSPLANTATION IN NON-UREMIC DIABETIC PATIENTS
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta
cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to
determine the safety and effectiveness of islet transplantation, combined with
immunosuppressive medications, specifically using Campath as induction, for treating type 1
diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic
episodes.
Principal Investigator, Study ID, Keywords |
A Randomized Trial to Prevent Congenital Cytomegalovirus Infection (CMV)Cytomegalovirus (CMV) is a common virus that usually presents withfew if any side effects. When first infected, some people may have symptoms similar to mononucleosis (i.e., fatigue, weakness, fever, swollen glands). Most people in the United States are infected during childhood or as adults if they work around children. Pregnant women, who have not been infected with CMV in the past and become infected during pregnancy (i.e. a primary infection), may cause their babies to get infected with CMV. Babies that are infected may develop permanent disabilities including hearing loss and a small portion will die from the infection.
Currently it is not routine practice to screen pregnant women for CMV infection. Additionally, there is no agreement about how to evaluate and manage pregnant women infected with CMV for the first time. There is also no evidence that treatment is beneficial for the baby.
The purpose of this research study is to determine whether treating pregnant women who have a primary CMV infection with CMV antibodies will reduce the number of babies infected with CMV.
Who Can Participate?Primary CMV infection in women with singleton pregnancy at less than 24 weeks.Principal Investigator, Study ID, Keywords Perinatology Cytomegalovirus immune globulin Cytogam CMVIG infusions primary CMV infection in pregnancy
For questions about this study, contact: |
A Registry of Interstitial Lung Disease PatientsThe purpose of this registry is to collect clinical information about people with interstitial lung disease (ILD) to help us better understand the causes of ILD and determine if particular types of treatment work better for some causes of ILD than others. The Registry will also be used to determine who might be eligible for and interested in participating in future studies related to ILD.
Participants agree to allow the collection of information from the medical record for research purposes and agree to allow us to contact them about future studies. Participants may also complete questionnaires during their standard of care visits, participate in an optional frailty study by taking a brief physical ability test at the time of standard of care visits, give optional blood for research, and optionally allow us to contact them about their health on an annual basis. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00060593 Click to Copy URL to Clipboard For questions about this study, contact: |
NCI 12H13: Molecular Mechanisms of Relapse After Therapy Discontinuation in Chronic Myeloid LeukemiaIn this research study, samples of bone marrow or peripheral blood will be collected from patients with chronic myeloid leukemia (CML) to learn more about the effect of some new drugs on CML cells in the laboratory. The purpose of this study is to understand how these new drugs stop leukemia cells from growing. This research may prove to be helpful in the design of new and more effective treatments for leukemia in the future. Who Can Participate?You may be eligible for this research study if you have been diagnosed with chronic myeloid leukemia, a cancer of the blood and are scheduled to have a bone marrow biopsy. Principal Investigator, Study ID, Keywords STU00074258 Click to Copy URL to Clipboard For questions about this study, contact: |
CENTER FOR BEHAVIORAL INTERVENTION TECHNOLOGIES (CBITs) RESEARCH SUBJECT RECRUITMENT REGISTRYWHAT IS THE REGISTRY ABOUT?
Becoming a member of this registry allows researchers at Northwestern University to get in touch with you to see if you might be interested in and eligible to participate in different research studies at CBITs. The research conducted at CBITs generally involves evaluating different aspects of technology-assisted health interventions.
WHAT WILL I BE ASKED TO DO?
You will be asked to provide some basic contact and background information, as well as continue on to complete a brief survey. There is no cost to join the registry. You can read more about the current studies and sign up for the registry on our website: http://cbitshealth.northwestern.edu
Who Can Participate?If you're an adult (18 years or older), living in the United States, who speaks English, and has Internet access, you may be eligible to join.Principal Investigator, Study ID, Keywords STU00076804 Click to Copy URL to Clipboard For questions about this study, contact: |
Targeting Siglecs in DiseaseThe study involves recruiting paid volunteers to donate blood. The goal of the studies is to isolate certain cells from the blood called eosinophils to examine certain proteins and their functions in the laboratory.
Who Can Participate?Adults with or without allergiesPrincipal Investigator, Study ID, Keywords STU00085003 Click to Copy URL to Clipboard For questions about this study, contact: |
NUDB 13C03: Northwestern Brain Tumor Institute Research DatabaseThe Northwestern Brain Tumor Institute (NBTI) currently uses an electronic database to collect and store information about patients who come to the NBTI for evaluations, including diagnosis, treatment, follow-up, and/or to obtain additional opinions. This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it was developed to replace older paper methods for collecting and storing information. The purpose of this study is to allow researchers involved with the NBTIDB to use data stored in it for future research studies and projects. The NBTIDB also allows researchers to track whether or not patients have agreed to allow their information to be linked to their leftover tissue samples, which are kept in the hospital’s pathology department, for future research studies. Who Can Participate?You may be eligible to take part in the research component of the NBTIDB if you are either a new or returning patient, over the age of 18, who is being seen by one of the clinicians at the NBTI and are or will be entered into the NBTIDB, or a patient who is not coming to the NBTI for evaluation, but would still like to participate in the NBTIDB. Principal Investigator, Study ID, Keywords STU00087359 Click to Copy URL to Clipboard For questions about this study, contact: |
Movement Disorders BiorepositoryThis is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples.
Who Can Participate?• Diagnosis of a movement disorder • Male or female 18 years of age or older when diagnosed • Ability to provide informed consent Principal Investigator, Study ID, Keywords STU00091585 Click to Copy URL to Clipboard For questions about this study, contact: |
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (LEGACY)A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (LEGACY)
Principal Investigator, Study ID, Keywords Registry Gastrointestinal Diseases Inflammatory Bowel Diseases Gastroenteritis Adalimumab Colitis Ulcerative Colitis Humira
For questions about this study, contact: |
Healthy Control Esophageal Registry and BiorepositoryThis study is being done to compare how the esophagus and upper stomach work in people who have Scleroderma with symptoms of reflux disease or difficulty swallowing (dysphagia) to healthy controls. We will collect skin, esophageal and stomach biopsies (small pieces of tissue) to be used for several studies.
Who Can Participate?Must not be:- Obese (i.e. BMI ≥30) - Known medical illnesses that could affect esophageal function, gene expression or histology - Have a diagnosis of an eating disorder - Have a diagnosis of an autoimmune disease - A current or previous smoker (smoked >100 cigarettes in lifetime) - Have a history of alcohol abuse or addiction or score of 2 or higher on the CAGE questionnaire - Taking antacids and/or proton pump inhibitors for heartburn - Allergies to Fentanyl or Midolazam (sedatives used during endoscopy) - Allergies to Lidocaine (Lidocaine anesthetic jelly used during manometry). - Pregnant or nursing (hormones associated with pregnancy and lactation are known to affect esophageal function) Principal Investigator, Study ID, Keywords STU00096856 Click to Copy URL to Clipboard |
Neural Systems for the Dynamic Use of MemoryThe Laboratory for Human Neuroscience at the Northwestern University Feinberg School of Medicine is seeking participants for research studies on how the brain develops across the lifespan. We are currently enrolling individuals 18-34 years of age in our research studies. Depending on your eligibility, you could take part in studies involving cognitive testing or studies involving noninvasive recording of brain function (using EEG, TMS, and MRI). Please contact us if you are interested in participating and we can determine your eligibility and provide additional details. All studies take place in downtown Chicago on the Northwestern University campus. Individuals will receive monetary compensation for participating, ranging from $10-$40 per hour depending on the experiment.
Please contact fill out our participant survey if you are interested at https://redcap.nubic.northwestern.edu/redcap/surveys/?s=w7RfNPbxwJ or contact us at lhn@northwestern.edu or 312-503-5613.
Principal Investigator, Study ID, Keywords STU00060723 Click to Copy URL to Clipboard For questions about this study, contact: |
Noninvasive Manipulation of Hippocampal-Cortical Brain Networks and MemoryThe Laboratory for Human Neuroscience at the Northwestern University Feinberg School of Medicine is seeking participants for research studies on how the brain develops across the lifespan. We are currently enrolling individuals 18-34 years of age in our research studies. Depending on your eligibility, you could take part in studies involving cognitive testing or studies involving noninvasive recording of brain function (using EEG, TMS, and MRI). Please contact us if you are interested in participating and we can determine your eligibility and provide additional details. All studies take place in downtown Chicago on the Northwestern University campus. Individuals will receive monetary compensation for participating, ranging from $10-$40 per hour depending on the experiment.
Please fill out our participant survey if you are interested at https://redcap.nubic.northwestern.edu/redcap/surveys/?s=w7RfNPbxwJ or contact us at lhn@northwestern.edu or 312-503-5613.
Principal Investigator, Study ID, Keywords STU00070522 Click to Copy URL to Clipboard For questions about this study, contact: |
Development of a Kidney Cancer Patient Outcomes DatabasePurpose
This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life.
Overview
A registry is a repository (database) of information about a group of people who share a common characteristic - in this case, kidney cancer. MYQOL registry participants enter information about their disease, treatment, symptoms, health status, and quality of life into an on-line, password-protected database on a regularly scheduled basis. Participants can use the registry to track many of their symptoms and their health status over time and to compare themselves (anonymously) with other groups of people (for example, how their level of fatigue compares with the average level of fatigue reported by other participants in the registry). Participants can also choose to share relevant information about themselves (from the registry) with their health care provider(s), by printing copies of their completed forms. Registry participants will be offered opportunities to join in other research studies when available.
Description of Treatment
Participants in this study will be asked to do the following for a 1-year trial period: 1) enroll in the on-line registry; 2) complete questionnaires about their health and treatment every 3 months ; and 3) be willing to have MYQOL researchers contact them confidentially about participating in other research studies. This does not mean that participants are obligated to participate in future research studies; only that they agree to be contacted.
Who Can Participate?Some of the eligibility criteria include:- Participants must have a kidney cancer diagnosis. - Participants must be 18 or older. - Participants must be able to read English well enough to complete questionnaires. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords STU00070200 Click to Copy URL to Clipboard For questions about this study, contact: |
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic EfficacyWe know that in rheumatoid arthritis (RA), considerable thickening of the lining layer (synovium) in the joints occurs. This represents the accumulation of new cells and tissue. We would like to learn more about what contributes to the disease progression of RA and why some people respond to RA therapy, while others do not. To do this, we will examine the
cells, genetic material, proteins and other features in the tissue from the inflamed
joints and blood of patients with RA. We hope that by studying this tissue and blood, we may learn information that may help lead to the development of new treatments for this disease.
Who Can Participate?• Diagnosis of rheumatoid arthritis (RA).• Must have been 18 years of age or older at the time of diagnosis of RA. • At least one swollen joint (elbow, writs, knee, ankle, or shoulder) due to active RA. Principal Investigator, Study ID, Keywords STU00104822 Click to Copy URL to Clipboard For questions about this study, contact: |
HOme-based moNitORed exercise for PADThis study will determine the effects of a home based walking exercise intervention on walking ability in people with peripheral artery disease (PAD).
Who Can Participate?Peripheral artery diseasePrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Ex vivo interactions between high-density-like nanoparticles and human bloodThis research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Prior to initiating large-scale in vivo animal and human studies it is imperative that we obtain an in-depth knowledge of the interaction of the HDL-NPs with human blood cells using safe ex vivo experiments.
Who Can Participate?Healthy, non-pregnant adult (age >18-75 years) volunteers.Principal Investigator, Study ID, Keywords STU00200368 Click to Copy URL to Clipboard For questions about this study, contact: |
NCI 15H01: Triad1 Regulates Myelopoiesis and Functions as a Leukemia SuppressorResearchers have found that about 60% of patients with acute myeloid leukemia (AML) will obtain a remission following treatment with combinations of chemotherapy drugs. However, relapse after treatment remains a problem, and can be as high as 80% in some types of AML patients. Therefore, it would be beneficial to identify specific treatment approaches for patients at a high risk for relapse. One characteristic associated with high relapse rates is an increase in proteins that are referred to as Hox proteins in the leukemia cells. Increase in Hox proteins prevents production of some other proteins, including a protein referred to as Triad1. An increase in Triad1 protein in bone marrow cells may be important to control the growth of such cells. Decreased Triad1 in leukemia cells may therefore promote their growth, but this has not been previously studied. The purpose of this study is to investigate if the lack of Triad1 in leukemia cells contributes to resistance of some leukemias to chemotherapy drugs. This research may prove to be helpful in the design of new and more effective treatments for leukemia in the future. At a time when you are having a bone marrow biopsy and aspirate performed as part of your standard medical care, about an additional 2.5 teaspoons (12.5 mL) of bone marrow will be collected for this research study. Who Can Participate?You may be eligible for this research study if you have been diagnosed with acute myeloid leukemia (AML), a cancer of the blood. Principal Investigator, Study ID, Keywords STU00200435 Click to Copy URL to Clipboard For questions about this study, contact: |
Low InTensity Exercise intervention in PAD: The LITE Trial.This study is being done to determine whether an exercise intervention that avoids continuous supervision and exercise-related pain in the legs can improve walking ability in people with lower extremity peripheral artery disease (PAD).
Who Can Participate?Peripheral artery diseasePrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation with a Short Cervix (PROSPECT)
This protocol outlines a randomized trial of 600 women evaluating the use of micronized
vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in
women carrying twins and with a cervical length of less than 30 millimeters.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Telmisartan Plus Exercise to Improve Functioning in PADThe purpose of this study is to establish whether the angiotensin receptor blocker (ARB) telmisartan improves walking performance in people with PAD. We will also determine whether telmisartan plus supervised exercise improves walking performance more than telmisartan alone and more than supervised treadmill exercise alone.
Who Can Participate?We are asking you to take part in this research study because you have or may have peripheral artery disease (PAD). PAD is a condition in which cholesterol blockages in the leg arteries prevent blood from getting down to the legs and feet during exercise.Principal Investigator, Study ID, Keywords peripheral artery disease atherosclerosis vascular disease cardiovascular disease telmisartan exercise
For questions about this study, contact: |
Chronic Kidney Disease Research BiorepositoryThe objective of this study is to create a biorepository of stored blood and urine specimens and demographic and clinical data collected from patients with chronic kidney disease and healthy volunteers for use in chronic kidney disease research
Principal Investigator, Study ID, Keywords STU00201546 Click to Copy URL to Clipboard For questions about this study, contact: |
Improving Outpatient Safety of Older Adults through Electronic Patient PortalsThe objective of this study is to assess whether providing caregivers of older adults proxy access to an electronic patient portal (MyChart) improves the outpatient medication safety and communication between caregivers and health care providers.
Who Can Participate?Adults age 65 and older, a patient in the General Internal Medicine and Geriatrics (NMFF GIM-GER) clinics, not currently enrolled in MyChart Electronic Patient Portal, English speaking, can identify a caregiver who assists with their care (can be informal e.g. adult child, spouse, caregiver agency). Additional eligibility criteria are focused on the caregiver identified: English speaking, assist the older adult with medications and communication with the health care team, and have internet access (either phone, tablet, or laptop/computer).Principal Investigator, Study ID, Keywords STU00201242 Click to Copy URL to Clipboard For questions about this study, contact: |
LIFT: Lupus Intervention for Fatigue TrialThis study is designed to evaluate the effectiveness of one-on-one counseling sessions on reducing symptoms of fatigue in persons with lupus by providing them with individualized coaching on increasing physical activity and improving diet.
Who Can Participate?Have lupus and experience fatigue as a result.At least 18 years old. Can participate in physical activity. Live in the Chicago area. Be able to speak and read English. Be able to consent to being in the study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The ENabling Reduction of low-Grade Inflammation in SEniors) Pilot StudyThe purpose of the ENRGISE Pilot Study is to look at the effect of anti-inflammatory drugs on physical functioning in older adults. This study will see if two study drugs (fish oil and losartan, a commonly used blood pressure medicine) have an effect on walking ability.
Who Can Participate?Age 70 or older, slow walking speed, and high levels of markers of inflammation in your blood.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
The main purpose of this study is to determine if taking the study drug, conjugated
estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the
breast tissue of the study subjects. The study drug is approved by the US Food and Drug
Administration in healthy postmenopausal women to treat certain symptoms of menopause such
as hot flashes. Since it is not approved in women with DCIS, its use in this study is
experimental. This study will also look at whether taking the study drug causes any
significant or undesirable side effects in women with DCIS. The researchers hope that this
study will help them determine if taking the study drug is safe in women taking DCIS and if
it can possibly reduce the risk of developing breast cancer in women with DCIS.
Who Can Participate?Some of the eligibility criteria include:- Participants must be postmenopausal women with newly diagnosed DCIS scheduled to undergo surgical therapy. - Patients must be able to swallow the oral medication. - Patients must be able to understand and the willing to sign a written informed consent document and comply to all procedures. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 15N01: Head and Neck Tissue BankResearchers would like to create a bio-specimen bank of tissue, blood, urine and saliva, which would then be used to study cancer and find better ways to detect, prevent, diagnose, treat and provide better care for future patients. Some of these studies may be about how genes affect the development of cancer, response or resistance to treatment as well as prognosis (course of disease and overall outcome including survival). Other studies may aim to identify measurable substances in the blood and/or urine (known as biomarkers) that can indicate early development of cancer, worsening or relapse of disease and response to treatment. Some studies may lead to new products, such as drugs or tests for detection of cancer. Who Can Participate?You may be eligible to take part in our head and neck specimen banking study if you have one of the following conditions: a) You have a tumor or an abnormal area in the head and neck area, suspicious for cancer, or pre-cancerous condition or other pathology of interest, and you’re scheduled to have biopsy and/or surgery at Northwestern Memorial Hospital. b) You will receive treatment and/or regular follow up for further management for your head and neck cancer or precancerous condition, or other pathology at Northwestern Memorial Hospital and/or Northwestern Medicine Developmental Therapeutics Institute (NMDTI). Principal Investigator, Study ID, Keywords STU00202177 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 15N02: Northwestern Head and Neck Cancer RegistryThe purpose of this registry is to collect clinical information on all consenting head and neck cancer patients seen at the Northwestern Medical Group (NMG) or Northwestern Memorial Hospital (NMH). With this information, researchers will conduct studies to learn more about the subtypes of head and neck cancers and determine the most effective treatments. The registry will also allow us to identify possible subjects for future studies. Who Can Participate?You may be eligible to take part in this research study if you are being treated or have been treated for a tumor or cancer of the head and neck. Principal Investigator, Study ID, Keywords STU00202162 Click to Copy URL to Clipboard For questions about this study, contact: |
Motivational Interviewing and Physical Activity in Parkinson’s DiseaseWe are conducting a study to evaluate ways to increase physical activity in people with Parkinson’s Disease.
Participants in this study will be placed into one of four groups:
1) motivational interviewing, a counseling/coaching style used to help people change their behavior;
2) a web-based application for participants to keep track of their physical activity;
3) a combination of the motivational interviewing and the web-based application; and
4) an educational program on various issues related to Parkinson’s disease.
Who Can Participate?Live in the communityAt least 18 years of age A diagnosis of Idiopathic Parkinson’s Disease Be able to walk for a distance of 50 feet or 10 minutes at a time Do NOT currently complete 150 minutes or 2.5 hours of moderate to vigorous physical activity per week Currently has and uses a smartphone, tablet, or computer to access the internet Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Semen quality in males with inflammatory bowel disease: Influence of medication for IBDSemen quality in males with inflammatory bowel disease: Influence of methotrexate, ustekinumab and tofacitinib treatment.
Principal Investigator, Study ID, Keywords STU00201469 Click to Copy URL to Clipboard For questions about this study, contact: |
Epidermolysis Bullosa Clinical Characterization and Outcomes DatabaseThe aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB. Who Can Participate?All candidates with a clinical diagnosis of epidermolysis bullosa are eligible for this study. The subjects can be from any age, male or female without restriction.Principal Investigator, Study ID, Keywords STU00202682 Click to Copy URL to Clipboard For questions about this study, contact: |
North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) StudyThis is a non-interventional study (i.e. no study drug)
NARCRMS is a highly collaborative effort involving investigators, industry, and, mostimportantly, patients. The goal of this effort is to make information on all aspects of MS availableto all stakeholders in real-time. The feedback that patients will eventually receive will allowthem to evaluate themselves as compared to the whole cohort, and permit themselves to beactive participants towards their care. The NARCRMS database is unique for the following reasons: 1. This is the only database in MS that is North American in scope. 2. This is the only database that is all encompassing. It examines every aspect of MS;clinical, imaging, biomarkers, pathology, healthcare economics, and pharmacotherapy. 3. This is the only database that makes available to all stakeholders in an anonymousformat the entire dataset, including imaging, in real-time.4. This is the only database that allows examination of therapeutic agents in a phase 4setting, after the launch of the agent. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00201852 Click to Copy URL to Clipboard For questions about this study, contact: |
LiveWell: A Mobile Intervention for Bipolar DisorderThis study is being done to evaluate the use of a mobile phone intervention for bipolar disorder that aims to improve patient self-management and increase the effectiveness of psychological interventions. The goal is to reduce symptoms and prevent relapse in people with bipolar disorder. If you are eligible for the study, your participation will last up to 12 months.
Who Can Participate?Individuals 18-65 years old who have been diagnosed with bipolar disorder and are currently working with a psychiatristPrincipal Investigator, Study ID, Keywords Bipolar Type 1 Mania Depression Bipolar Mood disorders Mental health Lithium Depakote Abilify Latuda Zyprexa Seroquel Smartphone
For questions about this study, contact: |
Efficacy of Couples-Based HIV Prevention in Vulnerable Young Men2GETHER is a relationship education program and study designed to help male couples navigate the complexities of being in same-gender loving and gay relationships. 2GETHER provides participants with relationship tools to help them in the years to come. 2GETHER participants will be asked to complete one of two different relationship programs, both of which focus on couples-specific skills and gay relationship coaching. Each relationship program involves: 2 group sessions with other male couples. 2 individual couples sessions with a trained 2GETHER facilitator
Participant couples will then be tracked for the following year and will receive surveys at 3, 6, 9, and 12 months. As an incentive for participating in the clinical trial of the relationship program, each member of the couple has the potential to make up to $250. Who Can Participate?Inclusion: You’re assigned male at birth and currently identify as male. You’re 18 or older. You are in a relationship with another cisgender male. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Cocoa to Improve Walking Performance in Peripheral Artery Disease: The COCOA-PAD StudyThe purpose of this study is to determine whether drinking daily cocoa-enriched beverages improves walking performance in people with PAD. Previous studies have shown that cocoa may improve blood flow, improve cardiovascular health, and improve muscle function and strength. Some evidence suggests that cocoa may also improve walking ability in people with PAD.
Who Can Participate?We are asking you to take part in this research study because you are age 65 or older and you have or may have peripheral artery disease (PAD). PAD is a condition in which cholesterol blockages in the leg arteries prevent adequate blood flow to the legs and feet.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
MAST CELLS IN MALE CHRONIC PELVIC PAIN AND LOWER URINARY TRACT DYSFUNCTIONThe purpose of this study is to figure out if drug treatments using cromolyn sodium and cetirizine hydrochloride lessen painful symptoms in patients suffering from chronic pelvic pain syndrome (CPPS).
Who Can Participate?Men diagnosed with Category IIIB Chronic Pelvic Pain Syndrome reporting pain or discomfort in any of the 8 domains of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). Symptoms must have been present for the majority of the time during any 3 months in the previous 6 months.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive MeningiomaPurpose
The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.
Overview
Bevacizumab (the study drug) is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. In order for tumors to grow they need to have a blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.
Optune (the study device) is also considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study device, Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient‰Ûªs brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.
Description of Treatment
Tumor treatment field therapy with Optune will be initiated at the same time as bevacizumab, with both treatments to start within a one-week period of each other. Bevacizumab will be given at current standard central nervous system (CNS) dosing of 10mg/kg q2 weeks in an outpatient setting. After 4 cycles (1 cycle=28days) of therapy (Cycle 5 day 1) patients may choose to switch to bevacizumab at a dose of 15 mg/kg q3 weeks. For patients who chose to make this switch, they have to do it on Day1 of a new cycle. Tumor treatment fields with Optune will be delivered for at least 18 hours a day at a frequency of 200 KHz and intensity of 1-3V/cm. Treatment will be continued until disease progression or up to 1 year.
Who Can Participate?"Some of the eligibility criteria include:- Patients must be age = 18 years. Both males and females and patients from all ethnic backgrounds are eligible. - Patients must have a histologic diagnosis of meningioma, WHO grade 2 or 3 (atypical or anaplastic). - All patients must have developed recurrent disease/progression after receiving all standard treatments. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial." Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 16B06: Investigation of Blood-Based Prognostic Biomarkers in Patients with Advanced Breast Cancer for Molecular Mechanisms Underlying Circulating Tumor Cell ClustersThis study is being done to help improve the knowledge on the biology of breast cancer in the future. Blood specimens from patients with breast cancer will be collected and utilized for future research projects known as biomarker studies. These blood based laboratory tests will ultimately evaluate molecules present in the blood of patients with breast cancer. These molecules could be, for example, a protein, tumor DNA, or tumor cells circulating in the blood. As research technology advances, blood samples from patients with breast cancer may help in understanding the course of disease and to check as to how effective a treatment is. Who Can Participate?You may be eligible for this research study if you have advanced stage (III/IV)breast cancer. Principal Investigator, Study ID, Keywords STU00203283 Click to Copy URL to Clipboard For questions about this study, contact: |
Evaluating the Circadian Response to Light in Delayed Sleep-Wake Phase DisorderThis study is looking at factors that contribute to the timing of sleep. Interested subjects will undergo screening to determine their sleep-wake habits, then will have an eye test and a blood draw. Participation will involve 2 outpatient visits, separated by up to 3 weeks of sleep-wake activity monitoring.
Who Can Participate?Individuals with delayed sleep-wake phase disorder and healthy controlsPrincipal Investigator, Study ID, Keywords STU00203647 Click to Copy URL to Clipboard For questions about this study, contact: |
A wearable myoelectric-computer interface to reduce muscle co-activation in acute and chronic strokeWe are conducting a study investigating the use of small wearable devices, called myoelectric computer interfaces, to reduce abnormal arm muscle coordination in individuals with impaired arm movement from a stroke. Training will take place predominantly at home, with some sessions in the lab as well. This study could potentially lead to improved arm function for stroke survivors who have abnormal arm coordination.
Who Can Participate?At least 18 years of age - Had a stroke more than 6 months ago - No large impairment in vision (glasses), memory, language or concentration - Not currently participating in another research study on the arm Principal Investigator, Study ID, Keywords STU00203644 Click to Copy URL to Clipboard For questions about this study, contact: |
Alzheimer’s Disease Neuroimaging Initiative 3The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.
This is a non-randomized natural history non-treatment study. Participants will need to be 55 - 90 years, otherwise healthy with no neurologic disease such as Alzheimer's disease. Approximately 1070 - 2000 participants will be enrolled at approximately 59 sites in the United States and Canada. Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts.
Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.
Who Can Participate?- No history of major psychiatric disorders such as major depression, bipolar disorder, or schizophrenia.- Must be between the ages of 55-90 years (inclusive). - Must have a study partner who has frequent contact with the participant (i.e., minimum average of 10 hours per week) and is available to accompany the participant to all clinic visits for the duration of the protocol. - Must have visual and auditory acuity adequate for neuropsychological testing. - Must be in good general health with no diseases expected to interfere with the study. - For females only: Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile). - Must be willing and able to participate in a longitudinal imaging study lasting up to 5 years. - Must have completed six grades of education or has a good work history (sufficient to exclude mental retardation). - Must speak English fluently. - Must be willing to undergo repeated MRIs (3Tesla) and at least two PET scans - must not have any MRI contraindications (i.e. pacemaker, claustrophobia) - Must agree to collection of blood for genomic analysis (including GWAS (genome-wide association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and biospecimen banking. - Must agree to collection of blood for biomarker testing. - Must agree to at least one lumbar puncture for the collection of CSF. - Must agree to share genomic data and biomarker samples. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NUDB 16Z01: The OncoSET Program Database and Biobank - Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid MalignanciesThe purpose of the study is to gather information about your cancer and the treatment you receive as a part of your routine clinical care. In this study, we are developing a research registry, which is a bank of information about many patients. We are interested in learning about the relationship between your cancer and the different types of tests available to identify the best treatment option for you. That is, we are interested in the tests that identify possible ‘mutations’ (e.g., changes) or ‘drivers’ within your tumor, what treatments you receive after getting these tests, and how your cancer responds to the treatments. The tests known as next generation sequencing or “NGS” are usually done on your cancer tissue or blood samples as a part of your routine clinical care. Your doctor can use the information to identify the best treatment option for you after discussing it with other doctors. These routine tests will be performed whether you participate in this study or not, but we want to collect the information about this process for this study. If you participate in this study, extra samples of your blood will be collected and stored, and your health information from your medical record and NGS lab results will be collected and stored. Who Can Participate?You may be eligible for this research study if you have a diagnosis of cancer and are being treated at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Principal Investigator, Study ID, Keywords STU00203944 Click to Copy URL to Clipboard For questions about this study, contact: |
MISCENDThis study is enrolling patients with moderate to severe mitral regurgitation who are considered to have high surgical risk for traditional open-heart surgery. Mitral regurgitation (MR) is a condition in which blood flow through the mitral valve flows in the wrong direction during part of the cardiac cycle, which negatively affects the blood flow to the rest of the body. The purpose of this study is to assess the safety and performance of a new bioprosthetic mitral valve device when implanted through groin (transfemoral) access. The new mitral valve replacement device is called the Edwards EVOQUE Eos System. The Edwards EVOQUE Eos System is experimental and is not yet approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. This device is implanted without the need for an open-heart procedure and without the need for a heart and lung machine. It is implanted using a delivery catheter, which is a long tube with the valve attached at one end and a handle attached at the other end to control the placement of the valve. The long tube will be inserted through an incision inside the left or right groin (transfemoral/transseptal).The standard medical treatments generally available to patients with mitral regurgitation who do not undergo surgery may temporarily alleviate some symptoms, but will not permanently alleviate the condition or cure mitral regurgitation. Participation in this study will last for approximately 5 years. Participants will be expected to attend a minimum of 7 scheduled study visits after discharge from the hospital at 1, 6, 12, 24, 36, 48 and 60 months after the procedure.
Who Can Participate?Patients with moderate to severe mitral regurgitation who are considered to have high surgical risk for traditional open-heart surgery. General Criteria:1. Greater than or equal to 18 years of age.2. New York Heart Associate Classification ≥ II3. Left Ventricular Ejection Fraction ≥ 30%.4. Mitral regurgitation (MR) ≥ Grade 3+ (moderate/severe, or severe).5. Patient is determined to be high surgical risk as assessed by the site’s ‘Heart Team’ (a minimum of one Cardiac Surgeon and one Interventional Cardiologist).Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Improve PAD PERformance with METformin: The PERMET TrialThe purpose of this study is to establish whether metformin improves walking ability in people with PAD.
Who Can Participate?We are asking you to take part in this research study because you have or may have peripheral artery disease (PAD). PAD is a condition in which cholesterol blockages in the leg arteries prevent blood from getting down to the legs and feet during exercise.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Investigating Serum Concentrations of Mood Stabilizing Medications in Pregnancy and PostpartumWe are working to understand how physiological changes during pregnancy and postpartum affect the metabolism of mood-stabilizing medications, such as lamotrigine (Lamictal), lithium (Lithium Carbonate), risperidone (Risperdal), aripiprazole (Abilify), lurasidone (Latuda), and olanzapine (Zyprexa). Changes in the metabolism of these medications can lead to less than therapeutic drug levels which may cause an increase in mood symptoms or recurrence of mood episodes. The study offers additional monitoring of mood symptoms and drug concentrations in the blood during pregnancy. Participating in this study may help researchers better understand how to adjust mood-stabilizing medications in pregnancy and postpartum, which will in turn help reduce the recurrence of symptoms.
Participation involves:
Este estudio tiene el fin de entender como ciertos cambios fisiológicos durante el embarazo y postparto afectan el metabolismo de medicamentos como lamotrigine (Lamictal), lithium (Lithium Carbonate), risperidone (Risperdal), aripiprazole (Abilify), lurasidone (Latuda), y olanzapine (Zyprexa). Cambios en el nivel del medicamento en sangre tienen el potencial de inducir un nivel terapeutico del medicamento menor al estándar lo cual puede llevar a un incremento en cambios de ánimo o recurrencia de episodios anímicos. El estudio incluye:
Who Can Participate?To qualify for this study you must:
Los requisitos parta participar en este estudio son:
Principal Investigator, Study ID, Keywords STU00203693 Click to Copy URL to Clipboard bipolar disorder major depressive disorder depression schizophrenia bipolar psychiatry pregnancy pregnant lamotrigine lithium risperidone aripiprazole lurasidone quetiapine olanzapine
For questions about this study, contact: |
Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease CohortThe purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Who Can Participate?Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.Principal Investigator, Study ID, Keywords STU00203021 Click to Copy URL to Clipboard For questions about this study, contact: |
ELUCDITATING THE MOLECULAR MECHANISMS UNDERLYING CYP2D6 INDUCTION DURING PREGNANCYWe know that over 90% of women take at least one drug during pregnancy. Because of the changes in a pregnant women’s body, processes such as the rate of drug metabolism can change over the course of the three trimesters.
Drug metabolism is controlled by certain genes in the body. This study will be examining the up-regulation of a certain enzyme in the liver called CYP2D6, which helps the body process many different drugs. We will measure compounds related to vitamin A, which we think might be involved in the process that speeds up the enzyme activity, from blood samples.
The primary goal of our research is to understand how drug metabolism changes across pregnancy. The secondary goal is to define how the activity of enzymes in the liver are up-regulated (increased) during pregnancy. This research will help to build a knowledge base for the prediction of drug metabolism changes and the design of optimal individualized dosage regimens for pregnant women.
Who Can Participate?• Are 18-45 years of age• Are currently at or less than 13 weeks pregnant • Speak English • Singleton Gestation (not pregnant with twins) • Able to present for blood sampling between 8am-noon once per each month of pregnancy, and for two months postpartum Principal Investigator, Study ID, Keywords STU00204600 Click to Copy URL to Clipboard For questions about this study, contact: |
Neuromodulation and Neurorehabilitation for Treatment of Functional Deficits after mTBI plus PTSDThe purpose of this study is to alleviate persisting attention deficits related to mTBI and PTSD by treating the neurocognitive system of attention.
Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
INtervention Study In OverweiGHT Patients with COPD (INSIGHT COPD)We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. There are many medications for patients with COPD, but there is little mention of weight loss as a possible treatment in current research. We are trying to find out if a lifestyle program that promotes modest weight loss and increased physical activity will improve COPD symptoms for those with a high BMI. We hope that the program will lead to weight loss and better exercise tolerance. We are also looking at the effects on shortness of breath, quality-of-life, and cardiovascular disease risk factors.
1 year, 2 visits. Who Can Participate?40 years of age or older with COPD, wants to participate in a healthy lifestyle intervention, body mass index of 25 -44.9Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The Role of Circadian Dysfunction in Hepatic Encephalopathy in Patients with CirrhosisIndividuals with advanced liver disease (cirrhosis) often report new or worsening sleep problems.
Who Can Participate?1) Diagnosis of end-stage liver disease or cirrhosis; 2) being evaluated for liver transplant; 3) Age >=18yo; 4) no severe kidney disease (for example, patients currently on dialysis are not eligible)Principal Investigator, Study ID, Keywords STU00204423 Click to Copy URL to Clipboard Cirrhosis End-stage liver disease hepatic encephalopathy sleep circadian cognitive impairment dementia transplant insomnia
For questions about this study, contact: |
Bimanual balanced reaching with visual biofeedbackThe purpose of this study is to increase understanding of error augmentation by applying it to visual feedback during motion tracking with a Leap Motion device - a recently developed optical hand tracking tool - and the LookingGlass - a new, portable virtual reality environment, as a feasible treatment method of upper extremity chronic stroke impairment when combined with a balancing task.
Who Can Participate?8 months post stroke Ability to actively flex and extend elbow when supported against gravity History of a single stroke event No Botox® injection in your arm within the past 4 months Ability to provide informed consent Principal Investigator, Study ID, Keywords STU00204661 Click to Copy URL to Clipboard For questions about this study, contact: |
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
Who Can Participate?• Age 18 and older• Presence of symptoms and signs of ataxia • Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member • Willingness to participate in the study and ability to give informed consent. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Partner 3 AVIV RegistryThis study will evaluate the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) Model 9600TFX and associated delivery systems for the aortic valve in valve procedure.
Participants in this study will have the investigational (experimental) Edwards SAPIEN 3 transcatheter aortic heart valve (study device) to replace the failing bioprosthetic aortic valve access through the heart through a small incision is in the chest.
The study device and its delivery system are investigational, which means they are not approved for commercial use by the U.S. Food and Drug Administration (FDA) for the valve in bioprosthetic valve procedure. The previous generation of SAPIEN valves, SAPIEN XT, was approved for commercial use by the FDA for a failed surgical bioprosthetic aortic valve in October 2015.
The study device is a bioprosthetic heart valve made out of man-made materials and animal tissue. It is an artificial device made to replace the diseased aortic heart valve. Each valve consists of a stent (mesh tube made of metal) to hold the study device in its intended position and valve leaflets (made of biological material derived from cows) to direct the flow of blood in the heart.
Study participation will last approximately 10 years. Participants will be asked to come to clinic for study visits at 30 days, 6 months, and 12 months after the study procedure and then annually until 10 years after the procedure.
We expect up to 19 people will be enrolled at Northwestern. The study expects to enroll up to 125 people internationally.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Long-Term Nicotine Treatment of Mild Cognitive ImpairmentThe purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with Mild Cognitive Impairment (MCI). Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function.
The study will enroll participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Randomized Trial of Pessary in Singleton Pregnancies with a Short Cervix (TOPS)Eligible and consented women who are pregnant with one baby and have a short cervix when measured during an ultrasound performed between 16 week - 23 weeks are assigned to pessary placement or standard of care (no pessary).
Who Can Participate?cervical length less than or equal to 20 mm when measured between 16 weeks -23 weeks of singleton pregnancyPrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Physical activity and DNA methylation among women with high breast densityThe purpose of this study is to learn more about how physical activity may influence your genes through a mechanism called DNA methylation. Our goal is to determine if being physically active may be associated with a healthy pattern of DNA methylation in your immune system cells. Exercising and being physically active are believed to be important for preventing cancer. It may be particularly important for women with high breast density, and may help reduce risk for breast cancer. However, we do not understand what physical activity changes within the body to alter risk of breast cancer. DNA methylation is a biological process that may help explain the relationship between physical activity and cancer risk.
Who Can Participate?Generally healthy women with a history of heterogeneously or extremely dense breasts, aged 40-74 with no history of cancer (other than non-melanoma skin cancer), diabetes, and cardiovascular disease.Principal Investigator, Study ID, Keywords STU00204639 Click to Copy URL to Clipboard For questions about this study, contact: |
Melanoma and Skin Cancer Tissue RepositoryThe purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. Northwestern University may use your medical record information, as well as tumor, blood, saliva, urine, and fecal samples (collectively called “tissue”) for research studies to help us understand melanoma and other skin cancers. Biopsies and surgery of your cancer will not be a part of this study but will be performed as part of your standard care. Who Can Participate?You may be eligible to take part in the research component of the Northwestern Melanoma and Skin Cancer Tissue Repository if you are either a new or returning patient and have a skin cancer or pre-cancer lesion. Principal Investigator, Study ID, Keywords STU00204151 Click to Copy URL to Clipboard For questions about this study, contact: |
Quantitative Detection of Coronary Microvascular Dysfunction in Long COVID Patients Using a Comprehensive, Rapid, Free-Breathing Cardiovascular MRIThis research study involves the use of Magnetic Resonance Imaging (MRI) to study the effects of COVID-19 on the heart. Since COVID-19 is a new disease, we do not yet understand the different ways that it may effect the body. There is some evidence that individuals with COVID- 19 are at higher risk for heart complications. The purpose of this study is to use recently developed MRI techniques to compare heart health of individuals with COVID-19 to people who were asymptomatic or are healthy. The new MRI techniques used in this experiment may also allow researchers and health care providers to take clearer pictures of the heart in other individuals. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00205520 Click to Copy URL to Clipboard For questions about this study, contact: |
Transformative Research In Diabetic Nephropathy (TRIDENT) (SP0043185)This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.
Who Can Participate?Inclusion Criteria• Type 1 and 2 Diabetes by ADA criteria (see appendix ) • Willingness to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site • Able to provide informed consent • Adult participants (no age restriction) • Planned medically indicated kidney biopsy, prescribed by a practicing nephrologist Exclusion Criteria • ESRD, defined as chronic dialysis or kidney transplant • History of receiving dialysis for more than 30 days • Institutionalized • Solid organ or bone marrow transplant recipient at time of first kidney biopsy • Less than 3-year life expectancy • Known alcohol or substance abuse • Unable to provide informed consent • No evidence of active cancer other than non-melanoma skin cancer Principal Investigator, Study ID, Keywords chronic kidney diease kidney disease diabetes renal biopsy kidney biopsy research study research study diabetes mellitus diabetic nephropathy
For questions about this study, contact: |
The Role of Positron Emission Tomography and Magnetic Resonance Imaging (without Fluorodeoxyglucose or Gadolinium) in Yttrium-90 Radioembolization Treatment Planning for Patients with Liver MalignanciesPatients who are already scheduled to receive Y90 radioembolization, will first be treated with Y90 radioembolization for liver cancer or metastasis in the liver. They will then have a Positron Emission Tomography (PET/MR) scan done a few hours after the treatment. You will be placed inside a small tube for 2-3 hours for the PET/MR scan. There is no contrast or radiation involved in the PET/MR scan. The purpose of the PET/MR scan is to capture specific images of the liver to see where the Y90 radioactive particles are a few hours after treatment. These images will be used to compare determine how much of the radioactive particles went to the tumor(s) compared to how much of them went to healthy liver tissue. We hope to use this information to help develop care that is more specific to the patient.
Who Can Participate?Inclusion Criteria (patients must meet these criteria):1. 18 years of age or older. 2. Diagnosed with primary liver cancer or metastasis in the liver. 3. Planning to have Y90 radioembolization treatment at Northwestern Medicine. 4. Be able to have an MRI- not claustrophobic or have any other contraindications to MRI. Principal Investigator, Study ID, Keywords STU00205918 Click to Copy URL to Clipboard For questions about this study, contact: |
Genetic causes and pathogenic mechanisms of adult epilepsiesThe purpose of this study is to look at genetic markers of epilepsy in patients and their families using blood, saliva, skin, and brain tissue analysis.
Principal Investigator, Study ID, Keywords STU00205877 Click to Copy URL to Clipboard For questions about this study, contact: |
NIH All of Us Research Program Precision Medicine Initiative® Precision Medicine Initiative Cohort Program Healthcare Provider Organization Enrollment Centers Research Program in Illinois. The mission of this ambitious National Institutes of Health (NIH) initiative is to speed up health research and medical breakthroughs. To do this, the All of Us Research Program is asking one million people to lead the way to provide the types of information that can help us create individualized prevention, treatment, and care for all of us. Visit nm.org/joinallofus to learn more and enroll.
WHATARE THE BENEFITS OF JOINING? · · · WHATWOULD I NEED TO DO? · · · Visit an All of Us Participant Center for physical measurements (bloodpressure, height, weight, waist/hip, & heart rate) and biosamples (blood& urine) Participants receive a $25 payment for completing all researchcomponents.You will also receive a voucher for free parking. Who Can Participate?- 18 years of age or older- Currently live in the United StatesPrincipal Investigator, Study ID, Keywords STU00204480 Click to Copy URL to Clipboard Precision Medicine genetics individualized medicine health care environment lifestyle biology biobank technology behavior
For questions about this study, contact: |
Clinical Database of Prostate Cancer at Northwestern UniversityThe goal of this study is to create a database of prostate cancer patients at Northwestern Memorial Group to better understand, learn about, prevent, treat or cure prostate cancer.
Who Can Participate?Men ages 18-89 years daignosed with prostate cancer.Principal Investigator, Study ID, Keywords STU00206270 Click to Copy URL to Clipboard For questions about this study, contact: |
Bilateral Priming plus Task Specific Training for Severe Upper Limb HemiparesisThis is a 16-week study testing a new rehabilitation approach that combines bilateral priming with high-repetition, task-specific training. Training will focus on the hand and arm. Training consists of 3 visits per week for 5 weeks. Evaluation sessions (including transcranial magnetic stimulation - TMS) will occur throughout the study.
Who Can Participate?Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Strengthening Circadian Signals to Enhance Cardiometabolic FunctionsPurpose: The purpose of this research is to determine whether when you eat and taking melatonin (a hormone naturally produced by the body) can improve health and sleep. There is growing body of evidence that disrupted sleep and circadian rhythms have negative effects on health. The goal of this study is to determine the impact of when you eat and melatonin on improving sleep and health in older adults who are at risk of disorders such as diabetes, heart diseases or stroke.
Who Can Participate?Eligibility Criteria:Men and women age 40-54 who have no diagnosis of diabetes or sleep disorders may be eligible for this study.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
APOLLOThis study is enrolling subjects with at least moderate-to-severe symptomatic mitral regurgitation to test a new investigational device for mitral regurgitation. A separate study cohort (MAC Cohort) will enroll subjects with at least moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of mitral annular calcification (MAC). The new investigational device is a mitral valve replacement called the Medtronic IntrepidTM Transcatheter Mitral Valve Replacement (TMVR) System. The purpose of the TMVR device is to function similarly to a standard bioprosthetic (man-made) valve implant in that it allows blood to flow only in the forward direction, relieving mitral regurgitation. A standard valve implant, however, is sewn directly into the heart during surgery in which the chest is fully open, the patient is put on heart-lung bypass support and the heart is temporarily stopped to sew in the valve. The IntrepidTM TMVR device is intended to be placed through a less invasive procedure, without sewing, and without requiring heart-lung bypass support or stopping the heart. Participation in this study will last for approximately 5 years. Participants will be expected to attend a minimum of 7 in-person scheduled study visits after discharge from the hospital at 1, 6, 12, 24, 36, 48 and 60 months after the procedure.
Who Can Participate?Enrolling participants with mitral valve regurgitation who are at high risk of experiencing major complications while undergoing open-heart surgery due to their current medical conditions or anatomical reasons (relating to how and where the heart, mitral valve, and blood vessels are placed within the body). Additionally, physicians have determined that these participants may not be optimally treated with currently approved transcatheter repair therapies.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2: The MACTEL StudySince 2005, a group of scientists and clinicians from around the world have identified and are studying hundreds of persons with MacTel Type 2. Progress has been made to find ways to help prevent the condition from developing and to find potential treatment(s) but more work is needed. Special scientists (geneticists) are working to understand if this disorder is inherited (passed down from your parents) and basic scientists are working to understand what happens to the eye tissue inside a MacTel eye. The purpose of this study is to identify persons with MacTel Type 2, and their affected family members to create a Registry of persons with MacTel Type 2. This Registry will be used to study participants with MacTel Type 2 now and may be used in the future to identify persons to be in a study that may help find a way to prevent or treat this eye condition. We also wish to keep in contact with persons who have told by their MacTel doctor that they have MacTel Type 2. In this document, the word “affected” means that it has been confirmed that you have MacTel Type 2. These persons may also be referred to as “Probands” when they are the first person in the family to be diagnosed with the disorder. “Unaffected” means that at this time, there is no evidence of MacTel Type 2. Who Can Participate?1. Must have a confirmed clinical diagnosis of MacTel Type 2. 2. Must be 18 years of age or older. Principal Investigator, Study ID, Keywords STU00206885 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United StatesThe purpose of this study is to collect information to help us understand how doctors treat and manage people with severe asthma and how the health of people with severe asthma changes with those treatments. At least 75 doctors in the United States will provide information on their patients for the study. There will be at least 1500 patients in this study. The length of each patient's participation will vary but the goal is to have patients involved for 3 or more years. Who Can Participate?18 years of age or older Diagnosis of asthma for at least 12 months Frequent, current symptoms of asthma Taking a daily asthma medication In the last 12 months has gone to ER or hospital or had prednisone for a flare Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Clinical Trial Readiness for SCA1 and SCA3Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain scan) and not weigh over 300 lbs.
Who Can Participate?Subjects aged 18 to 65 with presence of symptomatic ataxic disease or asymptomatic mutation carrier or subjects with definite molecular diagnosis of SCA1 or SCA3 or another affected family member or Subjects of age >18 with previous diagnosis of early stage SCA1 and SCA3. Subjects must not make changes in physical/occupational therapy status within two months prior to enrollment. Subjects must not weigh over 300 lbs.5) 6) No changes in sical/occupational therapy status within two months prior to enrolment Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CHRONIC VENOUS THROMBOSIS: RELIEF WITH ADJUNCTIVE CATHETER-DIRECTED THERAPYThe purpose of this study is to help improve your quality of life due to your chronic blood clots. You will be randomly assigned (like a flip of a coin) to either the high quality medial care (including receiving free compression stockings and reviewing your medications) treatment group or a low risk out-patient procedure to place a stent (a metal mesh tube) to open your veins to hopefully help reduce the severity of your blood clot symptoms. This group will also receive the high quality medical care treatment.
If you decide to participate in the study, the study team will: 1. Ask you to sign a consent form that you are agreeing to participate in the study 2. Review your health history and collect a small amount of blood to check your general health 3. Perform a physical exam and measure your leg 4. Perform imaging to assess your blood flow in your leg 5. Ask you to complete questionnaires 6. Ask you to come in for follow-up visits at 2 months, 4 months, 6 months, 12 months, 18 months and 24 months. Treatment assignment: 1. If you are randomly assigned to the low-risk stent procedure, you will return about 1 week after you consent to participate in the study to have the procedure If you participate in the study, you will receive $100.00 after completion of each follow-up visit. Enrolled participants will also receive compression stockings at enrollment and every six months during their participation. Who Can Participate?You are eligible to participate in the study if:1. You are 18 years of age or older 2. You have been diagnosed with a blood clot in your leg in the past (more than 3 months ago) 3. You now have leg heaviness, fatigue, swelling, aching, or pain Principal Investigator, Study ID, Keywords blood clot venous thrombosis varicose ulcer leg ulcer postthrombotic syndrome vascular disease iliac vein obstruction embolism and thrombosis peripheral vascular diseases varicose veins cardiovascular disease superficial venous reflux venous insufficiency phlebitis deep vein thrombosis
For questions about this study, contact: |
Mitochondrial Dysfunction and Disability in Peripheral Artery DiseaseThe reasons for walking impairment and functional decline in patients with PAD are not well understood, and few treatments are available to improve walking performance. This study will look at the association of walking difficulty with calf muscle abnormalities. In addition, the study will compare the changes in calf muscle tissue between participants with PAD and those without PAD. Knowledge gained from the study may lead to the development of new treatments for patients with PAD. You will be asked to undergo baseline testing including walking tests and a calf muscle biopsy and asked to return one year later and two years later to repeat the tests performed at baseline.
Who Can Participate?The MDD study is recruiting indivdiuals of any age with peripheral artery disease, as well as individuals without PAD who do not have diabetes and are age 60 and older. Peripheral artery disease can cause leg pain on walking. You may be at risk of PAD if you have a history of smoking, diabetes, high cholesterol, and/or high blood pressure.Principal Investigator, Study ID, Keywords STU00206722 Click to Copy URL to Clipboard For questions about this study, contact: |
Vasculitis Clinical Research Consortium (VCRC) Genetic Repository One Time DNA ProtocolThe study is being done to identify genes that increase the risk of developing vasculitis. The purpose of the study is to: Collect clinical data and genetic information (DNA) on patients with vasculitis; Discover genetic markers that increase the risk of developing vasculitis; Discover genetic markers linked with certain symptoms of vasculitis. The study involves donating one tube of blood for the collection of genetic information (DNA) at one study visit.
Who Can Participate?- Giant Cell Arteritis- Takayasu’s Arteritis - Polyarteritis Nodosa - Granulomatosis with Polyangiitis (Wegener’s) - Microscopic Polyangiitis - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Principal Investigator, Study ID, Keywords STU00206908 Click to Copy URL to Clipboard For questions about this study, contact: |
Evaluation of Renal Microvascular Perfusion by Contrast Enhanced UltrasoundContrast Enhanced Ultrasound Study:
Who Can Participate?INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Principal Investigator, Study ID, Keywords STU00206894 Click to Copy URL to Clipboard CKD Kidney Disease Healthy Volunteers Contrast Enhanced Ultrasound CKD Stage 1 CKD Stage 2 CKD Stage 3 CKD Stage 4 CKD Stage 5 Renal Microvascular Perfusion
For questions about this study, contact: |
Longitudinal Early-onset Alzheimer’s Disease Study (LEADS)The Longitudinal Early-onsetAlzheimer's Disease Study (LEADS) is a non-randomized, natural history,non-treatment study designed to look at disease progression in individuals withearly onset Alzheimer's disease (EOAD). Clinical/cognitive, imaging, biomarker,and genetic characteristics will be assessed across two cohorts: (1)individuals with cognitive impairment and (2) cognitively normal controlparticipants. The primary objectives of the LEADS study are to: collectlongitudinal assessments and biomarker data; to compare baseline andlongitudinal cognitive and functional characteristics between cognitivelyimpaired and cognitively normal individuals, and EOAD and Late OnsetAlzheimer's Disease (LOAD) individuals from the Alzheimer's DiseaseNeuroimaging Initiative (ADNI); and to study the associations of longitudinalclinical and cognitive assessments with multimodal imaging and biofluid markersthat capture different elements of the AD pathophysiological cascade. Who Can Participate?Inclusion Criteria (Cognitively Impaired Cohort Only):
Inclusion Criteria (Cognitively Normal Cohort Only):
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Effects of device-assisted practice of activities of daily living in a close-to-normal pattern on upper extremity motor recovery in individuals with moderate to severe strokeIntervention study on hand and arm function in individuals with stroke
Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Randomized Controlled Trial of a Mindfulness-based Intervention in a Federally Qualified Center (FQHC)Northwestern University and Near North Health are currently recruiting participants for a research study to understand if mind and body approaches such as breathing techniques, mindfulness meditation, and gentle yoga work to improve stress. Up to $110 in compensation for full participation! Participants will either be assigned to receive an 8-week, 90 min per session group or to the wellness check-in group. For more info, please call 773-683-1275.
Who Can Participate?Inclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosisThe purpose of this study is to better understand the development of scleroderma-related lung fibrosis (ILD). We would like to investigate the role of macrophages and other important cells in the development of ILD. Macrophages are types of white blood cells important in the immune system. In healthy people, macrophages produce proteins that activate the immune system to assist in tissue repair. However, there is evidence that in people with scleroderma, the macrophages behave abnormally and contribute to scarring in the lungs.
Patients who participate in this study will:
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00207083 Click to Copy URL to Clipboard systemic sclerosis scleroderma interstitial lung disease ILD SSc-ILD fibrosis SSc endoscospy bronchoscopy
For questions about this study, contact: |
A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of Sparsentan, A Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis(ACTIVE, NOT RECRUITING) This is a randomized, multicenter, double-blind, parallel, active-control study. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor agonist. The active control is irbesartan. Patients who meet eligibility criteria will require wash out from renin-angiotensin-aldosterone system (RAAS) blockers, if applicable prior to their first dose of study drug. Patients will be randomly assigned in a 1:1 ratio to receive either sparsentan or active control (irbesartan).
Who Can Participate?Inclusion Criteria:1. Primary FSGS 2. Male or Female aged 18-75 years 3. Urine protein/creatinine ratio ≥ 1.5 g/g 4. Estimated glomerular filtration rate (eGFR) ≥ 30 5. Blood pressure criteria: ≥100/60 mmHg and ≤160/100 mmHg 6. Women of child bearing potential must agree to the simulataneous use of 2 medically accepted methods of contraception from randomization until 90 days after the last dose of study medication. Males, unless surgically sterile, must agree to use highly reliable methods of contraception from randomization until 90 days after the last dose of study medication. Exclusion Criteria: 1. Secondary FSGS 2. History of type 1 diabetes, uncontrolled type 2 diabetes, organ transplantation, heart failure (Class II-IV), malignancy, significant valvular disease, or alcohol/substance abuse. 3. History of significant cerebrovascular disease and/or coronary artery disease within 6 months 4. Body Mass Index (BMI) > 40 3. Females who are pregnant, plan to become pregnant through the course of the study, or are breastfeeding. Males who plan to father a child during the course of the study. Principal Investigator, Study ID, Keywords focal segmental glomerulosclerosis fsgs glomerulonephropathy glomerulosclerosis primary fsgs primary focal segmental glomerulosclerosis
For questions about this study, contact: |
A pragmatic trial of two strategies for implementing an effective eHealth HIV prevention program (Keep It Up! 3.0)We would like to reach about 250 – 500 people. Our eligibility criteria: (1) 18 – 29 years old, (2) HIV-negative, (3) male assigned at birth & currently identify as male, (4) live in one of 22 counties (please see counties below) in the USA.
state county AZ Maricopa County TX Dallas County TX Bexar County TX Travis County MI Wayne County PA Allegheny County MA Suffolk County CA
San Bernardino County NJ Essex County NY Nassau County AL Jefferson County VA Arlington County WA Snohomish County CA Fresno County TN Shelby County CT Hartford County MO Jackson County OH Hamilton County WA Pierce County MO St. Louis city DE New Castle County FL Lee County
Who Can Participate?Keep It Up! (KIU!) is an online, interactive program for gay, bisexual, and queer men that has been proven by the CDC to be effective at reducing the risk for HIV and sexually transmitted infections (STI). KIU! uses a variety of content (e.g., web-series, animation, activities) to encourage healthy relationships and increase sexual health knowledge through information on topics such as pre-exposure prophylaxis (PrEP), Undetectable = Untransmittable (U = U), and sexual agreements with partners. The content is divided into five episodes that each take approximately 20 minutes to complete.By joining KIU!, you will receive FREE at-home HIV & STI kits, a $10-$25 gift card for completing the first three episodes, entry to $200 raffle prizes, and other awesome goodies! Your participation will help inform the development of future programs and services for young men.You may be eligible to participate if:• You are between the ages of 18–29• You are a man who has sex with men• You are HIV-negativeIf you are interested in finding out if you are eligible for KIU!, please click the link below to complete the registration form.https://ikeepitup.isgmh.northwestern.edu/register/new?link=25Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Gut Microbial remodeling with Resistant Maltodextrin for motor and non-motor symptoms in Parkinson's disease: safety and tolerability study.The objective of this study is to examine thesafety and tolerability of resistant maltodextrin (RM), a prebioticnon-digestible fiber, and its effect on the gut microbiome, as well as motor and non-motorsymptoms, in Parkinson's Disease.
We will conduct a randomized, parallel-groupdouble-blinded controlled trial assessing resistant maltodextrin to placebo. You will be randomized (like a coin flip) toreceive either resistant maltodextrin or maltodextrin to take once a day in themorning for 4 weeks. Participation in this research study lasts 6-7 weeks and includes 3 in-person visits and 4 phone assessments. Who Can Participate?You may be eligible if you:Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Project 1, Adaptations of the brain in chronic pain with opioid exposureIn this project, we will study brain reorganization and behavioral responses in chronic pain with opioid exposure. Chronic back pain (CBP) is the most prevalent chronic pain condition in the US. Opiates are commonly prescribed to treat CBP; as such, these patients are a primary contributor to the opioid epidemic. Although millions of people with CBP regularly use opioids, little is known about the impact of long-term opioid use on the chronic pain brain. Through pain tracking, MRI scans, and various other methods, this study will look at understanding the effect of long-term opioid use on the chronic pain brain.
Who Can Participate?Must have a history of low back pain for a minimum of 6 months with or without signs and symptoms of radiculopathy Male or female, age 18 years or older Must be in generally stable health Must have a smartphone that will allow downloading of the pain app Must be on regular opioid or NSAID therapy for at least 3 monthsPrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Wearable sensors and video recording for children (birth to 24 months) to monitor motor developmentThe purpose of this study is to test flexible body-worn sensors and video technology to provide high-resolution measures of motor development in infants, starting from a very young age and continuing up to 2 years of age. This study will enroll up to 200 infants: 100 infants expected to have typical motor development and 100 infants at risk of atypical motor development (based on clinician diagnosis or risk factors such as prematurity, neonatal hypoxic ischemic encephalopathy, neonatal stroke, etc.). During each study visit, sensors will be placed on the legs, arms, chest, and head using soft bandage wraps or a gentle adhesive. The sensors will record the child’s movements in various postures and tasks. Their movements will also be recorded on video. These measurements will be completed at the approximate ages of 1-2 weeks, 1 months, 3 months, 6 months, 9 months, 1 year, and 2 years old. Each study visit will take about 1-2 hours. Compensation will be provided. If ever it’s too difficult to travel to one of these locations, another option is that we can come to you, and do a study visit at your home. Who Can Participate?Infant must meet the following criteria:
Principal Investigator, Study ID, Keywords STU00207900 Click to Copy URL to Clipboard infant cerebral palsy atypical motor development typical motor devleopment video recording wireless sensor
For questions about this study, contact: |
The Collaborative, National Quality and Efficacy Registry (CONQUER)The CONQUER Registry will enable researchers to:
Who Can Participate?Patients must: 1. Be 18 years of age and older 2. Have a confirmed diagnosis of systemic sclerosis (meeting the 2013 SSc ACR/EULAR criteria) 3. Have had symptoms of SSc for less than 5 years (other than Raynauds - it is okay if this has been going on for greater than 5 years) Principal Investigator, Study ID, Keywords STU00207506 Click to Copy URL to Clipboard For questions about this study, contact: |
Brain pathophysiology of osteoarthritis painThis research study is being done to better understand the causes of knee pain in people with osteoarthritis, and to identify factors that lead to persistent pain after total knee replacement or recovery of knee pain following a total knee replacement. We are also trying to better understand the changes in brain function, senses, personality and performance abilities after a total knee replacement surgery. Participants will be enrolled in the study for about 13 months and will undergo up to 3 MRI scans of their brain.
Who Can Participate?Must have a history of osteoarthritis in a knee and have elected to undergo total knee replacement surgery (TKR) in the knee. Or may have a history of osteoarthritis in a knee and have not elected to undergo a TKR. Must be 40 years or older and be in generally stable health. Must have a smartphone that will allow downloading of a pain app. If female, must be post-menopausal for at least one year or practicing an accepted, highly effective method of contraception or abstinence and plan to continue during the course of the study.Principal Investigator, Study ID, Keywords STU00207973 Click to Copy URL to Clipboard For questions about this study, contact: |
AF STOP: AF Substrate as an Outcome and Predictor of successful AF ablationTo improve the understanding of factors associated with the atrial myopathy in people with AF or people at risk for developing AF
Who Can Participate?Primary Inclusion Criteria:
Primary Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00207885 Click to Copy URL to Clipboard For questions about this study, contact: |
Real-time Wideband Cardiac MRI for Patients with a Cardiac Implantable Electronic DeviceThis study aims to capture a better image of the heart using MR imaging. This enables comprehensive evaluation of the heart, including cardiac function, perfusion, edema, and scar/fibrosis. Who Can Participate?eGFR<45 (good kidney function) Principal Investigator, Study ID, Keywords STU00207728 Click to Copy URL to Clipboard For questions about this study, contact: |
PK and Safety of Commonly Used Drugs in Lactating Women and Breastfed InfantsWe are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of that drug is consumed by breastfed infants.
Principal Investigator, Study ID, Keywords STU00208328 Click to Copy URL to Clipboard For questions about this study, contact: |
The effect of inflammatory bowel disease flares on serum prostate specific antigenThis study will measure PSA values in men with IBD before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of the disease (rectal vs. other). Study findings may help men with IBD by identifying pitfalls in prostate cancer screening for this population and help to stratify and understand the effect IBD has on the prostatic milieu. By optimizing how men with IBD are screened for prostate cancer, future unnecessary healthcare encounters and expenditures may be reduced for this patient group.
Who Can Participate?Men with a confirmed diagnosis of inflammatory bowel disease (IBD) between the ages of 40-69 years old.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CalorieHarmony for ObesityThe purpose of this study is to learn about the factors that most influence participants in their ability to perform specific daily activities with varying intensity, while also measuring calorie expenditure. Using self-report questionnaires, we will collect a participant's medical history and determine their perceived ability to perform certain activities. We will also use data collected from wearable sensors to build a more accurate energy expenditure estimator. Participants are asked to put on two wearable devices as well as a mask to measure breathing and perform 12 specific physical activities in the lab. The in-lab session lasts 3 hours. Lastly, participants will be asked their opinion about the wearability of the devices. Who Can Participate?This study is looking for men and women who:
Principal Investigator, Study ID, Keywords STU00208545 Click to Copy URL to Clipboard For questions about this study, contact: |
CLASP IID/IIFThe objectives of this pivotal clinical trial are to evaluate the safety and effectiveness of the PASCAL System for transcatheter mitral valve repair compared to the MitraClip system in the treatment of patients with symptomatic degenerative mitral regurgitation (DMR) and who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team.
Who Can Participate?Primary Inclusion Criteria: Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 18B05: A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated BreastThe benefits of anti-estrogen medications taken by mouth as pills (such as tamoxifen) are well-proven to reduce the risk of breast cancer in studies with more than 10 years of follow up. However, because tamoxifen is taken by mouth, it circulates through the whole body and may cause harmful effects to other organs. When tamoxifen is taken by mouth, it is broken down by the liver into two main active forms, one of which is 4-hydroxytamoxifen, also called 4-OHT. Tamoxifen is approved by the Food and Drug Administration (FDA) while 4-OHT is not and is, therefore, considered investigational. However, 4-OHT has anti-cancer activity, and has been developed as a quick drying medicated gel that can be applied to the breast skin. Early results from two previous studies show that 4-OHT gel, when applied to the skin, gets into the breast and blocks breast cancer cell growth as effectively as oral tamoxifen. Unlike oral tamoxifen, the gel is concentrated in the breasts and therefore very little tamoxifen reaches the blood or other parts of the body. Also, some women lack the proteins that are responsible for the break-down of tamoxifen. It is possible that the use of 4-OHT gel will be more effective than oral tamoxifen in these women.
Who Can Participate?Patients who had radiation for breast cancer in one breast and their other breast has not undergone radiationPrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea.The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy (GDMT), who have central sleep apnea (CSA).
Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Characterization of the microbiome in cutaneous T cell lymphomaThe purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00209226 Click to Copy URL to Clipboard For questions about this study, contact: |
Northwestern TIPS Research StudyALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions.
Who Can Participate?Undergoing a Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement Subjects over the age of 18 able to provide consent or have a legally authorized representative to provide consent in the event the subject is unable to consent due to a transient clinical condition Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug). Who Can Participate?You could be in this study if:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin ConditionsThe purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience. Additionally, researchers are interested in:
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00209616 Click to Copy URL to Clipboard Immune-mediated Inflammatory Skin Condition Atopic Dermatitis Psoriasis Alopecia Vitiligo Hidradenitis Suppurativa
For questions about this study, contact: |
A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)The purpose of this study is to test your tumor tissue for certain biomarker (which may be the cause of your cancers, such as specific mutations in certain proteins). This will help determine your eligibility to participate in either matched sub-studies involving investigational agents that targets the specific mutated protein or alternatively to un-matched sub-studies. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Modulating stimuli intensity to improve clinical outcomes in aphasia treatmentA study is available for persons with aphasia The Shirley Ryan AbilityLab is conducting a research study that will help us understand how to better schedule speech and language therapy. If you should qualify, you will receive 10 hours of speech and language therapy. Therapy will be scheduled for either: a)two weeks (1 hour a day, 5 days a week) or b)five weeks (1 hour a day, 2 days a week) Who Can Participate?Diagnosis of aphasia from a single stroke More than 6 months since stroke onset At least 18 years old English-speaking before the stroke Principal Investigator, Study ID, Keywords STU00209618 Click to Copy URL to Clipboard For questions about this study, contact: |
A Prospective, Multicenter Study of Artemis a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage (MIND)This study addresses a type of bleeding in the brain called an intracerebral hemorrhage (ICH). This is a serious medical condition and the rate of death resulting from it is very high. Many of those who survive are disabled. The amount of brain injury seems to be related to the size of the blood clot that forms in the head from the bleeding. The purpose of this study is to better understand how well and how safely the Artemis Neuro Evacuation Device (Artemis Device) impacts patients that have bleeding in their brain and compare that with patients who are not treated with the Artemis Device. The Artemis Device, used with the Penumbra Aspiration Pump, is designed to help remove blood and blood clots from the brain. This study will help to determine if more patients survive and have a better recovery after removing an ICH than if it wasn’t done.
The Artemis Device is a medical device that has been cleared by the United States Food and Drug Administration (FDA) for controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in combination with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration System. The device is commercially available in the United States. Who Can Participate?Patients with bleeding in the brain causing a type of stroke (intracerebral hemorrhage or ICH) may be eligible for this study. Principal Investigator, Study ID, Keywords ICH Intracerebral hemorrhage Minimally invasive surgery Stroke MIS Neuroendoscopy Clinical trial Brain hemorrhage Brain bleed
For questions about this study, contact: |
NU MTBC 18M02: International Melanoma Tissue Bank Consortium Site at Northwestern UniversityThe purpose of this research study is to create a MTBC biorepository (the “MTBC Biobank”) of human biospecimens (the “Biospecimens”) and medical and health history information, for example, test and treatment results, age, gender, history of sun exposure (the “Annotating Data”). This part of the project is called the “Biobanking Study”. The second purpose is for MTBC to provide the Biospecimens and/or Annotating Data from the MTBC Biobank to researchers around the world for them to use in specific studies in order to study melanoma (“Future Use Study). Melanoma is a lethal form of skin cancer and more research is necessary to help scientists to understand what causes it, how to diagnose it, how it can be prevented, and how it can be treated. To do this research, scientists need biospecimens (like biopsied tissue and blood samples) from people who have been diagnosed with melanoma and other skin disorders. This study will help scientists learn about melanoma and the projects being conducted on behalf of the Melanoma Tissue Bank Consortium(“MTBC”).
Who Can Participate?We are asking you to take part in this research study because you have melanoma or another skin disorder.Your participation is completely voluntary. You may choose not to take part.Your decision to sign this informed consent and authorization form in order to participate in the Biobanking Study and to allow the use of your Biospecimens and Annotating Data in a Future Use Study will not change the treatment you receive for your skin disorder. Principal Investigator, Study ID, Keywords STU00209847 Click to Copy URL to Clipboard For questions about this study, contact: |
Alliance A041703: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-negative CD22-positive B-lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory DiseaseThepurpose of this study is to test the good and bad effects of the combination ofdrugs called inotuzumab ozogamicin and blinatumomab. The study doctors hope tolearn if the combination of study drugs will cause cancer to go away andprevent leukemia from coming back.
Inotuzumabozogamicin and blinatumomab have already been approved by the FDA to treatrelapsed or refractory ALL as well as other cancers. The combination ofinotuzumab ozogamicin and blinatumomab is considered investigational for thisstudy.
Participantswith ‘untreated ALL’ or ‘relapsed or refractory ALL’, will get a combination ofdrugs called inotuzumab ozogamicin and blinatumomab. This combination of drugsis known to be effective in patients with relapsed or refractory leukemia, butit is not the usual chemotherapy for patients with ‘untreated ALL.’Participants will also get a drug called methotrexate to prevent cancer cellsfrom entering the central nervous system.
Who Can Participate?Diagnosed with Acute Lymphoblastic Leukemia (ALL) that is untreated or has come back. Participants with untreated ALL must be 60 years of age or older. Participants with ALL that has relapsed or come back must be at least 18 years of age or older.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic DecompensationNon-Alcoholic Steatohepatitis (NASH) is a liver disease that isassociated with an increased amount of fat and inflammation in the liver. Having NASH increases the chances of gettingheart disease. In time, liver cells may be so badly damaged that scar tissueforms (fibrosis) within the liver where healthy cells used to be. When this happens, your doctor might diagnoseyou with “NASH fibrosis”. When enoughscarring happens and the liver gets even more diseased, the liver becomescirrhotic and stops working which causes serious complications in your body. NASHfibrosis can only be accurately diagnosed by taking a sample of tissue called a“biopsy” directly from the liver. There are currently no approved medicines forNASH.
MadrigalPharmaceuticals, Inc. (the Sponsor of the study) is running this medical researchstudy to see if a test medicine named MGL-3196 (resmetirom), will help in thetreatment of NASH fibrosis and also to find out how safe it is to use in peoplewith NASH. MGL-3196 is an ‘investigational’ drug, i.e., it is not approved foruse by the U.S. Food and Drug Administration (FDA) MGL-3196 was previouslytested in a 9-month study in patients with NASH and was found to be safe andwell-tolerated, caused a decrease in the amount of fat in the liver, and causeda decrease in NASH compared with placebo patients (placebo patients arepatients that did not receive MGL-3196 (“active drug”) in the 9-month study).
Who Can Participate?You may qualify for this study if you have been diagnosed with NASH or are suspected ofhaving NASH (fatty liver disease).
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)This study is being done to answer the following questions:1. Is adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plusobinutuzumab) better, the same as, or worse than the usual treatment alone for untreatedolder patients with CLL?2. Can patients who have no detectable CLL after a year of receiving the usual treatmentplus the new anti-cancer drug discontinue therapy?
Who Can Participate?Some of the eligibility criteria include: - Participants must have intermediate or high-risk chronic lymphocyticleukemia that has not been treated before - Participants must be 18 or older - Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Yttrium-90 Radiation Lobectomy: Dose Optimization and Prediction of FLR Hypertrophy to Enable Resection of Hepatic MalignanciesIn the study, there will be many patients, like you, with hepatocellular carcinoma (HCC) who are eligible to receive a treatment called Y90 radioembolization and who may also be liver resection candidates. Y90 radioembolization is a non-invasive, out-patient treatment that uses radioactive beads (microspheres), which are tiny glass particles that are loaded with radiation. The beads are injected into an artery of the liver that supplies blood to the tumor(s). The beads flow to the tumor(s) and become trapped inside. The beads release the Y90 radiation inside the tumor(s). Liver resection is used to remove the part of the liver that has the liver tumor(s). It has been shown that Y90 radioembolization can increase the untreated liver’s size and volume. Patients with HCC may be liver resection candidates if they have a large enough liver. The purpose of this research is to determine if there is an ideal Y90 dose to increase liver volume. This research may help determine the best Y90 dose for future patients who need a larger liver to have a liver resection. If you participate in this study, you will have standard-of-care Y90 radioembolization as well as study-specific imaging and two optional liver biopsies. You will participate in the study for up to 3 months. Your health status will continue to be followed for up to 5 years. Patients enrolled in the study will receive up to $195.00 for their participation. Who Can Participate?You are eligible to participate in this study if:1. You are an adult 18 years of age or older 2. You have been diagnosed with hepatocellular cancer and may be a liver resection candidate to remove your disease Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Natural history study of ALS and other motor neuron disordersThis is one of the largest non-interventional observational study of patients with ALS and other motor neuron disorders. It is both prospective and retrospective. It does not require blood sampling. Who Can Participate?1. A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS. 2. Other motor neuron disorders, including but not limited to spinobulbar muscular atrophy (SBMA, Kennedy’s disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP). 3. Excluded are any disease that does not meet criteria for any motor neuron disorder Principal Investigator, Study ID, Keywords STU00209860 Click to Copy URL to Clipboard For questions about this study, contact: |
Parkinson’s Foundation Genetic Research InitiativeThe main objective of this study is to assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of their clinical care for People with Parkinson’s disease (PWP). Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
GSO 18-01 (REDUCE PAS)This study is enrolling patients who have a patent foramen ovale (PFO), have had a stroke of unknown origin (cryptogenic stroke), and whose doctor has decided they are a candidate for a transcatheter procedure (a procedure performed through a flexible tube inserted through a narrow opening into a small incision in the skin) to close their PFO. A PFO is a common opening in the wall (septum) between the two upper chambers (the right and left atria) of your heart. In most cases, this opening closes around the time of birth. If the opening remains after birth, it can allow the blood to mix in the two upper chambers of the heart. This post-market study will look at closing the PFO to reduce the risk for another stroke using a market-approved medical device called a septal occluder. This device is called the ‘GSO device’ in this description. The GSO device is a minimally invasive device intended for the closure of a PFO using cardiac catheterization. It is a permanent implant consisting of a near circular wire frame covered with thin material. The soft, conformable material, invented and manufactured by Gore, has been used in open-heart surgery for more than 40 years and has been shown to be safe in implanted medical devices. The wire frame is made of a nickel-titanium metal alloy called nitinol with a platinum core (so that it may be seen on X-ray images).
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
BTCRC HN17-111: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinomaThis study is being done to study two investigational drugs called pembrolizumab and goserelin to see if they shrink your cancer or stop it from growing.
Who Can Participate?You may be eligible for this research study if you have salivary gland carcinoma that has grown or has come back after treatment.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr [PDIGREE]This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? We are doing this study because we want to find out if this approach isbetter or worse than the usual approach for your advanced kidney cancer. The usual approach is defined as care mostpeople get for advanced kidney cancer. Who Can Participate?-Participants must be 18 years of age or older-Participants must be diagnosed with advanced kidney cancer Principal Investigator, Study ID, Keywords kidney cancer Renal Cell Carcinoma Metastatic Cabozantinib Nivolumab Ipilimumab Immunotherapy Chemotherapy
For questions about this study, contact: |
Parkinson's Disease: Intervening Early Concerning Employment (PIECE) Aims 2 and 3Partner with our study team to check in about your Parkinson's and work twice a year for three years. Every six months, you'll have a phone call and fill out an online survey where you'll answer questions about your Parkinson's, symptoms, and work status. Altogether, it'll take about 45 minutes each time, and you'll receive $25 for each six-month check-in.
Who Can Participate?You are eligible to participate if you meet all of these main criteria:
Principal Investigator, Study ID, Keywords STU00210681 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) NCI CIRB NRG GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumThe purpose of this study is to compare the treatment of carboplatin/paclitaxel and letrozole hormonal therapy to letrozole alone. The use of the hormonal therapy drug letrozole without chemotherapy may shrink or stabilize cancer in the same way that chemotherapy also does, but without the added side effects of chemotherapy. Letrozole is a drug called an aromatase inhibitor, which indirectly stops the body from producing estrogen. This study will investigate if this approach is better, the same, or worse than the usual approach. In order to determine if the use of letrozole alone helps to improve treatment for patients with low-grade serous ovarian or peritoneal cancer compared to combined chemotherapy and letrozole, half of patients in this study will receive letrozole with paclitaxel/carboplatin and the other half will receive letrozole alone. The study doctors will be looking to see if the letrozole alone prolongs the time cancer is in remission, or the duration of time participants are alive after treatment. Letrozole is approved by the FDA for breast cancer, but is not FDA approved for ovarian cancer and is therefore considered experimental in this setting. Participants will get either the combination of paclitaxel and carboplatin for four and a half months followed by letrozole or letrozole alone. Patients who are assigned to letrozole monotherapy will continue taking the letrozole for as long as they are tolerating the drug (i.e., have not developed any allergies or severe side effects with the medication) and have not experienced a recurrence or progression of their disease. After participants finish their study treatment, their doctor and study team will continue to follow their condition and watch for side effects during clinic visits or by phone. Participants will be checked every 3 months for the first 3 years after treatment. After that, this will happen every 6 months for two years. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Project 1, Adaptations of the Brain in Chronic Pain with Opioid ExposureIn this project, we will study brain reorganization and behavioral responses in chronic pain with opioid exposure. Chronic back pain (CBP) is the most prevalent chronic pain condition in the US. Opiates are commonly prescribed to treat CBP; as such, these patients are a primary contributor to the opioid epidemic. Although millions of people with CBP regularly use opioids, little is known about the impact of long-term opioid use on the chronic pain brain. Through pain tracking, MRI scans, and various other methods, this study will look at understanding the effect of long-term opioid use on the chronic pain brain.
Who Can Participate?Must have a history of chronic pain for a minimum of 6 months with or without signs and symptoms of radiculopathy. Male or female, age 18 years or older. Must be in generally stable health. Must have a smartphone that will allow access to a pain diary website. Must be on regular opioid therapy for at least 3 months. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) NCI CIRB: Alliance A071701: Genomically-Guided Treatment Trial in Brain MetastasesThe purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes.
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2) (Protocol #: B01-04)A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Who Can Participate?Primary Inclusion Criteria:
Primary Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease (Protocol# 254PD101)The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.
Who Can Participate?2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia. 3. Not on any medication for PD or on stable therapy for 8weeks prior to screening. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Pathogenesis of Heart Failure with Preserved Ejection Fraction in Chronic Kidney DiseaseHeart failure (HF) and chronic kidney disease (CKD) commonly coexist and increase risks of hospitalizations and mortality. Insights into mechanisms of concurrent HF and CKD are urgently needed to improve outcomes. Critical barriers to therapeutic breakthroughs for patients with CKD and HF include lack of in-depth understanding of early changes in cardiac function and poor knowledge of CKD-specific mechanisms for both HF and heart failure with preserved ejection fraction (HFpEF). Who Can Participate?Inclusion Criteria:Inclusion criteria for all: >18 years of age Inclusion criteria for CKD: eGFR 20-60 ml/min/1.73m2 on stable doses of diuretics and/or angiotensin converting enzyme inhibitor or angiotensin receptor blocker, unless contraindicated. Inclusion criteria for the non-CKD group: eGFR >60 ml/min/1.73m2 and UACR <30 mg/g. Exclusion Criteria: Exclusion criteria for all: presence or history of diabetes, coronary revascularization within the last 6 months, hemodynamically significant valvular disease, significant lung disease requiring home oxygen, angina, non-revascularized myocardial ischemia, systolic BP <100 or >180 mmHg, pregnancy, clinical HF symptoms, history of systemic disease processes that can cause HFpEF, such as amyloidosis or sarcoidosis, any musculoskeletal or chronic condition that will interfere with completion of cardiac testing, or active cancer, immunosuppressive therapy. Participants will also be excluded from continuing in the study if the pre-exercise echocardiogram demonstrates a reduced ejection fraction ≤50% or hemodynamically significant valvular disease at the baseline study visit. Exclusion criteria for the non-CKD group: eGFR <60 ml/min/1.73m2 and UACR >30 mg/ Exclusion criteria for CKD: currently on sodium glucose cotransporter 2 inhibitor (SGLT2i) therapy, SGLT2i hypersensitivity, liver disease, ALT/AST> 3x normal, history of recurrent urinary tract infections (in the opinion of the investigator) or a urinary tract infection in the last 3 months. Principal Investigator, Study ID, Keywords STU00210997 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) Social Processing in Remitted Adolescent DepressionParticipate in a paid research study at Northwestern University Feinberg School of Medicine! We are actively recruiting for study on mood and phone use. Teens age 13-18 who use iPhones or Androids may be eligible. Teens may earn up to $519. Parents will also be compensated $25 for their time.
The study will consist of four total sessions – three virtual and one in person. The initial video call and in-person visit will take about 4 hours each. The remaining two video calls will take place approximately 6 and 12 months after the start of the study and will take about 2 hours each. Participation will also involve the use of a study-specific smartphone app throughout the 12-month study period.
Interested teens/parents can email us directly at NUCU@northwestern.edu or complete the contact form at https://sites.northwestern.edu/nearlab/participate/.
IRB Study Code: STU00211494 /Principal Investigator: Stewart Shankman, Ph.D. Who Can Participate?Eligibility Criteria:
Principal Investigator, Study ID, Keywords STU00211494 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) NCI CIRB ECOG-ACRIN 2182: A Randomized Phase II Study of De-Intensified ChemoRadiation for EarlyStage Anal Squamous Cell Carcinoma (DECREASE)This study will helpthe study doctors find out if this different approach is the same as the usualapproach. To decide if it is aseffective, the study doctors will be looking to see if the study approach showsat least the same results as the normal approach. This study has 2 studygroups. · Participants in groupA will get the standard dose of chemoradiation therapy: this includesMitomycin-C and 5-Fluorouracil or Capecitabine, as well as radiation. Therewill be 28 radiation treatment sessions in this group. · Group 2 (Arm B) Participants in group2 you will get the lower dose of chemoradiation therapy: this includesMitomycin-C and 5-Fluorouracil or Capecitabine, as well as radiation. Therewill be 20 or 23 radiation treatment sessions in this group, depending on thesize of the tumor. Who Can Participate?Participants who are 18 years of age or older with anal cancer will beinvited to participant in this study.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG KO-MEN-001: A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid LeukemiaThe main purpose of this study is to determine the tolerability and the potential safety of a new drug called KO-539 in treating your cancer.
Who Can Participate?You may be eligible to take part in this research study if you have a type of cancer called acute myeloid leukemia (AML) that has not responded to standard therapy.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
RV Ischemia & Fibrosis in CTEPHThis study is enrolling patients who have been diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) and who are scheduled for a pulmonary endareterectomy (PEA) or balloon pulmonary angioplasty (BPA) procedure for treatment. CTEPH is high blood pressure in the arteries in the pulmonary system (lungs) caused by clots. Over time the clots typically leave scar tissue (fibrosis) in the arteries and lead to poor blood supply to the heart. In patients with CTEPH symptoms of heart failure commonly result from dysfunction (not working correctly) in the right ventricle (RV), or the chamber of the heart that pumps blood to the lungs. However, little is currently known about why or how that chamber of the heart becomes dysfunctional in patients with this condition. In another chamber of the heart, the left ventricle, it is known that elevated blood pressure in that chamber causes the development of diffuse fibrosis, or scarring between the muscle fibers, and a similar process may take place in the right ventricle of patients with CTEPH.
For this study a cardiac magnetic resonance imaging (MRI) stress test (also known as stress CMR) will be done to look at the RV in patients with CTEPH before and 6 months after treatment. A stress CMR is a specialized scan of the heart that examines fibrosis (scarring) and blood flow (perfusion) both at rest and under stress. A gadolinium contrast agent (MRI dye) is given to highlight the heart muscle in areas receiving a good blood supply. Areas receiving less blood do not highlight as well as the good areas, which can be an indicator of ischemic heart disease (undersupply of blood and oxygen to the heart). Principal Investigator, Study ID, Keywords STU00210998 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 19H08: Signal Transduction of Type I Interferons in Malignant CellsThis is a lab study of a group of diseases called myeloproliferative neoplasms (MPN). MPN is abnormal blood coagulation (abnormal or irregular blood clotting) and includes polycythemia vera (PV) and essential thrombocytosis (ET). The purpose of this research is to learn more about how a drug called interferon stops the growth of MPN blood cells in the laboratory. Alpha-interferon is a natural protein present in the body in small amounts. Treatment with interferon is known to have significant activity in MPN, but the way that this drug works is not fully known.
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00211647 Click to Copy URL to Clipboard For questions about this study, contact: |
Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complicationsProstate cancer is the most commonly diagnosed malignancy in U.S. men. There are approximately 1 million prostate biopsy performed annually in the U.S. Almost all biopsies are performed as an office based procedure in under 15 minutes. The precision of biopsy has improved over the last decade with the introduction of MRI guidance/targeting of suspicious lesions within the prostate. However, significant limitations remain with this approach, including a significantly increasing risk of post-biopsy infection. This arises because more than 97% of all prostate biopsy are performed via a transrectal approach that introduces rectal bacteria with each pass of the biopsy needle into the sterile urinary tract. The current risk of post-transrectal biopsy infection, even with antimicrobial prophylaxis, is high at approximately 7% overall with 3% (30,000 men) requiring hospitalization annually. Transperineal biopsy is an alternate approach that eliminates the direct introduction of bacteria from the rectum to the prostate. This approach, which is perfomed without antimicrobial prophylaxis, instead passes the biopsy needle through the perineal skin and pelvic floor. Transperineal biopsy has not been widely adopted for several reasons. Historically, it has been considered too painful for patients in the clinic and thus was traditionally performed under general anesthesia. The added time, inconvenience and cost has limited its national adoptance. Second, when transrectal biopsy was initially adopted over 40 years ago, antibiotic resistance of rectal flora was not a challenge. Beyond the potential for in-office transperineal biopsy to significantly reduce or eliminate biopsy infections, transperineal biopsy may also improve cancer detection: studies of transperineal biopsy (performed under general anesthesia) demonstrate higher detection rates for prostate cancer, particularly for anterior zone tumors, compared to transrectal biopsy. This is notable, as anterior tumors are difficult to sample with transrectal. Anterior tumors are also twice as likely to occur in African American men. In fact, our research demonstrates that some of the outcomes disparities in African American men may stem from an underdiagnosis of anterior prostate cancers. Although transrectal biopsy is used widely, it is associated with a significant and increasing risk of biopsy infections due to growing antibiotic resistance, highlighting the urgent need for a safer alternative approach to prostate biopsy. The study investigators have refined a transperineal approach under local anesthesia with MRI-targeting/guidance without the need for antibiotic prophylaxis. The investigators hypothesize that transperineal MRI targeted biopsy will: (1) largely eliminate post-biopsy infections and costly hospitalizations for urosepsis; (2) be performed in the office with similar discomfort and non-infectious complications compared to transrectal MRI targeted biopsy; and (3) have significantly better detection of prostate cancer. This multi-center randomized controlled trial will be conducted to evaluate in-office transperineal MRI targeted vs. transrectal MRI targeted biopsy, the current gold standard. This has transformative impact to change current standard of practice. Who Can Participate?This study will include allmen who are recommended to undergo prostate biopsy as part of routine clinicalcare.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
xIRB ALLFTD: ARTFL-LEFFTDS LONGITUDINAL FRONTOTEMPORAL LOBAR DEGENERATIONALLFTD is a comprehensive study targeting most varieties of frontotemporal lobar degeneration (FTLD). FTLD is a neurological disease that causes Frontotemporal Dementia (FTD) syndromes including Primary Progressive Aphasia (PPA) and Behavioral Variant Frontotemporal Dementia (bvFTD), among others. This study is an international multi-site study and Northwestern University is one of 19 sites. The overall goal of ALLFTD is to prepare for treatment trials in FTLD by focusing on several major activities: 1. Characterizing FTLD patients (including familial FTLD [f-FTLD] and sporadic FTLD [s-FTLD]) followed at expert centers who can potentially be available for treatment trials 2. Collecting comprehensive cognitive and behavioral assessment data, in addition to imaging, blood, and cerebrospinal fluid (CSF), with the following goals: o Identifying the best clinical measurements and biomarkers for following patients with FTLD in treatment trials o Identifying clinical measurements and biomarkers that indicate when a person with a high risk of developing FTLD due to a mutation will begin to have symptoms. 3. Sharing clinical data, images and biological samples from participants affected by FTLD with the scientific community to address additional scientific questions about FTLD Who Can Participate?ALLFTD includes symptomatic and “at-risk” participants. FTLD may be sporadic, with no known cause. It may also be familial, due to genetic mutations. We are still learning about mutations that cause FTLD, so a strong family history of FTLD is sufficient to enroll as: Familial FTLD (f-FTLD). You are eligible to enroll in the familial FTLD cohort if 1) you have a mutation in one of the three most common genes associated with FTD –microtubule associated protein tau (MAPT), progranulin (GRN), or chromosome 9 open reading frame 72 (C9orf72), regardless of whether you have symptoms or not, 2) you have a blood relative with a mutation in one of those genes, or 3) you have a strong family history of FTLD but no genetic mutation has been identified. Sporadic FTLD (s-FTLD). You are eligible to enroll in the sporadic cohort of the study if you have one of the following FTLD spectrum diagnoses: frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exercise: 80-85% HRmax. The endurance exercise will be 4 days per week for approximately 30 minutes per session for 18 months. Who Can Participate?-Diagnosis of Parkinson's disease for less than 3 years -Cannot be treated with any PD medication Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
TAMBE Pivotal AAA 17-01This study is enrolling patients who have an aortic aneurysm involving the visceral branch blood vessels (vessels that provide blood to the kidneys) that requires treatment. The aorta is a large blood vessel that carries blood away from the heart to organs in the rest of the body. This research study will look at treating thoracoabdominal or pararenal aneurysm disease with a new device design known as the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (the ‘Study Device’).The Study Device that will be used to treat the aneurysm is called a “stent-graft”. The Study Device combines a surgical graft material with an outer metal mesh-like form (stent). The nonmetal graft component of the Study Device is made of a soft, polymer material (ePTFE). This material is routinely and safely used for surgical procedures throughout the world today. The graft is surrounded on the outside with a metal frame made from an elastic metal (nitinol wire or stainless steel) bent into a wave pattern and shaped to fit the graft. The materials used in the Study Device are not investigational and have a long, safe history of performance in similar applications.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
REPAIR-MRThe purpose of this research study is to compare health outcomes of patients diagnosed with Primary MR who have their MV repaired with open heart surgery, which is the current standard treatment, to patients who have their Mitral Valve repaired with the MitraClip System. The MitraClip System uses a less invasive procedure to repair the mitral valve.
Subjects are asked to participate in this Study because they have moderate-to-severe or severe MR and it has been determined to have symptoms due to heart failure despite being treated with currently available therapies. MR occurs when the leaflets of the mitral valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart needs to pump more blood with each beat to push the same amount of blood forward. The Study will enroll approximately 500 subjects at up to 60 sites in Europe, United States, and Canada. The Study consists of two arms: Device Arm and Control Arm. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTSThis study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors.
Who Can Participate?Participants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone (Loma Linda)We are only recruiting patients who have not started their edaravone treatment. Location of study: Les Turner ALS Center at Northwestern Medicine, 259 E. Erie St., Lavin 19, Chicago, IL 60611. Who Can Participate?Inclusion: Either possible, probable, or definite ALS,predominantly lower motor neuron disease Predominantly upper motor neuron disease, orbulbar With or without cognitive involvement Willing to participate On no experimental treatment Ages 18 - 85 No prior exposure to Radicava On a stable dose of riluzole for 30 days or offriluzole Male or female Females of childbearing age must usecontraception Exclusion: Unstable medical illness Abnormal liver function (>2x ULN) Unlikely to survive for at least 26 weeks Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Angiotensin II for Distributive ShockAngiotensin II as a first-line vasopressor for distributive shock for heart transplant and left ventricular assist device implantation recipients: A Pilot Study Who Can Participate?Onset of distributive shock within 48 hours after heart transplantation or VAD placement at Northwestern Memorial Hospital Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
TOPAZ TRIAL OF PARKINSONS AND ZOLEDRONIC ACID A Randomized Placebo-controlled Trial of Zoledronic Acid for PreventionThe Topaz study will test if a medicine call zoledronic acid can prevent fractures in people with Parkinson's Disease. A team of doctors who are experts in bone health and Parkinson's Disease are leading the study. the use of zoledronic acid in this study is investigational.
Who Can Participate?Interested participants must meet the following eligibility criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CPIRA-2Finding a way to reduce pain is consistently named as one of the top priorities for patients with RA. Previous research has found that this ongoing pain may in part be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will identify factors that lead to the development of pain centralization, so that in future studies we can learn more about how to prevent the development of this kind of chronic pain in RA. Participants will complete a total of 3 study visits (baseline, 3 months and 12 months). At each study visit, participants will have a physical exam, have blood drawn, answer questionnaires, and undergo quantitative sensory testing to assess responses to pressure and coldness. A subset of patients who are interested and eligible will undergo a brain MRI at baseline and the 12-month study visit. Participants will receive $50 for the completion of each study visit and an additional $100 for completing each MRI. Who Can Participate?Study participants must be 18 years or older with active Rheumatoid Arthritis and symptoms starting no more than one year prior to study participation. Participants taking pain medications must be on a stable dose for at least 3 months. Patients with Raynauds requiring treatment are not eligible to participate. Participants must refrain from taking prednisone (greater than 10 mg) or opioids within 24 hours of their study visit.Principal Investigator, Study ID, Keywords STU00211593 Click to Copy URL to Clipboard For questions about this study, contact: |
Sensory-specific peripheral stimulation for tremor managementHealthy Participants: The Shirley Ryan AbilityLab is seeking healthy adults to study the effect and ability of muscle stimulation to reduce tremor. We are seeking Healthy adults to participate as a comparison group. During the study, participants will be stimulated with non-invasive muscle electrostimulation and/or transcranial magnetic stimulation (TMS) while seated in a comfortable chair. To measure muscle activity, electrodes will be attached to the forearm. In one visit, magnetic resonance imaging (MRI) will be used to observe your brain. Clinical Participants: The Shirley Ryan AbilityLab is seeking patients with Parkinson’s disease or Essential Tremor, to study the effect and ability of muscle stimulation to reduce tremor. Exclusion criteria include epilepsy/seizures and incompatibility with MRI or transcranial magnetic stimulation (TMS). During the study, participants will be stimulated with non-invasive muscle electrostimulation and TMS while seated in a comfortable chair. To measure tremors, sensors will be placed over the wrist, elbow and shoulder and in some visits to the head. In two visits, magnetic resonance imaging (MRI) will be used to observe the brain. Who Can Participate?Healthy Participants: (recruitment closed)
Clinical Participants:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Cure GlomerulonephropathyCure Glomerulonephropathy (CureGN) is an NIH-sponsored cohort study of patients with biopsy-proven glomerular disease. Participants will be followed longitudinally with annual blood/urine collection to better understand the causes of disease, response to therapy, and disease progression. There is no study drug/intervention. Who Can Participate?
Biopsy-proven Membranous, Minimal Change, FSGS, or IgAN within 5 years of study enrollment Principal Investigator, Study ID, Keywords STU00212470 Click to Copy URL to Clipboard FSGS IgA Nephropathy IgAN Membranous Nephropathy Minimal change disease glomerulopathy glomerular disease
For questions about this study, contact: |
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL, Protocol #: J3Z-MC-OJAA previously called PRV-PD101)PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain).
Who Can Participate?1. 40-75 years of age. 2. Diagnosis of PD with H&Y 3-4. 3. On stable PD therapy for 8 weeks prior to baseline. 4. At least 1 GBA gene mutation. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The role of the cortex and brainstem in motor preparation for proximal and distal upper extremity movementsThis study will take place over 3, each lasting about 4 hours. First we will do a hearing screening and right handedness screening to make sure you are a good fit for out study. For this study, you will be required to place your arm in a robot that tracks your movement, and then perform arm lifting and hand opening movements. We will measure your muscle placing electrode stickers on your arm, and measure your brain activity by asking your to wear a close fitting mesh cap. During one of the visits, we will also ask you to get an MRI to take a picture of your brain. The MRI scan will take between 5 and 10 minutes. Additionally, you will receive free parking for each visit as well as monetary compensation for your time. Please contact us to learn more information about the study, or if you are interested in participating.
Who Can Participate?In order to be in this study you must be a right-handed individual between the ages of 18-80 years old. We also ask that you have normal hearing and arm function.Principal Investigator, Study ID, Keywords STU00212195 Click to Copy URL to Clipboard For questions about this study, contact: |
NU COVID-19 MSK20H04: Examining COVID19 Course and Outcomes in Patients Previously Diagnosed with Chronic Lymphocytic Leukemia (CLL)This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter.
Primary Aim: To determine the 28-daymortality rate from the time of COVID 19 diagnosis for CLL patients infectedwith SARS-CoV2 at MSKCC and other institutions. Secondary Aims: To describe baseline characteristics, prior and current CLL directed therapies, COVID19 clinical course and outcomes for CLL patients infected with SARS-CoV2. To examine relationships between CLL directed therapy and COVID19 disease course and outcomes. To examine current practices regarding management of CLL directed therapy in CLL patients infected with SARS-CoV2. Who Can Participate?Chronic lymphocytic leukemia (CLL) patients diagnosed with COVID19.Principal Investigator, Study ID, Keywords STU00212455 Click to Copy URL to Clipboard For questions about this study, contact: |
NU FC19L02: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smokedThe purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in patients with sensitizing EGFR mutation induced NSCLC or patients with NSCLC who are never-smokers as compared to the combination without Tecentriq.
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. A computer will by chance assign patients to one of the two arms in the study. This is called randomization. •Arm A: Carboplatin + Pemetrexed + Avastin + Tecentriq •Arm B: Carboplatin + Pemetrexed + Avastin Arm A: Participants will receive carboplatin, pemetrexed, Avastin and Tecentriq for 4 cycles in the treatment phase, followed by pemetrexed, Avastin and Tecentriq for the rest of the cycles, called the maintenance phase. Arm B: Participant will receive carboplatin, pemetrexed and Avastin for 4 cycles in treatment phase, followed by pemetrexed and Avastin during the following cycles of the maintenance phase. Participants will be asked to take the study drugs as long as they are benefitting from the treatment or their disease does not get worse. Participants will be removed from the study if the study doctor thinks that they have unacceptable toxicities due to the study drug/s and it is in their best interest to stop participating in the study. All the drugs will be administered intravenously on Day 1 of each cycle. Each cycle is made of 21 days. The number of cycles will depend on how participants respond to treatment. During the study, participants will have a CT scan every 6 weeks (every 9 weeks during the maintenance phase). Participants will also undergo a physical exam, blood tests, performance status, and vital signs. Blood will be collected during the study. A biopsy for tissue will be collected if the participant agrees. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: •Stage IV advanced non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation or without a history of smoking •Age of at least 18 years Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords Phase II Carboplatin Pemetrexed Bevacizumab Atezolizumab Non-Small Cell Lung Cancer NSCLC EGFR mutation
For questions about this study, contact: |
Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen. The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1 ratio to either study drug or placebo. The following regimens are active in the trial: Regimen A - Zilucoplan Regimen B - Verdiperstat Regimen C - CNM-Au8 Regimen D - Pridopidine Regimen E - Trehalose New regimens will be continuously added as new investigational products become available. The HEALEY ALS Platform Trial will enroll additional participants as each new regimen is available. Who Can Participate?The basic eligibility criteria include: 1. Onset of ALS WEAKNESS within the last 3 years.2. FVC (breathing test) > 50% 3. If on riluzole, must be on a stable dose for 30 days. Must not start riluzole during the study. 4. If on radicava, must be on a stable dose for 30 days. Must not start riluzole during the study. 5. Must be able to swallow for the next 6 months 6. No history stem cell treatment 7. No history of cancer within the last 5 years Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Cardio-TTRansform (ION-682884-CS2)This study is enrolling patients who have transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) which is a disease caused by change in a protein called transthyretin (TTR). This change can either be sporadic which is known as wild-type (wtATTR-CM) or due to a mutation of the TTR gene which is hereditary (hATTR-CM). In both cases, these changes can cause the TTR to clump and build up in certain parts of the body such as the nervous system, stomach, intestines, and heart. This build up is called an amyloid deposit. Amyloid deposits can sometimes cause heart disease or neuropathy (nerve damage). When amyloid is deposited into the heart, it can result in a condition referred to as cardiomyopathy. ION-682884 is an investigational drug. “Investigational” means that ION-682884 is not yet approved for use in any settings outside of clinical research studies like this one and is considered experimental. ION-682884 reduces the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in the blood may reduce the amount of amyloid deposits in the body and may keep cardiomyopathy from getting worse over time. However, it is not known if ION-682884 will help cardiomyopathy. The purpose of this study is to evaluate the safety of ION-682884 and determine if it can help people with this type of cardiomyopathy.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NP-SLEThis study will examine different proteins and cell types in blood and cerebrospinal fluid (CSF) of patients with systemic lupus (SLE) who may or may not currently be experiencing neuropsychiatric manifestations of the disease. We aim to identify specific factors that affect the regulation of genes to help explain what goes wrong in systemic lupus. Then, we hope to develop treatments that will target these factors. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00211615 Click to Copy URL to Clipboard For questions about this study, contact: |
The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD CohortThe purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples and complete some questionnaires.
Principal Investigator, Study ID, Keywords STU00212785 Click to Copy URL to Clipboard For questions about this study, contact: |
Screening for Coronavirus Antibodies in Neighborhoods (SCAN)Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than others. By taking part, you will help us find out how many peoplein specific areas have been exposed to SARS-CoV-2, and if these antibodiesprotect people against re-infection.
Who Can Participate?Adults age 18 years and older living in the Chicagoland area or Illinois. Principal Investigator, Study ID, Keywords STU00212472 Click to Copy URL to Clipboard For questions about this study, contact: |
Immune checkpoint inhibitor-associated acute kidney injurySince 2011, six immune checkpoint inhibitors (ICIs), a type of immunotherapy, have been approved by the Federal Drug Administration for use in patients with cancer. These medications have been demonstrated to have great promise for treating a variety of cancers. However, there are toxicities associated with these agents, known as immune-related adverse events (AKI), some of which can be fatal. Affected organs include the skin (rash), gastrointestinal tract(diarrhea), and the kidneys (acute kidney injury [AKI]). This study, led by Drs. Shruti Gupta and David Leaf at Brigham and Women’s Hospital, has the goal of collecting data on over 300 ICI-associated acute kidney injury cases from more than 30 academic medical centers worldwide. We will characterize the clinical features of ICI-associated AKI in the hope that this will help us to determine predictors of toxicity and best practices for management.
Principal Investigator, Study ID, Keywords STU00212602 Click to Copy URL to Clipboard |
COVID-19 and the impact on the Immune SystemThis study will characterize immune responses specific to the virus that causes COVID-19 and how they contribute to favorable or poor outcomes. We hope to identify factors that predict the development of long COVID to improve medical care of COVID-19 and related complications. The visit itself will consist of reviewing and signing the consent form, a blood draw of approximately 2 tablespoons of blood, optional stool/nasal samples and a brief questionnaire to review demographics, medications, and medical conditions. You will receive a gift card of $20 for your participation and donation. Individual results generated from this study cannot be shared with the study participant. Who Can Participate?Age between 18 and 90 years old Have had a positive COVID test within the last two years Does not have any symptoms lasting more than 6 weeks post infection Principal Investigator, Study ID, Keywords STU00212583 Click to Copy URL to Clipboard For questions about this study, contact: |
Amplify Gait to Improve Locomotor Engagement in Spinal Cord Injury (AGILE SCI) TrialThis study is investigating if participation ina 10-week high-intensity walkingintervention can improve walking balance of individuals who have had an incomplete spinal cord injury.
Who Can Participate?• Age 18 to 75 years • Have an incomplete spinal cord injury • Able to walk 10 meters without physicalassistance. • Able to tolerate 30 minutes of standing. • Must not have severe cardiovascular andpulmonary disease, a history of recurrentfractures, or concomitant neurological injury. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
AHEAD 3-45 StudyThis study will test an investigational drug called BAN2401 for the treatment of individuals with preclinical Alzheimer's Disease. Participation may last up to 4 years. Who Can Participate?This study is composed of two research trials aimed at preventing Alzheimer's Disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. You may qualify to join one of the AHEAD Study prevention trials because you're aged 55-80 years and have normal memory and thinking abilities. General Inclusion Criteria:
https://www.aheadstudy.org/about/ Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Prospective evaluation of an applied ATTR-CM Machine Learning model to a health system electronic health record (EHR)This study is enrolling patients who have a diagnosis of congestive heart failure in their medical record, and is interested in determining whether one can use an automated, computer-based method to diagnose a specific cause of heart failure (“transthyretin cardiac amyloidosis”) based on other diagnoses in the medical record. Transthyretin cardiac amyloidosis is a rare disease that results from a protein in the body that becomes misfolded and starts depositing into the heart, a process known as amyloidosis. Because of these proteins getting into the heart muscle, the heart can get stiff and weak, thereby leading to congestive heart failure. Typically this form of heart disease (cardiac amyloidosis) is diagnosed late in its course and it associated with poor survival. However, there are now treatments for this disease, so earlier diagnosis is better. A machine learning (artificial intelligence)-based method to find potential patients with cardiac amyloidosis has been developed. This computer program automates finding patients who may have cardiac amyloidosis based on their other diagnoses in the electronic health record. This study seeks to validate the computer algorithm prospectively to see if it can be useful in patients to determine whether or not cardiac amyloidosis is the cause of heart failure. Principal Investigator, Study ID, Keywords STU00211906 Click to Copy URL to Clipboard For questions about this study, contact: |
A Sequenced Strategy for Improving Outcomes in People with Knee Osteoarthritis Pain (SKOAP)This research is being done to compare treatmentsfor knee osteoarthritis pain.
Knee osteoarthritis (KOA) occurs when the cartilagethat cushions your knee joint wears down over time or from trauma. Symptoms of KOA include pain, swelling,tenderness, stiffness, and loss of flexibility in the knee. People with KOA pain are often treated withopioids, which can lead to opioid addiction. In this study, we are comparing non-opioid treatments in an effort tolessen your pain and improve knee function. If you qualify for this study your participation will last between 18 and 48 months
Who Can Participate?Knee pain Diagnosis of knee osteoarthritisNot Pregnant or breastfeeding Meets American College of Rheumatology Classification criteria for knee osteoarthritis English speaking Internet connectivity Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)You are invited to participate in a research study at Northwestern University that provides skills and training to fathers who have a partner with prenatal depression. The research study aims to give guidance on how fathers can optimize their support of their partner during this difficult time. ALL SESSIONS WILL BE VIRTUAL.
Who Can Participate?-Pregnant African-American mother and male partner -Available to begin study in 2nd trimester -Mother in treatment for depression with current symptoms -Parents are 18 y/o or older Principal Investigator, Study ID, Keywords STU00212595 Click to Copy URL to Clipboard For questions about this study, contact: |
COVID Prevention Trials RegistryAfteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open the consent and registry survey in your web browser by clickingthe link below: COVID PreventionTrials Registry Consent . If thelink above does not work, try copying the link below into your web browser: https://is.gd/NUVaccineStudy
Who Can Participate?The NorthwesternCOVID Prevention Trials Registry is open to all adults who are interested inbeing contacted about upcoming COVID vaccine and other prevention studies.TheCOVID vaccine trials will enrollpersonswhoareatrisk of infection and COVID-19 disease. This· · · - - - Racial/ethnic groups such as African Americans, Latinx, and NativeAmericanpopulations. Principal Investigator, Study ID, Keywords STU00213110 Click to Copy URL to Clipboard For questions about this study, contact: |
Phase 1/2 trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device and treatment with albumin-bound paclitaxel in patients with recurrent glioblastomaEligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be implanted at the end of the procedure. In phase 1, about two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening. Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression. The planned albumin-bound paclitaxel starting dose is 40 mg/m2, to be escalated in the absence of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be collected before and after each sonication. In phase 2, pre-sonication carboplatin at AUC 5 will be added to the regimen, with a safety run-in for the first 6 patients. Who Can Participate?Inclusion Criteria: Measurable or evaluable disease For patients with a childbearing potential Exclusion Criteria: Have multifocal disease that cannot be encompassed in the ultrasound fields: Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Human-like Robot Controllers for Enhanced Motor LearningThe Shirley Ryan AbilityLab is seeking healthy adults to study how humans interact with robots to program human-like behavior. This study involves an ankle robot and a lower limb robotic suit that track movements; participants may test only one robot or both. If testing the ankle robot, participants will wear the robot on their dominant foot and move their ankle while sitting. If testing the robotic suit, the participants will wear the robotic suit on both legs and the hips, and perform various movements like standing, squatting, or walking. Who Can Participate?Healthy Participants:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG 7465-CL-202 : An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9. Who Can Participate?• Participants must have a diagnosis of breast, lung, head and neck (HNSCCs), gastric, gastroesophageal junction, or esophageal cancer • Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NRG HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity CancerThis study is being done to answer the following questions: 1) will neck and shoulder function and discomfort be better if you have a procedure called sentinel lymph node (SLN) biopsy instead of the usual surgery for this type of cancer; and 2) is SLN biopsy the same as the usual surgery in extending the time you have without cancer returning? The usual approach is defined as care most people get for this cancer. This study has 2 parts. In the first part,doctors will try to learn the answer to question #1 above. If the answer shows that neck and shoulder function and discomfort is better in patients who have the SLN biopsy, then the study will go on to the second part, and doctors will try to answer question #2. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
COVID-19 TestUS an initiative of RADx AcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection)We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visit to collect nasal swabs (less than one inch into each nostril) for new and standard tests. You will also complete surveys through a web browser, App on mobile device, or telephone interview with research staff. These surveys take approximately 30 minutes and they collect information on prior COVID-19 testing, COVID-19 exposures, demographics, and brief medical history. Who Can Participate?Adults and children (over 10 years of age) with or without symptoms who are interested in getting tested for COVID-19 and willing to complete on-line or verbal surveys. Principal Investigator, Study ID, Keywords STU00213330 Click to Copy URL to Clipboard For questions about this study, contact: |
Impact of immunotherapy-related skin diseases on quality of lifeThe purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey.
Who Can Participate?Participants need to be 18 years and older, receiving immunotherapy, and may be experiencing a dermatologic side effect.Principal Investigator, Study ID, Keywords STU00212205 Click to Copy URL to Clipboard For questions about this study, contact: |
R1: Telehealth Pain Self-Management for Employed Adults (E-TIPS)The E-TIPS trial will evaluate an evidence-based, telehealth pain self-management intervention compared to standard care (a wait-list) for chronic pain in adults with physical disabilities who are employed. Participants from anywhere in the US will be randomized to either E-TIPS, a cognitive-behavioral pain self-management intervention delivered by telephone, or a wait-list control. Outcomes, including pain interference, will be assessed at baseline, mid-treatment, post-treatment, and 6-month follow up.
Who Can Participate?Inclusion Criteria:
Principal Investigator, Study ID, Keywords Chronic Pain Traumatic Brain Injury Multiple Sclerosis Amputation Spinal Cord Injuries Cognitive Behavioral Therapy
For questions about this study, contact: |
DRUG CCTL019B2003I: Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to provide access for patients with out of specification leukapheresis product and/or out of specification manufactured tisagenlecleucel (CTL019; Kymriah®).The purpose of this Managed Access Program(MAP), which is an intermediate size patient population Expanded Access, is to allowtreatment with tisagenlecleucel (CTL019) for eligible patients diagnosed with B-cell acutelymphoblastic leukemia (ALL) or large B-cell lymphomas who meet all of thefollowing criteria: are 1) consistent with the approved prescribing information,2) unable to receive commercially manufactured product due to failure of the incomingapheresis material to meet acceptance specifications or final outgoing productto meet the commercial release specifications or other specification within theprescribing information, and 3) where no overwhelming safety concerns has beenidentified for manufacture and release of the out of specification product. Participation inthis treatment plan involves an experimental approach called gene transfer forALL or large B-cell lymphoma that involves cells in your blood called B cells(your tumor cells and also normal antibody-producing cells). During thistreatment, some of your own white blood cells (T cells) will be taken andchanged to turn against your tumor cells. T cells from your body will bechanged in a way that may allow them to identify and kill your tumor cells.This change may allow your T cells to go to the tumor cells, turn"on" and potentially kill the tumor cells. The modification is doneby gene transfer and results in a genetic change to your T cells. This mayallow the changed T cells to recognize your tumor cells but also normalantibody-producing cells called B cells. These changed cells are calledtisagenlecleucel cells. If you are eligible andchoose to participate in this MAP, you will be asked to come to the doctor’soffice/clinic/study site at least 3 times in order to make sure you areeligible to receive the tisagenlecleucel cells, and to prepare you for theexperimental treatments. Once you receive the tisagenlecleucel cells, acaregiver, relative, or friend should be in your presence at all times for thefirst 10 days to monitor your well-being and contact your study physician incase of fever or changes in your condition. If you become ill, immediatelycontact your study physician. Additionally, you may be required to spend about4 weeks after you have received tisagenlecleucel cells in close proximity tothe trial treatment center while the doctor and study team see how thetreatment is working and monitor your safety.
Note:This is only a partial description of treatment. Please contact the Robert H.Lurie Comprehensive Cancer Center of Northwestern University if you areinterested in this Managed Access Plan (MAP). Who Can Participate?Some of the eligibility criteria include: · Age of at least 18 years Diagnosis of acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse or have been diagnosed with relapsed or refractory large B-cell lymphoma after two or more lines of therapies including diffuse large B cell lymphoma not otherwise specified, high grade B cell lymphoma and Diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this Managed Access Plan (MAP). Principal Investigator, Study ID, Keywords Managed Access Program CTL019 CAR-T acute lymphoblastic leukemia ALL large B-cell lymphoma out of specification leukapheresis tisagenlecleucel
For questions about this study, contact: |
Evaluating the EVO treatment optimized for resource constraints: Elements Vital to treat ObesityEVO is a 12-month healthy lifestyle and weight loss research study taking place in the Department of Preventive Medicine at Northwestern University. Researchers are looking to determine the best strategy for weight loss and healthy living. Participants enroll in the 12-month study and receive a free 6-month health program.
Who Can Participate?You are between the ages of 18 - 70 years old. You are NOT currently pregnant, trying to become pregnant, or breastfeeding.You do NOT have an unstable medical condition.You own an Android or iPhone smartphone.You are willing to track your lifestyle behaviors for 6 months, and attend remote sessions with study staff over the course of 12 months.Principal Investigator, Study ID, Keywords STU00212742 Click to Copy URL to Clipboard For questions about this study, contact: |
xIRB Consortium of Early Arthritis Cohorts USA (CATCH-US) -- A prospective cohort study of adults with new onset inflammatory arthritis symptoms to understand predictors of optimal outcomesThis is an observational research study to provide data to better understand what characteristics and treatment approaches predict an optimal outcome (i.e., remission and no joint damage) in real world patients with new onset RA. We want to learn more about the factors that predict how patients’ disease might progress over time and what their response to treatment might be. Participation involves approximately 10 study visits: every 3 months for the first year, every 6 months until the end of year 2, and at year 3, year 4 and year 5. These visits will be at the time of routinely scheduled visits with the participant's Northwestern rheumatologist. Research procedures include collection of questionnaires and clinical information collected from the patient's rheumatologist at each visit. If participating in the optional biological specimen and genetic testing study component, participants may be asked to give research blood (during standard of care blood draws) and leftover joint fluid collected at the time of standard of care joint aspirations. Who Can Participate?• Age > 18 years at time of referral, AND • Joint symptoms for ≤12 months, AND • At least one of the following (summarized in checklist below): o two (2) or more swollen joints OR o one (1) swollen metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint and any one (or more) of the following:
Principal Investigator, Study ID, Keywords STU00213564 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) NCI CIRB SWOG 1823: A Prospective Observational Cohort Study to Assess mRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell TumorsThe purpose of this study is for the study doctors to learn if miRNA 371 is useful for predicting relapse in patients with germ cell cancer. A germ cell tumor is a type of cancer that occurs in the ovaries (for females) or the testes (for males). This tumor may also be found in the pelvis along the tailbone, the chest, the abdomen and in other structures of the body, generally along the midline of the body. A sample of your blood will be collected during regular clinic visits to look for the presence of a tumor marker called miRNA 371. The study doctors do not know if the test is as good as the usual care (tumor scans and bloodwork) in predicting when cancer will return (relapse) in patients with germ cell cancer. If better, this blood test could change the way patients are monitored for relapse in the future. If you decide to take part in this study, an extra tube of blood will be collected during your regular clinic visits for miRNA 371 analysis for up to 3 years from enrollment into the study. Who Can Participate?Participants 18 years of age or older who have germ cell cancer will be enrolled. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Tape Strip Analysis in Dermatologic DiseasesThe main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls.
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00213591 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) NCI CIRB ETCTN 10276: A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesPhase 1:
The purpose of this study is to test the safety of a drugcalled M3814 in combination with avelumab and hypofractionated radiation. This combination of drugs has been tested inanimals but has not been tested in people. This study tests different doses of the drug to see which dose is saferfor people.
Participants enrolled in Phase 1 will get standard dose ofradiation therapy every other day over 10 days. This will be followed by a combination of avelumab and M3814 for as long as your doctor feels that the combination ishelping you and you are not experiencing too many side effects. Phase 2: Phase 2 has twostudy groups:
Group 1 Participants in Group 1 will receive radiation therapy and the study drugsavelumab and M3814. These drugs are not approved by the FDA for treatment of your disease.
Group 2 Participants in Group 2 will receive radiation therapy and the study drug avelumab.Avelumab is not approved by the FDA for treatment of yourdisease. All participants, regardless of which phase they areenrolled in, will be followed for 12 months and watched for side effects.Participants will be asked to return to the clinic approximately 30 days aftertheir last dose of study treatment. Afterthat time, participants will be contacted by telephone at regular intervals forup to five years. Who Can Participate?This study hastwo phases. Participants will participate in either Phase 1 or Phase 2.
Phase 1: Participants whoare 18 years of age or older who have an advanced/metastatic solid tumor willbe enrolled. Phase 2: Participants whoare 18 years of age or older who have an advanced/metastatic hepatobiliarytumor will be enrolled. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Alliance A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerThis study is being done to answer the following question:
Can we increase the chance of your pancreatic cancer staying away by giving you chemotherapy before and after surgery?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your pancreatic cancer. The usual approach is defined as care most people get for removable pancreatic cancer. Who Can Participate?
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
OPT2MOVEAbout the Study Opt2Move is a 6-month smartphone-based study to help adolescent and young adult cancer survivors become more active. What’s involved? Assessments Complete before starting study and at 3 and 6 months:
Physical Activity Program All Participants
How can I learn more? For questions: Phone: 312-503-3465; Email: O2M@nm.org To complete online screening: https://redcap.link/O2M Who Can Participate?Who can participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Use of Glenohumeral Injections for Management of Shoulder Pain in Individuals with ALSThe purpose of this study is to develop a practice for measuring the efficacy of ultrasound-guided shoulder joint injections in patients with ALS who have exhibited shoulder pain and/or adhesive capsulitis. Patients will receive corticosteroid injections as part of their normal or standard care for shoulder pain in ALS (not provided by the study). They will then be asked to complete questionnaires at Baseline and over the phone over approximately 3 months.
Who Can Participate?1. Diagnosed with ALS2. Being referred for evaluation for glenohumeral shoulder injections for management of shoulder pain 3. Able to utilize written, typed or verbal communication, independently or with the assistance of a caregiver 4. Able to understand study procedures, answer questionnaires, and provide informed consent Principal Investigator, Study ID, Keywords STU00213465 Click to Copy URL to Clipboard For questions about this study, contact: |
A Prospective and Retrospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the HospitalThe purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00212714 Click to Copy URL to Clipboard For questions about this study, contact: |
TRISCEND IIThis study is recruiting patients with Tricuspid Regurgitation (TR), a condition in which the heart’s tricuspid valve does not close tightly which causes the blood to flow in the wrong direction during part of the cardiac cycle (heart beat). This condition increases the workload on the heart and if left untreated, it can increase the risk of worsening heart failure. The goal of this trial is to evaluate the safety and effectiveness of the Study Device with Optimal Medical Therapy (OMT) compared to OMT alone in the study of subjects with severe or greater tricuspid regurgitation.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington DiseaseThe purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)
Who Can Participate?1. >25yrs of age. 2. Diagnosis of HD with CAG repeat > 36 Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
High vs. Standard Dose Influenza Vaccine in Adult SOT RecipientsThe influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. The first study compared HD-IIV vs. SD-IIV in adult SOT and noted HD-IIV was safe and reported higher immunogenicity; however, the median post-transplant period was 38 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV a month apart compared to one-dose SD-IIV revealed increased immunogenicity, with a median post-transplantation period of 18 months. Therefore, these studies lack evaluation in the early post-transplantation period in this vulnerable population when influenza disease is most severe. The administration of two-doses of HD-IIV in the same influenza season has also not been studied in SOT recipients. Moreover, the vast majority of SOT influenza vaccinations studies have not substantively evaluated prolonged immunogenicity. Thus, the optimal immunization strategy for SOT recipients less than 12 months post-transplant is poorly-defined. In addition, the immunologic predictors and correlates of influenza vaccine immunogenicity in SOT recipients have not been defined. The investigators hypothesize that adult solid organ transplant recipients that are 1-11 months out from transplant and are receiving high-dose inactivated influenza vaccine will have higher hemagglutination inhibition (HAI) geometric mean titers to influenza A antigens compared to adult SOT recipients receiving standard-dose inactivated influenza vaccine. To test this hypothesis and address the above critical knowledge gaps, The investigators propose to conduct a phase II multicenter randomized controlled trial comparing either two doses HD-IIV, two doses of SD-IIV, or one-dose of HD-IIV in adult kidney, heart, and liver SOT recipients 1-11 months post-transplantation. The results of this study will address significant gaps in knowledge regarding influenza vaccine strategies and immune responses in adult SOT recipients and will guide vaccine recommendations in this vulnerable population. Who Can Participate?Criteria Inclusion criteria Exclusion criteria Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Serial Monitoring of Circulating Tumor Cells During Radiotherapy for Women with Non-Metastatic Breast Cancer: A Prospective Observational Cohort StudyThe purpose of this research is to determine whether radiotherapy after surgery to remove a breast cancer can help decrease the number of circulating tumor cells (CTCs) in the blood. Circulating tumor cells are cancer cells that are shed from the tumor into the blood stream and are believed to be one of the first indicators that breast cancer cells may remain after surgery. Approximately 20% of women with early-stage breast cancer can be found to have CTCs in a small sample of blood taken several weeks after surgery. Radiotherapy is used after surgery to remove a breast cancer in order to sterilize any cancer cells that may be remaining in the breast. It is not known if radiotherapy can help decrease or eliminate CTCs that are found in the blood. This study aims to find out if testing for CTCs can be clinically useful for guiding radiotherapy treatment decisions. Another aim of this study is to evaluate whether CTCs can be used to measure the effectiveness of radiotherapy in an individual patient. Who Can Participate?Eligible participants are post-menopausal women that have been diagnosed with non-metastatic, ER-positive and Her2-nonamplifed breast cancer and are planning on receiving radiation and hormone therapy. Principal Investigator, Study ID, Keywords STU00212971 Click to Copy URL to Clipboard Serial Monitoring of Circulating Tumor Cells During Radiotherapy for Women with Non-Metastatic Breast Cancer: A Prospective Observational Cohort Study radiotherapy non-metastatic breast cancer CTCs CellSearch
For questions about this study, contact: |
A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)The purpose of this study is to evaluate the effect of aninvestigational drug called tasimelteon on the sleep-wake cycle of patientswith Delayed Sleep-Wake Phase Disorder (DSWPD) and to assess the safety oftasimelteon. Participants in this study will randomly be assigned totasimelteon or placebo, to take over a period of 35 days. During this time,participants will be required to go to bed at certain fixed times and keep anelectronic daily sleep diary. Additionally, there will be 4 visits to yourstudy doctor's clinic, where you will be assessed for eligibility and safety.At the clinic, your study doctor will perform a physical examination, blooddraws, heart tests, questionnaires, and test your urine for drugs and alcohol.You will not be charged for any of these procedures and you may be compensatedfor your time.
If you complete the initial 35 days of the study, you willhave the option of receiving treatment with tasimelteon for up to 11 monthsafter. No matter which treatment you were randomly assigned during the first 35days, tasimelteon or placebo, you will receive tasimelteon during theadditional 11 months, if you choose to continue. During those 11 months, therewill be 4 additional visits to your study doctor's clinic (spaced 60-90 daysapart) to assess your health and safety. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Glycemic Observation and Metabolic Outcomes in Mothers and OffspringAbout the StudyGestational diabetes mellitus (GDM) is a type of diabetes, or high blood sugar, that starts during pregnancy and may go away after the baby is born. GO MOMs researchers want to find a better way to detect GDM, so that moms can get the care they need and their babies can be healthy.We are looking for 2,150 pregnant women to join this study happening at clinics across the country. If you join you will be in the study during your pregnancy and up to three months after your baby is born.Why is this study being done?Many women get GDM during pregnancy, which can cause problems for the mother and her baby. Her baby may grow too large, which can cause problems during delivery. These babies are also more likely to become overweight or get diabetes in childhood. Moms who have GDM are more likely to get diabetes after their baby is born.Doctors need better ways to test for GDM. GO MOMs hopes to improve testing and treatment for GDM. Mothers will use a glucose sensor to track glucose levels during their pregnancy.When is GDM testing normally done?Most doctors test for GDM around 24 to 28 weeks. If you join our study, we will also test you at that time. If you have GDM then, we will share that with your doctor so your doctor can treat you.What happens if I join?You will have four study visits during your pregnancy. We will also come to see you in the hospital after you deliver your baby and call you a couple of months after you go home.
Who Can Participate?You may be able to join if you: --Are 18 years or older --Are less than 14 weeks pregnant --Are pregnant with one baby --Do not have diabetes --Do not use certain medications Principal Investigator, Study ID, Keywords Gestational diabetes pregnancy blood sugar continuous glucose monitor oral glucose tolerance test GDM OGTT CGM glucose tolerance test glycemic regulation
For questions about this study, contact: |
(xIRB) NCI CIRB ECOG-ACRIN 8191: Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical RecurrenceThe purpose of this study is to compare the usual treatment alone to using PET/CT imaging to look for cancer that has spread to the pelvis plus the usual treatment. We want to see if we can provide a more targeted treatment to this type of cancer by treating up to 5 specific lesions that are seen on the PET/CT scan. Part of the purpose of this study is also to see whether adding apalutamide and directed radiation works better than the usual approach to help treat prostate cancer that has returned after surgery. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the time before cancer growth or if the cancer causes major additional symptoms. This study has 4 study groups. Participants will be assigned to 1 of 4 possible treatment groups depending on the results of your PET/CT scan. After you finish your study treatment, your doctor will continue to follow your condition for up to 10 years and watch you for side effects and monitor the progression of your cancer. Group 1 (Negative for Extra Pelvic-Metastases) If you are in this group, it means your PET/CT scan did not show evidence that your cancer has spread to outside of the pelvis. You will get the usual appropriate care that is used to treat this type of cancer, the planned standard of care treatment with radiation therapy (SOC RT) and STAD for 6 months. Group 2 (Negative for Extra Pelvic-Metastases) If you are in this group, it means your PET/CT scan did not show evidence that your cancer has spread to areas outside of the pelvis. You will get a study treatment, planned SOC RT + STAD + apalutamide for 6 months. Group 3 (Positive for Extra Pelvic-Metastases) If you are in this group, it means that your cancer has spread to areas outside of your pelvis. You will get planned SOC RT + STAD + apalutamide for 6 months. Group 4 (Positive for Extra Pelvic-Metastases) If you are in this group, your cancer has spread to areas outside of your pelvis. You will get a planned SOC RT + STAD + apalutamide for 6 months + directed radiation therapy to where the cancer has spread. Each patient will undergo another (or additional) PET/CT scan, which will take place about one year after starting treatment or if clinically necessary at an earlier time point. Who Can Participate?Male participants 18 years of age or older who have prostate cancer that has come back after surgery will be enrolled into this study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Social Correlates Of Variation In Intestinal And Oral Microbiome Among Hematopoietic Stem Cell Transplant Patients: A Geographic Exploration In The City Of ChicagoThis study is being done to learn how the microbiome evolves through stem cell transplantation, how it can be shaped by socioeconomic status, the neighborhoods that people reside in, and their diet, as well as certain clinical factors (such as antibiotic usage). Study participants will be asked to provide a saliva sample and complete a questionnaire. Who Can Participate?You may be eligible for this study if you have been diagnosed with a hematologic malignancy (also known as a blood cancer) and are being considered for an allogeneic hematopoietic stem cell transplantation (sometimes also referred to as a bone marrow transplant). Principal Investigator, Study ID, Keywords STU00213358 Click to Copy URL to Clipboard For questions about this study, contact: |
Depression MRI Research StudyMany people experience sadness or depressed mood from time to time. For some people, these feelings are present almost constantly and can interfere with daily activities and well-being. This research study uses brain scans (MRI) to understand how painless electrical currents applied to the head, a method called “transcranial electrical stimulation” or tES, might change the way the brain works to relieve symptoms of depression. Who Can Participate?If you have had depression for 1 year or longer, and are currently under the care of a psychiatrist, psychologist, or other clinician for your symptoms, you may be eligible to volunteer for our study. Other criteria include: 18-65 years old, able to have an MRI scan, and no history of other major health issues (cancer, substance abuse, head injury, neurological, neuropsychiatric, or severe mood disorder). Principal Investigator, Study ID, Keywords STU00213826 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) DRUG BB2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming for Commercial ReleaseThe purpose of this study is to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. Participants will be asked to take part in this study if they previously agreed to receive idecabtagene vicleucel (ide-cel), for the treatment of their disease as part of routine care and not a clinical research study. Participants already had the blood collection (leukapheresis) procedure, and your T cells were collected and genetically modified in a laboratory in order to manufacture the ide-cel T cells for your disease treatment.
The ide-cel T cells that were produced do not meet all of the prespecified release criteria to be used as a routine prescription drug as required by the governing health authority. After review of its attributes, this product has been assessed by the Sponsor and your study doctor as potentially effective to treat your disease with potential benefits that outweigh the risks and is being offered to you as a treatment option in a research study. Approximately 3 months after receiving your nonconforming ide-cel, your participation in this study will end. Who Can Participate?Some of the eligibility criteria include:1) documented diagnosis of Multiple Myeloma who was eligible for treatment with ide-cel. 2) Participant had ide-cel manufactured to be used for commercial treatment, however, the final product was nonconforming. 3) Participants must be 18 or older. Principal Investigator, Study ID, Keywords |
Neural Correlates of Acute Pain DynamicsThe studies aim to understand the neural mechanisms governing how pain changes in response to a changing stimulus. Thus, the studies involve applying a device on your arm that heats up (a “thermode”) enough to cause moderate pain. (Note, we use temperatures that should not be hot enough to cause skin damage.) The temperature of the stimulus and the pain you feel will change over time. The two studies will use the above paradigm but differ in their approach. Briefly, Who Can Participate?No history of heart conditions, glaucoma, chronic pain, substance abuse disorder, neurological impairment, or mental illness; must be between the ages of 18 and 65; must not be pregnant; must have a BMI under 30; must be able to safely undergo an MRI; and must not be taking monoamine oxidase inhibitors. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NAV3-32: A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA)This trial is being done to determine the ability of technetium Tc 99m tilmanocept (study drug) to find inflammatory cells in the joints of patients with rheumatoid arthritis (RA) via imaging. The imaging results will also be compared to the different types of cells present in the joints affected by RA. The goal is to determine if imaging can be used to better characterize inflammation for rheumatoid arthritis patients, which may be helpful in diagnosing and treating patients.
Patients who participate will attend 3 clinic visits and 2 phone calls over 45 days and will complete the following:
A stipend will be offered to participants for each completed study visit. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) NCI CIRB NRG BN009: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/YearThe purpose of this study is to compare the usual treatment of SRS alone to SRS plus HA-WBRT (whole brain radiation therapy with hippocampus avoidance) and memantine for patients with cancer that has spread to the brain and come back in other areas of the brain after earlier treatment with SRS. The addition of HA-WBRT and memantine to the usual treatment could better control your brain cancer. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Memantine is FDA approved for treating dementia and is commonly used off-label (that is, for a purpose for which it is not FDA approved) for patients receiving whole-brain radiation therapy for cancer that has spread to the brain. This study has 2 study groups. You will be told which group you are in. Group 1 If you are in this group, you will get the usual treatment, SRS. In addition to the usual SRS treatment, you will also receive HA-WBRT. You will also be given the drug memantine, which has also been shown to preserve memory function. Memantine will be taken for up to 6 months. Group 2 If you are in this group, you will get the usual treatment of SRS. After you finish your treatment, your doctor and study team will watch you for side effects and follow your condition. They will check you every 2 to 3 months for at least 1 year after you finish SRS. If you are receiving memantine, your doctor will continue to see you in the clinic as needed. Who Can Participate?Participants age 18 years or older who have receivedstereotactic radiosurgery to treat cancer that spread to the brain, and now thecancer has returned in other areas of the brain will be enrolled into thisstudy. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Double-Blind Placebo-Controlled, Randomized 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinectics of Oral UCB0599 in Study Participants with Early Parkinson’s DiseaseThis study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last about 21 months. If you join the study, you will have regular scheduled appointments with the study staff and will have medical procedures and tests during these visits, like imaging studies, body function tests, and questionnaires. Who Can Participate?You might be a candidate for this study if:
There are additional eligibility criteria that will be discussed with you. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CatalystThis study is enrolling patients in whom the Amulet device could be beneficial in reducing the risk of ischemic stroke due to non-valvular atrial fibrillation (AF). The purpose of this research study is to compare the safety and effectiveness of the Amulet device compared to non-vitamin K antagonist oral anticoagulants (NOACs) for ischemic stroke risk reduction. NOACs are a class or type of drugs taken daily, which thin the blood to reduce blood clots and the risk of an ischemic stroke. An ischemic stroke occurs when a small clot prevents blood and oxygen from reaching part of the brain. While NOACs are effective in preventing blood clots and ischemic stroke, thinning of the blood can increase the risk for bleeding events. The Amulet device is intended to be permanently implanted within the LAA. The LAA is a small pouch attached to the upper left chamber of the heart, the left atrium. In patients with non-valvular atrial fibrillation, clots can form in the LAA and travel to the brain, sometimes causing an ischemic stroke. The Amulet device is designed to seal off the LAA from blood flow, preventing clots from leaving the LAA and traveling to the brain. This is accomplished without the need for NOACs or warfarin in most cases.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Precision MRI of Left Atrial Fibrosis for Patients with Atrial FibrillationTo develop new MRI approaches that can better quantify the severity of left atrial fibrosis, for the purposes of predicting whether patients will revert to atrial fibrillation (AF) following an initial successful procedure Who Can Participate?Primary Inclusion Criteria:
Primary Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00213834 Click to Copy URL to Clipboard For questions about this study, contact: |
Evaluating Fenofibrate for Prevention of Diabetic Retinopathy WorseningEvaluating Fenofibrate for prevention of DR worsening- Screening visits then 2 visits per year for 4 years. Who Can Participate?Mild to Moderate NPDR Vision 20/25 or better No prior treatment for DME or DR Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DAPA ACT HF-TIMI 68This study is recruiting patients who are hospitalized for acute heart failure. This study will test whether the drug dapagliflozin is safe and has beneficial effects when added to conventional heart failure therapy in patients who have been admitted to the hospital for acute heart failure and whose heart is not pumping enough blood with each heartbeat.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Stimulating neuroplasticity in TBI with acute intermittent hypoxiaWe are studying whether briefly reducing oxygen consumption, equivalent to being on top of a mountain, is safe and stimulates neuroplasticity in people who have had a concussion or a mild to moderate traumatic brain injury (TBI). Neuroplasticity indicates that the brain is changing positively to help you function and learn. The aim of this study is to determine if acute intermittent hypoxia is safe and effective for treating cognitive and motor deficits in TBI patients.
Who Can Participate?Inclusion criteria: · first-time, mild to moderate TBI · fluent in English · able to type on keyboard with both hands
Exclusion criteria: · stroke · spinal cord injury · history of seizures/epilepsy · severe psychiatric disorders (psychosis, schizophrenia) · severe hypertension (>160/100) · ischemic cardiac disease · obstructive lung disease (asthma, COPD, pulmonary fibrosis) Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial ReleaseThe purpose of this expanded access protocol is to allow patients to receive lisocabtagene maraleucel T cells that did not meet all of the prespecified release criteria (nonconforming) to be used as a routine prescription drug. The study will evaluate the safety and effectiveness of this therapy through the collection of information. Participation in this treatment plan involves receiving the nonconforming product and performing tests as part of your routine clinical care. The information or results from these evaluations will be collected for research purposes. If you are eligible and choose to participate in this EAP, you will be asked to complete test as part of routine care, you will undergo lymphodepleting therapy (chemotherapy administered to help prepare your bone marrow and immune system to receive lisocabtagene maraleucel), and receive the nonconforming lisocabtagene maraleucel product through your vein as an intravenous (IV) infusion. Approximately 3 months after receiving your nonconforming lisocabtagene maraleucel, your participation in this study will end. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: •Age of at least 18 years Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
xIRB TRC-PAD Program: In-Clinic Trial-Ready CohortTRC-PAD (Trial-Ready Cohort for the Prevention of Alzheimer's Dementia) is an observational study that advances Alzheimer's research by matching healthy people with clinical trials to prevent Alzheimer's disease. People who are in the TRC are routinely assessed at twice yearly in-person visits until they are found to be eligible for a clinical trial.
Who Can Participate?Inclusion Criteria:
https://trcpad.org/ Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NRG GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)Participants ages 18 years or older who have high-risk prostate cancer will be enrolled into this study.
This study is being done to answer the following questions:
If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment?
If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment?
The study doctors want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer.
This study has 4 study groups.
If you have a low Decipher risk score, you will be randomly assigned to one of these two study groups:
· Group 1: If you are in this group, you will get the usual approach, hormone therapy and radiation therapy, used to treat this type of cancer.
· Group 2: If you are in this group, you will get the usual radiation treatment and a shorter period of hormone therapy used to treat this type of cancer.
If you have a high Decipher risk score and/or positive pelvic node(s), you will be randomly assigned to one of these two study groups:
· Group 3: If you are in this group, you will get the usual approach, hormone therapy and radiation therapy, used to treat this type of cancer.
· Group 4: If you are in this group, you will get study drugs called apalutamide and abiraterone acetate with prednisone plus the usual approach (hormone therapy and radiation therapy) used to treat this type of cancer.
After you finish your study treatment, your doctor will continue to follow your condition for at least annually and watch you for side effects. Principal Investigator, Study ID, Keywords |
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL)The purpose of this research study is to evaluate an investigational cell and gene treatment called MB-CART2019.1 that may help to eliminate cancer cells in subjects who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL. In order to produce the investigational treatment, white blood cells (T-cells) will be collected at the study center by a process called leukapheresis.
Participation in this study is for up to two years, and additionally subjects must enroll in the separate Gene Therapy Long-Term Follow Up protocol for 13 years (total study participation to equal up to 15 years). The T‑cells (obtained from blood) will be modified in order for them to express molecules called chimeric antigen receptors (CARs) on their surfaces. When the modified cells, called CAR T‑cells, are reinfused into the body, the new receptors will enable them to bind onto specific antigens on cancer cells and by doing so destroy them. The CAR T-cells act as a “living drug” against your cancer cells.
Before your cells are reinfused, participants will first receive a conditioning regimen consisting of two chemotherapy drugs, fludarabine and cyclophosphamide. The conditioning regimen helps make room in the bone marrow for new blood stem cells to grow, and helps prevent rejection of the transplanted cells, as well as helps kill any cancer cells that are in the body.
Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: · Age of at least 18 years · Diagnosis of diffuse large B cell lymphoma (DLBCL).
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
PLS Natural History Study (PNHS)This is a non-interventional (no study drug), natural history study of patient with primary lateral sclerosis (PLS). The purpose of this study is to to develop a natural history dataset and biorepository of early PLS and well-established PLS cases for future clinical trials. The study will also evaluate differences in disease progression in early PLS and well-established PLS cases. Patients will be enrolled over 24 months and complete assessments in person and over the phone. Who Can Participate?Some of the BASIC, but not full, list of eligibility criteria are below: 1. PLS diagnosis is based on the new PLS diagnostic criteria2. Symptom onset was no more than 15 years prior to baseline 3. Ability to independently walk with or without an assistive device (e.g., walker) at the baseline evaluation 4. Some bulbar symptoms (dysarthria, dysphagia, drooling or pseudobulbar affect) 5. UMN symptoms and signs in a region other than the legs Principal Investigator, Study ID, Keywords STU00214272 Click to Copy URL to Clipboard For questions about this study, contact: |
Web-based Automated Imaging Differentiation of ParkinsonismThis study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a brain MRI (without dye or contrast) along with a web-based automated software tool that analyzes the MRI data automatically. The study requires two visits, one at the start and one 12-18 months later. The MRI is only performed at the first visit. At each visit, there are assessments of movement and thinking, along with several questionnaires. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00214779 Click to Copy URL to Clipboard For questions about this study, contact: |
MRI vs Echo: MR-TRThis study is recruiting patients who have had or are scheduled to have an intervention to repair or replace their mitral or tricuspid valve. The purpose of this study is to improve the assessment of mitral or tricuspid regurgitation before and after percutaneous or surgical intervention.
Principal Investigator, Study ID, Keywords STU00214668 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) NCI CIRB ETCTN 10285: Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor TherapyParticipants 18 years or older who have metastatic melanoma, and the cancer has a change in the gene called the BRAF, and is not responsive to treatment with MEK and BRAF inhibitors will be enrolled.
This study has two phases. Phase 1 and Phase 2.
The purpose of Phase 1 is to test the safety of the study drug, tazemetostat, in combination with the usual treatment, dabrafenib and trametinib. This study tests different doses of tazemetostat with the usual dose of dabrafenib and trametinib to see which dose of tazemetostat is safest for people. Tazmetostatis not approved by the FDA for treatment of this type of cancer.
All people taking part in this study will get the same dose of the usual intervention, dabrafenib and trametinib. However, people in this study will get different doses of the study drug, tazemetostat. Once the highest safe dose is found, phase 1 of the study is stopped.
The purpose of Phase II is to compare the combination of tazemetostat, dabrafenib, and trametinib to tazemetostat alone. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Another purpose of this study is for the study doctors to learn if a genetic test is helpful to decide if tazemetostat is more effective in patients whose cancer has an abnormal EZH2 gene. The combination of tazemetostat, trametinib, and dabrafenib, has not been administered together in patients and the combination of these agents are not FDA approved for the treatment of this type of cancer.
Participants who take part in this study will either get a combination of usual approach of dabrafenib and trametinib, and the study drug, tazemetostat or will get the study drug, tazemetostat alone, until their disease gets worse or the side effects become too severe. Who Can Participate?Patient must be ≥18 years. Patient must have a diagnosis of BRAFV600E/K-mutated metastatic melanoma. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) NCI CIRB SWOG 1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL StudyThe purpose of this study is to compare the early treatment(before you have symptoms) of venetoclax and obinutuzumab (V-O) to the usual treatment of V-O after you have symptoms. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Another purpose of this study is to find out how early V-O treatment affects patients’ physical, social, and emotional well-being, compared to patients receiving the standard delayed V-O treatment.
The antibody, obinutuzumab, and the drug, venetoclax are already approved by the FDA for use in patients with previously untreated CLL or SLL. Most of the time these drugs are not used until a patient has symptoms that make treatment necessary.
Participants who decide to take part in this study will either get treatment with venetoclax and obinutuzumab (V-O) that starts before symptoms start (now), or participants will get treatment with venetoclax and obinutuzumab (V-O) that will start after symptoms start (later). For all patients, the treatment with V-O will continue for 12 months or until the cancer gets worse, or the side effects are too great.
After treatment is finished, participants will be followed for up to 10 years after enrollment. Who Can Participate?Participants ages 18 years or older who have chronic lymphocytic leukemia or small lymphocytic lymphoma and who do not have symptoms and do not need to start treatment now will be enrolled into this study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) NCI CIRB Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and TucatinibThe purpose of this study is to compare the usual treatment with T-DM1 alone toT-DM1 plus tucatinib. This study will help the study doctors find out if this different approach is better than the usual approach. T-DM1 is already approved by the FDA for use in patients with HER2-positive cancer. Tucatinib has not been FDA-approved to treat breast cancer.
Participants who decide to participate will either get treatment with T-DM1 and placebo (a pill that looks like the study drug but contains no medication) or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. After study treatment is finished, the study doctor will follow participants to watch for side effects and for signs of breast cancer returning. This may include a clinic visit every 6 months for 10 years. Who Can Participate?Participants age 18 years or older who have HER2-positive breast cancer, and who have already received treatment with chemotherapy and anti-HER2 targeted therapies followed by surgery. At the time of the surgery, cancer was still present in the breast and/or lymph nodes and was removed by a surgeon, will be enrolled into this study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU MSK20C04: PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating FieldsStudyparticipants are being treated with Tumor Treating Fields (TTFields) formalignant glioma. The TTFields device uses low-intensity electrical fields totreat cancer, and this type of therapy can cause skin side effects, such asitching, sores, or infections. Researchers want to know if using clindamycingel and triamcinolone topical (on the skin) lotion before these side effectsoccur may be able to prevent their appearance, so that TTFields can be usedwith less need for interruptions Who Can Participate?Key eligibility criteria include:
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) NU MC21B02: Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen gel vs. Control in Women with Atypical Hyperplasia or Lobular Carcinoma In SituThe purpose of this research is to evaluate short-term changes in background breast tissue induced by oral tamoxifen or 4-OHT gel in women with atypical hyperplasia or LCIS. Study participation involves taking Tamoxifen or a placebo capsule by mouth and applying 4-OHT or placebo gel topically to your breast daily for 4 weeks. Prior to starting the drug and 4 weeks later participants will be asked to complete some tests and exams. If eligible and willing to participate in this study participants will be randomized to either oral tamoxifen, 4-OHT gel, or a placebo. Neither the participant nor the investigator will know which one he/she is receiving. Participants will be taking a capsule (with or without Tamoxifen) and using a gel (with or without 4- OHT). This study will take about 4-6 weeks to complete. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of Atypical Hyperplasia or Lobular Carcinoma in Situ Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords Phase IIB Randomized Trial Oral Tamoxifen Topical 4-hydroxytamoxifen gel Atypical Hyperplasia Lobular Carcinoma in Situ
For questions about this study, contact: |
(XIRB) Drug R5668-ONC-1938: Phase 1/2 Study of REGN5668 (MUC16 X CD28, a Costimulatory Bispecfic) Administered in Combination with Cemiplimab OR REGN4018 (MUC16 X CD3)The main purposes of this study are to learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to patients with ovarian cancer and to look for signs that the study drugs can treat ovarian cancer Who Can Participate?Age of at least 18 years Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xirb) Drug BGB-11417-101: A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell MalignanciesThis study will look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. In addition, this study also aims to look at the safety of BGB-11417 when given in combination with zanubrutinib (also known as BGB-3111).
BGB-11417 is made by BeiGene, Ltd. BGB-11417 is an experimental drug. This means that it has not been approved for treatment by the Food and Drug Administration (FDA) in the United States or other regulatory agencies outside the United States where the Sponsor seeks approval of BGB-11417. As of 04 February 2021, BGB-11417 as a single drug has been given to over 9 participants enrolled in this research study.
This study aims to determine the range of BGB-11417 doses that can safely be used, the safest dosing schedule to minimize side effects when first taking BGB-11417, what side effects may be experienced when taking this drug, how your body processes this drug, and if this drug is effective against your cancer. Who Can Participate?Key eligibility criteria include:
· · Age of at least 18 years
Allprospective patients will undergo screening tests to determine if they areeligible to take part in the study
Note: This is only a partial list of eligibility criteria. Pleasecontact the Robert H. Lurie Comprehensive Cancer Center of NorthwesternUniversity for complete screening information if you are interested in thisclinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Health Literacy and Cognitive Function among Middle-Aged Adults: The MidCog StudyThe purpose of the MidCog study is to investigate how health literacy (HL), self-management (SM) skills, and psychosocial factors may evolve over the adult life course and affect cognitive and health outcomes in older age. We will do this by recruiting a cohort of 1200 middle-aged adults to begin novel investigations of less-studied, modifiable, midlife determinants of later-life cognitive impairment, specifically targeting psychosocial factors in midlife that might independently affect health status and cognitive function in mid-life. Participants will be asked to complete one 2.5 hour in person cognitive assessment, one 1 hour phone interview, and wear a sleep watch for 2 weeks. Participants may be compensated up to $125 for their time. Who Can Participate?1) Ages 35-64 2) English-speaking 3) Receive primary care at a participating clinic within the Access Community Health Network or Northwestern Medicine internal medicine practices in the last 1.5 years or have an upcoming visit in the next 6 months 4) Without severe, uncorrectable vision, hearing, or cognitive impairments Principal Investigator, Study ID, Keywords STU00214736 Click to Copy URL to Clipboard For questions about this study, contact: |
Robotic Interventions for Spasticity TreatmentThe Shirley Ryan AbilityLab is seeking individuals post-stroke to study the benefits of receiving visual and physical feedback during ankle exercises to improve movement and reduce stiffness caused by spasticity.
This study involves using an ankle robot to deliver treatments to target spasticity. Participants will wear the robot on their weaker foot and move their ankle while sitting. Our visual feedback will look like a video game. You will control a character on the screen based on your ankle muscle contractions and ankle position. The ankle robot will provide physical feedback based on your muscle contractions. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Prospective, Randomized Study to Assess the Patient Satisfaction, Morbidity, and Stone Free Effect of High-Powered Stone Dusting vs. Fragmentation and Basketing at Time of UreteroscopyThe purpose of this study is to determine the differences in stone free results, patient side effects, and patient satisfaction between dusting vs. basket extraction for kidney and ureteral stones (a kidney stone located in the tube between the kidney and bladder) 6 mm and greater in size undergoing ureteroscopic treatment. Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine. Basket extraction is when a small wire basket is used to remove stone fragments. Who Can Participate?Patients undergoing ureteroscopic kidney or ureteral stone extraction. Stone size must be 6mm stones or greater.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Training Swallowing Initiation during Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck CancerDr. Bonnie Martin-Harris and her team are studying a new swallowing therapy to improve eating, drinking, health, and quality-of-life of individuals with head and neck cancer. Therapy will be conducted remotely.
Who Can Participate?If you were recently diagnosed with head and neck cancer, you might be eligible to participate in this study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG MORAb 202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor TypesThere are two parts to this study: The Dose Escalation part, was toidentify the highest tolerable safe dose of MORAb-202 and is now complete. The DoseConfirmation part is to further evaluate the safety, tolerability and effectivenessof MORAb-202 in subjects with ovarian cancer and endometrial cancer at selecteddoses. Who Can Participate?Ovarian cancer or primary peritoneal cancer orfallopian tube cancer and had progression of disease after previous treatmentwith a platinum-containing chemotherapy regimen. · · Age of at least 18 years.
Note: This is only apartial list of eligibility criteria. Please contact the Robert H. LurieComprehensive Cancer Center of Northwestern University for complete screeninginformation if you are interested in this clinical trial.
Allprospective patients will undergo screening tests to determine if they areeligible to take part in the study Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A5386: Il-15 Superagonist with and without bNAbs to induce HIV controlScientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. This Phase I clinical trial will evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), VRC07-523LS and 10-1074, to control HIV. A year after starting study treatment, participants will stop antiretroviral therapy (ART) for up to 24 weeks to see how well their immune system controls growth of HIV (analytic treatment interruption or ATI). Who Can Participate?· People living with HIV · Have an undetectable viral load for at least 2 years. · Be willing to take a superagonist and broadly neutralizing antibodies · Be willing to temporarily stop taking anti-HIV medications · Not have active hepatitis B or C infection or history of AIDS-defining conditions. · Current CD4 cell count greater than 500 or never had a CD4 cell count less than 200 Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
XIRB A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis
Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
xIRB Evaluation of Applaud Medical’s Acoustic Enhancer with Laser Lithotripsy in the Treatment of Urinary StonesA pivotal study to evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser lithotripsy (URS-LL) in the treatment of subjects with urinary stones.
Who Can Participate?Patients with at least one urinary stone and up to 3 stones located proximally to the iliac vessels on one side may be enrolled. 3a. Urinary stone(s) should be apparent on a CT scan with 30 days prior to the study enrollment. 3b. Patients with at least 1 urinary stone measuring at least 6mm but not more than 20mm in diameter. For patients with multiple stones, up to 3 stones may be treated on the treated side, with a cumulative stone diameter not exceeding 20mm. All 1-3 stones are to be treated. Stone measurement will be conducted using CT imaging.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 21B01: Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID)The purpose of this study is to assess if the use of a 3D imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room for breast conservation surgery. If you are undergoing breast conservation surgery and meet all criteria, the 3D imaging device, VSI, will be used to guide and assist the surgeon in identifying and removing all positive margins while in the operating room. The lumpectomy procedure will be performed per standard practice. If eligible, the lumpectomy procedure will be performed per standard practice. Promptly after excision, the tumor specimen will be imaged using the VSI device to take additional 3D images of the removed tissue during the standard of care surgery.
During surgery, after the tumor has been removed, the investigators will use the VSI device to identify the margins on the main sample. The surgeon will use this information to remove additional tissue from the cavity. The surgeon will then complete the standard of care surgery according to standard of care practices which may include additional shaves of the remaining issue. The amount of tissue removed as a result of VSI-directed shaving will not be more than the amount that your surgeon would normally remove as part of standard of care.
Participants will be asked to come for a post-operative visit as per standard of care and will be followed-up up to 2 months after surgery.
Note: This is only a partial description of the study procedures. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: · Age 18 or older · Must have histologically confirmed invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component · Planning to undergo breast conservation surgery with planned localization and intraoperative imaging for the management of invasive breast cancer
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The PROMISE Study: PROspective study of Mothers’ and Infants’ Social and Epidemiologic determinants of healthThe purpose of the PROMISE study is to identify relationships between lifestyle factors (e.g., sleep, nutrition) and health outcomes for women and their children. Who Can Participate?Between the ages of 18-44 undergoing IVF for the first time without use of donor eggs or a gestational carrier.Principal Investigator, Study ID, Keywords STU00215252 Click to Copy URL to Clipboard For questions about this study, contact: |
COASTPrimary SLT provides better clinical outcomes, fewer side effects, obviation of the need for daily self-dosing, and is cost-effective compared to topical medications. The recent publication of the LiGHT (Laser in Glaucoma and Ocular Hypertension) trial1 is likely to drive an overdue paradigm shift from our current medications-first approach to an SLT-first practice pattern in the management of primary open-angle glaucoma (POAG). The overall goal of the study is to identify the optimal application of SLT therapy to provide maximal medication-free survival in trial participants with mild-moderate POAG or high-risk OHT. The optimal energy and repeat interval for SLT have not been established. The trabecular meshwork (TM) undergoes ongoing cumulative damage from both the underlying glaucoma process and from SLT.2-5 Low energy SLT may cause less TM damage and extend TM responsivity to subsequent SLT treatments, thus extending medication-free survival. Repeated annually to maintain TM cell health (rather than delaying repeat SLT until TM cells become dysfunctional and IOP rises) may further extend medication-free survival. Who Can Participate?1. Age 18 or older and in good health 2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes): a. High-risk ocular hypertension (OHT): IOP > 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of >0.2 between eyes) [enrollment of trial participants with High-risk OHT will be capped at 25% of total enrollment] b. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° <15 dB (see figure on next page) c. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points <15 dB or mean deviation -12.0 dB or better with 1 central 5° points <15 dB (see figure on next page). 3. Each eye with BCVA 20/200 (UK 6/60) or better Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CY6022A FOLLOW-UP, OPEN-LABEL, RESEARCH EVALUATION OF SUSTAINED TREATMENT WITH AFICAMTEN (CK3773274) IN HYPERTROPHIC CARDIOMYOPATHY (HCM) Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 MutationTofersen (also called BIIB067) is currently being evaluated for the treatment of adults with familial ALS associated with a mutation in the SOD1 gene. The optimal timing for initiation (i.e., prior to or after the emergence of clinically manifested disease) of tofersen is unknown. This study will evaluate the impact of initiating tofersen based on biomarker evidence of disease activity, prior to the emergence of clinical symptoms or signs that definitively indicate ALS. Who Can Participate?There are four parts to this study, each with different eligibility criteria. Please contact the study coordinator and he/she will determine whether you are eligible. In order to enroll in the study (Part A), here are a few basic (but not complete) eligibility criteria:1. 18 years or older 2. Must have one of the following SOD1 mutations confirmed by a central reader. Please contact the study coordinator for a complete list. 3. If a SOD1 mutation is not listed, your mutation will be adjudicated by a Mutation Adjudication Committee. 4. Plasma neurofilament (NfL) level less than 44 pg/mL during Screening 5. Clinically pre-symptomatic for ALS (i.e., must not have clinically manifested ALS) at Part A Screening Visit 6. History or positive test result at Screening for HIV, Hep-B, or Hep-C Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgarisThe purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Prospective, Randomized Controlled Trial Investigating Pecs Blocks Types I and II as a Method for Administering the Non-Opioid Anesthetic Exparel in Order to Mitigate Postoperative Pain, Narcotic Usage and Hospital Stay in Patients Undergoing Implant-Based Tissue Expander Breast Reconstruction Surgery.We will be investigating theuse of a novel type of local drug administration as well as assessing whether anon-opioid based drug will result in more positive pain outcomes while reducingreliance on narcotics (opioid-based drugs) following your surgery. Who Can Participate?NA, must be pursuing breast reconstruction already.Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
PROTECT IV TrialThis study is recruiting patients who are scheduled to have a heart procedure called a Percutaneous Coronary Intervention (PCI) and may be at risk of potential problems during the procedure because they have complex heart disease and reduced left heart function. The purpose of this study is to assess if using an Impella device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function, and health after the heart procedure compared to the current standard of care.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Clinical Trial of Approaches to Prostate Cancer SurgeryThis study will include adult men undergoing radical prostatectomy for clinically localized prostate cancer. Who Can Participate?Inclusion Criteria
Exclusion Criteria
Principal Investigator, Study ID, Keywords |
IMPACT-Pain-RAFinding a way to reduce pain is consistently named as one of the top priorities for patients with RA. People living with RA commonly report persisting pain which on average is 30% more intense than the general population. Previous research has found that this ongoing pain may in part be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will examine the relationship between immune cells (cells that are part of the immune system, that help the body fight infections and other diseases) and pain centralization. This study will also search for biomarkers (substances that can be measured in the blood) that may be associated with pain centralization, so that we can determine who may be at at risk for developing this kind of chronic pain and how to treat and/or prevent it in the future. Participants will be in this research study for one study visit, lasting about 2 hours. Participants will undergo a physical examination to assess joint inflammation, complete questionnaires, undergo quantitative sensory testing (QST) assessments, and provide blood samples. Who Can Participate?Key Criteria:
Principal Investigator, Study ID, Keywords STU00215712 Click to Copy URL to Clipboard For questions about this study, contact: |
LUX-Dx TRENDSThis study is recruiting patients whose medical tests show they have heart failure, and whose doctors have determined that they would benefit from an insertable cardiac monitor (ICM). Heart Failure is a condition that makes the heart muscle weak and the heart cannot pump as much blood as the body needs. Sensors have been added to the ICM to determine whether they can provide doctors who treat patients with similar conditions with additional information to help analyze their heart failure condition. The study will gather information about the sensors.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 20H09: Phase II, Single-arm, Open-label, Multicenter study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hodgkin’s LymphomaWe are asking you to take part in this research studybecause you have and aggressive B-cell Non-Hodgkin’s Lymphoma that couldbenefit from standard of care , chimeric antigen receptor (CAR) T-cell therapy.CAR T-cell therapy is a promisingtreatment where immune cells originally collected from your body called T-cells (a type of white blood cell), are modifiedand then reintroduced into your body to fight and destroy lymphoma cells.However, CAR T-cell therapy can sustain anti-cancer response beyond 6 months in only 30-40% ofcases. Thus, there is need to enhanceefficacy of CAR T-cell therapy in lymphoma. Lymphoma cells are also known to make a protein called Burton’s TyrosineKinase (“BTK” ), that helps in the proliferation of these cancers. Zanubrutinib is targeted drug that is FDAapproved for a related lymphoma called “Mantel Cell Lymphoma” ( MCL). It isknown to inhibit the BTK protein ( BTK inhibitor ) and can enhance T cell function. Thus, it is expected that it couldenhance CAR T-cell therapy. The investigators of his clinical trialhypothesize that the administration of Zanubrutinib before CAR T-cell therapy and after CAR T-cell therapy can enhance itsanti-cancer effect for your lymphoma
Who Can Participate?· Participantsmust be 18 years or older The target populationfor this study is patients with aggressive B-cell Non-Hodgkin’s LymphomaPrincipal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU SARC041Dedifferentiated liposarcoma often has a protein called CDK4 that is over-active. Researchers think that abemaciclib (the study drug), which blocks CDK4, may slow or stop the growth of the liposarcoma tumors. This study is being done to see if the study drug can slow or prevent liposarcoma from growing. The US Food and Drug Administration (FDA) has not approved abemaciclib for liposarcoma, although it is approved for breast cancer. The use of abemaciclib in this study is considered investigational. Who Can Participate?Key eligibility criteria include: · Histologically confirmed diagnosis of dedifferentiated liposarcoma which is locally recurrent and/or metastatic. · At least one site of measurable disease on CT/MRI scan as defined by RECIST 1.1 criteria. Baseline imaging must be performed within 28 days of Day 1 of study · Age of at least 18 years All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASEThis is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Who Can Participate?• Diagnosis of PD for at least 6 months to maximum 3 years at screening and between 50-85 years of age • On symptomatic PD medication for at least 6 months, with a stable dose for 3 months prior to baseline • No dyskinesisa or motor fluctuations (i.e. MDS-UPDRS Part IV = 0) Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SKIP-ArthralgiaThe main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are: Participants can complete all parts of the study at home. They will: Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords Breast cancer survivorship aromatase inhibitor endocrine therapy pain arthralgia adherence pain coping skills training cognitive behavioral therapy
For questions about this study, contact: |
VIVA MIND StudyThis study will test an oral investigational drug called varoglutamstat (PQ912) for the treatment of individuals with mild cognitive impairment due to AD or probable mild Alzheimer's Disease. Participation may last up to 20 months. Who Can Participate?General Inclusion Criteria:
General Exclusion Criteria:
https://www.viva-mind.org/ Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsThis study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00216645 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 21C01: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastomaThe purpose is to determine if mycophenolate motfetil (MMF) combine with temozolomide (TMZ) can stop glioblatoma. Mycophenolate Mofetil is an antimetabolite immunosuppressant and is FDA approved for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplant, and is used in combination with other immunosuppressants. Group S (Pre-surgical): Window of Opportunity Study, pre-operative MMF and temozolomide (TMZ) Participants with suspected newly diagnosed or recurrent glioblastoma who plan to have surgical resection are eligible. Study treatment must begin within 7 days after registration. Group S will open in Part 1 after one participant in Group 1 has successfully completed the first dose level DLT period and subsequent DSMB review. The MMF dose for Group S will be adjusted each time DSMB has approved a subsequent dose escalation. The MMF dose for Group S will always be 1 dose level below the current enrolling dose level (the last safe dose level as indicated by the DSMB) in Group 1. Participants will have 5 days of pre-operative MMF (BID) and TMZ (200 mg/m2 QD) Group 1 (Adjuvant): Adjuvant therapy+ MMF (dose escalation) Four to six weeks after the completion of chemoradiation, participants will be registered to the study. Study treatment must begin within 7 days after registration. On study, participants will receive maintenance TMZ and MMF. Each maintenance cycle is 28 days long. TMZ will be taken orally once a day on Days 1-5, at a dose of 150 mg/m2, for up to 6 cycles. On Cycles 2-6, the TMZ dose may be increased to 200 mg/m2 in the absence of toxicity. Starting Cycle 1 Day 1, MMF will be taken orally twice daily for up to 6 cycles (each cycle is 28 days). The dose of MMF will depend on the dose level each participant is accrued to. See MMF Dose Level table in Section 4.2. The DLT period for Group 1 is the duration of Cycle 1 (28 days), and 7 days thereafter. Group 2 (Chemoradiation): RT + MMF for MGMT unmethylated tumors (dose escalation) About 4 weeks after surgical resection, participants confirmed to have unmethylated glioblastoma will be registered and treated with concurrent MMF and TMZ (75 mg/m2 daily) and 6 weeks of focal radiation therapy (60 Gy). Study treatment must begin within 7 days after registration. MMF will be taken twice daily for the entire 6 week period of focal radiation therapy. The dose of MMF will depend on the dose level each participant is accrued to. After radiation therapy, participants will start adjuvant treatment with TMZ. TMZ will be taken orally once a day on Days 1-5, at a dose of 150 mg/m2, for up to 6 cycles. On Cycles 2-6, the TMZ dose may be increased to 200 mg/m2 in the absence of toxicity The DLT period for Group 2 is the duration of radiation therapy (6 week period), and 7 days thereafter. Group 3 (Expansion): MMF during RT and during adjuvant phase. Enrollment to begin only AFTER the completion of groups 1 and 2. About 4 weeks after surgical resection, participants will be registered and treated with concurrent MMF and 6 weeks of focal radiation therapy (60Gy) and concurrent TMZ at a dose of 75 mg/m2 daily. Study treatment must begin within 7 days after registration. After completion of chemoradiation, participants will go on to have adjuvant TMZ (at a dose of 150 mg/m2 on days 1-5 of each cycle, may be up to 200 mg/m2 during cycles 2-6) with concurrent twice-daily MMF for a total of 6 planned cycles (each cycle is 28 days). The dose of MMF during radiation therapy and during adjuvant treatment will be the RP2D determined in dose escalation Groups 1 and 2. Optune® Device (Tumor Treating Fields) Concurrent use of the Optune® device (TTFields) is permitted, but not required for participation on this study. It’s use will be according to standard of care. Who Can Participate?Some of the eligibility criteria include: •Participants must be 8 years of age or older. •For Groups 1-3: Histologically confirmed glioblastoma (GBM), IDH wild-type (by IHC R132H neg or sequencing). Astrocytoma with molecular features of GBM are eligible. •For Groups 1-3: Newly diagnosed glioblastoma and: a) Group 1: Received surgical resection or biopsy followed by chemoradiation; b) Group 2: Received surgical resection or biopsy only and have documented unmethylated glioblastoma (may have been done at an outside facility); c) Group 3: Received surgical resection or biopsy only •For Group S: Newly suspected glioblastoma or recurrent glioblastoma, and scheduled to undergo a standard of care surgical resection or biopsy Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Testing of bevacizumab, erlotinib, and atezolizumab in combination for advanced-stage kidney cancerThe purpose of this study is to see if using a combination of bevacizumab, atezolizumab, and erlotinib is safe and will cause your tumors to shrink.
The use of bevacizumab and atezolizumab in this study is considered investigational which means this combination has not been approved by the U.S. Food and Drug Administration (FDA) to treat kidney cancer. However, the FDA has given us permission to use bevacizumab and atezolizumab in this study. Who Can Participate?Some of the key eligibility criteria include: · Patients with cytologically or histologically confirmed RCC and a diagnosis of HLRCC (Cohort 1) or sporadic/non-HLRCC papillary RCC (Cohort 2). · Age ≥12 years · Adequate organ and marrow function
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Principal Investigator, Study ID, Keywords |
PROMOTERFinding a way to reduce pain is consistently named one of the top priorities for patients with RA. People living with RA commonly report persisting pain which, on average, is 30% more intense than the general population. Previous research has found that this ongoing pain may, in part, be caused by problems in the way the brain processes pain signals. This is called pain centralization. This study will identify factors associated with pain centralization, so that, in future studies, we can learn more about how to prevent the development of chronic pain in RA. This study will also identify biomarkers that could provide insight into targeted therapies for future clinical trials. This study includes two in-person study visit to complete quantitative sensory testing (QST), blood draws, joint counts, blood pressure assessment, and patient-reported outcome (PRO) questionnaires. If participants are unsure of their height and/or weight off-at the time of the visits, they may also have height and/or weight assessed. The first visit will occur at baseline within 3 weeks of the patient starting their DMARD. The second visit will occur 12 weeks (+/- 3 weeks) after starting their new DMARD. Who Can Participate?Key Eligibility Criteria
Principal Investigator, Study ID, Keywords STU00216431 Click to Copy URL to Clipboard For questions about this study, contact: |
Investigation of Sleep and Health Outcomes in Women Reporting Normal and Heavy Menses FlowWe are interested in understanding how the menstrual cycle and severity of menses (lheavier menstrual flow) affects sleep. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00215465 Click to Copy URL to Clipboard For questions about this study, contact: |
Drug BNT152-01C: Phase I, first-in-human, open-label, dose escalation trial to evaluate safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BNT152+153 in patients with solid tumorsThis research study is ultimately designed to evaluate a new drug called BNT152+153. Since this drug is a combination of two investigational drugs called BNT152 and BNT153, the sponsor must first evaluate each of the two drugs separately (called “monotherapy”). “Investigational” means that BNT152 and BNT153, whether given as monotherapy or combination therapy, are not approved by the United States (U.S.) Food and Drug Administration (FDA) or by any regulatory authority in the world.
In this research study, BNT152 monotherapy, BNT153 monotherapy, and BNT152+153 combination therapy will be tested in humans for the first time.
The overall purpose of this research study is to assess the safety and to establish a safe and effective dose of BNT152 and BNT153 when each is given alone (monotherapy) and when given in combination (BNT152+153). The study will also collect information about how well the drug(s) works against cancer. Who Can Participate?• Histologically or cytologically confirmed solid tumor that is metastatic (Stage IV) or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy. If there is no contraindication, patients should have exhausted all SoC therapies before entering the trial. • Measurable or evaluable disease per RECIST1.1. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NRG GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMICRISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)Purpose The purpose of this study is to determine if radiation therapy alone is as effective at controlling unfavorable intermediate risk prostate cancer, cancer compared to the usual combination of radiation and hormone therapy.
Who May be Eligible: Some of the key eligibility criteria include: · Cytologically or histologically confirmed diagnosis of adenocarcinoma of the prostate. · Unfavorable intermediate risk prostate cancer · Age ≥18 years
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study.
Principal Investigator, Study ID, Keywords |
Veri-T StudyThis study will test an oral investigational drug called Verdiperstat (BHV-3241) for the treatment of individuals with Semantic Variant Primary Progressive Aphasia (svPPA). Participation may last up to 6 months. Who Can Participate?General Inclusion Criteria:
General Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Assessment of Follitropin Delta Efficacy and Safety for Treatment of Men with Idiopathic InfertilityTo test the efficacy and safety of FE 999049 for the potential treatment of idiopathic male infertility. The main goal of the study is to find out whether men with idiopathic infertility treated with FE 999049 have a higher chance that their partner conceives naturally. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Impella BTR EFSUse of the Impella BTR™ in Patients with Heart Failure: An Early Feasibility Study Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaThe purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
RADIANCE Continued Access Protocol (RADIANCE CAP)RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
REBIRTHThe study will enroll women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized trial of bromocriptine therapy to evaluate its impact on myocardial recovery. Who Can Participate?Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
LIDAlmost 100 million Americans have gotten COVID-19. If you recently tested positive, team up from the comfort of home and collect your own fluid samples (like nasal swabs, saliva and blood). Your participation might help lead to better testing methods! Who Can Participate?Inclusion: - 18 - Must have tested positive for Covid-19 or presumed positive due to significant exposure Addition screening question: Do you live within 2 miles of Northwestern Memorial Hospital Arkes Pavillion or the Northwestern Evanston campus? Principal Investigator, Study ID, Keywords STU00216945 Click to Copy URL to Clipboard For questions about this study, contact: |
NU 22H01: Serial Monitoring of Circulating Plasma Cells and Plasma Cell Components in Adults with Plasma Cell DisordersThis study is being done to collect, process, and store blood samples of plasma cell disorder patients. The collected blood samples will be used for research projects to study the abnormal plasma cells and compare the results to current tests being done. This will provide an opportunity to better understand how a patient is responding to treatment and to assess the stage of the patient’s disease. This study will use different tests that are not FDA approved. This test is being studied as a less invasive way to monitor amount of disease in a patient (versus invasive bone marrow biopsy). Current blood tests show the levels of the product of the cancer cell - not the levels of the cells themselves. Sometimes the cancer cells do not make this product and can therefore go undetected in standard tests. This study will show the number of cells. These tests will help identify, and analyze circulating plasma cells (CPCs), which are cells that have escaped into the bloodstream (a characteristic of plasma cell disorders). We will also look at any plasma cell components, such as genes in the DNA and RNA. Part of your samples will be used for Next Generation Sequencing (NGS) to evaluate any changes in your genes. NGS is a useful tool that determines the sequence of your DNA. Who Can Participate?You may be eligible for this research study if you have a plasma cell disorder. Principal Investigator, Study ID, Keywords STU00216869 Click to Copy URL to Clipboard For questions about this study, contact: |
The Role of Low Testosterone in Perioperative Surgical OutcomesThis study aims to understand how low testosterone may impact surgical complications, such as frailty. By understanding the risks associated with low testosterone around the time of surgery, we can develop interventions to treat low testosterone in advance of surgery. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00216934 Click to Copy URL to Clipboard For questions about this study, contact: |
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE)The purpose of the PREVENTABLE research study is to determine if taking a statin may help older adults live well for longer by preventing dementia, disability, and disease. A statin is a commonly used drug to lower cholesterol. Who Can Participate?Inclusion criteria: Community-dwelling adult Age >= 75 years old English or Spanish as primary language Exclusion criteria: Clinically evidence cardiovascular disease Hospitalization for heart failure within past 12 months Dementia Severe hearing impairment Unable to talk Statin use in the past year or for longer than 5 years previously Active liver disease Documented intolerance to statins Principal Investigator, Study ID, Keywords STU00217426 Click to Copy URL to Clipboard For questions about this study, contact: |
NU DF21B07: Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trialIn this research study, we are examining how effective talazoparib is in patients with metastatic breast cancer with a BRCA mutation in their tumor.
The U.S. Food and Drug Administration (FDA) has not approved talazoparib for your specific disease but it has been approved for metastatic breast cancer with a germline (inherited) BRCA mutation. Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called “poly (ADP-ribose) polymerases” also called “PARPs”. PARPs are proteins (made from genes which are part of your DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells. Cancer cells may be killed by a study drug, like talazoparib, that stops the normal activity of PARPs. In clinical trials, the use of talazoparib and other PARP inhibitors have shown that these drugs can reduce tumor size and slow tumor growth in some cancer patients with BRCA1 or BRCA2 mutations
Who Can Participate?Key eligibility criteria include:
· Metastatic breast cancer with deleterious somatic BRCA 1 or 2 mutations detectable by cell-free circulating tumor DNA or tumor tissue, by CLIA certified clinical assay (including but not restricted to MGH-Snapshot cfDNA assay, Guardant360, Foundation One).
· Patients with germline BRCA 1 or 2 mutations will not be eligible.
· Patients with only a Variant of Unknown Significance or non-functional BRCA mutation, without a deleterious somatic BRCA 1 or 2 mutation will not be eligible.
· The following disease subtypes are eligible:
· Triple negative breast cancer (defined as ER < 1%, PR < 1%, HER2 negative, as per ASCO CAP guidelines), with disease progression on at least one prior chemotherapy regimen in the metastatic setting.
· Hormone receptor positive, HER2 negative disease with disease progression on at least one prior endocrine therapy in the metastatic setting or be considered inappropriate for endocrine therapy
· Patients must have evaluable or measurable disease. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) ECOG-ACRIN 9213: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)This study is being done to answer the following question: Can daratumumab-hyaluronidase reduce the level of MRD in T-ALL patients previously treated with chemotherapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your T-ALL. The usual approach is defined as care most people get for Acute Lymphoblastic Leukemia (ALL). The usual approach for patients who are not in a study is treatment with chemotherapy, and possibly stem cell transplant. Sometimes, combinations of these treatments are used. Currently there is no SOC treatment for MRD positive T ALL. Many patients if eligible would undergo stem cell transplant, but still have a high risk for T ALL relapse if MRD positive The purpose of this study is to test the good and bad effects of the drug called daratumumab and hyaluronidase. Daratumumab and hyaluronidase could be effective in preventing your cancer from returning, but it could also cause side effects. The study doctors hope to learn if the study drug will be effective in treating patients with MRD positive T-ALL and preventing reoccurrence of your disease. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study (NeoPOWER)The purpose of this study is to test any good and bad effects of the study drug called Libtayo(cemiplimab) in patients with the diagnosis of Cutaneous Squamous Cell Carcinoma (CSCC,) when given before resection surgery. This investigational approach could shrink your cancer, but it could also cause side effects. Researchers hope to learn if the use of this drug before surgery will reduce the amount of cancer cells by at least 50% compared to the original amount in more than 40% of patients. Libtayo (cemiplimab) is FDA-approved to treat metastatic CSCC. Cemiplimab will be administered as an IV infusion over 30 minutes in an outpatient setting. Cemiplimab will be used at a flat 350 mg IV dose every 21 days for a total of 9 weeks (or 12 weeks). One cycle is 21 days. After discontinuation of treatment, if the tumor is potentially resectable, the patient will proceed with surgical resection.
Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete description of treatment. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically confirmed, measurable, and potentially resectable Cutaneous Squamous Cell Carcinoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
The MOOD study – external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the treatment of Major Depressive Disorder (MDD)Depression is a common illness worldwide, with more than 264 million people affected.* Many depressed people do not get sufficient benefit from antidepressant medications and are seeking alternative treatment options. You may qualify to participate in a research study to evaluates a new treatment for alleviating Major Depressive Disorder (MDD) symptoms that is self-administered with an investigational medical device. The study device is non-invasive and is used by participants at home at convenient times. Compensation for time and travel is available for eligible participants Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous MelanomaPatients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include: · Participants must have a diagnosis of Cutaneous Melanoma, Stage II · Participants must be 18 or older · Patient must be able to give informed consent and comply with the treatment protocol and follow-up plan. · Surgery (which refers to the staging sentinel node biopsy and wide local excision as these are both to be done on the same day) must be completed within 120 days of the original diagnosis.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
NU-Age Research RegistryNU-Age is looking for adults of all ages who are interested in research opportunities on aging to join the NU-Age Research Registry.
What is involved? Who Can Participate?All adults are eligible to join the NU-Age registry Principal Investigator, Study ID, Keywords STU00217467 Click to Copy URL to Clipboard For questions about this study, contact: |
STELLARThe STELLAR Program is a healthy lifestyle telehealth program designed for individuals who have been diagnosed with cancer, completed active treatment, and have 2 or 3 of the following health behaviors: 1) have a BMI of 25 or greater, 2) perform less than 90 minutes a week of moderate or vigorous physical activity, 3) currently smoke. Our central mission is to increase the accessibility of equitable health support and resources for cancer survivors within Northwestern Medicine’s network. Spanning over the course of 12 months, trial participants are randomly assigned to one of two distinct study arms. One arm involves telehealth sessions with a health promotionist, fostering a close and supportive partnership between participants and health coaches across a sequence of 16 remote sessions. The second arm offers a self-guided avenue, empowering participants with personalized tools for self-paced progress. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Pippa Fitness Pessary Clinical TrialThis is an effectiveness and safety study of a pessary that will be available over the counter for stress incontinence. Who Can Participate?Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®The goal of this study is to generate additional evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) Alliance A211801: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline MutationThis phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) NRG GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)This Phase II/III trial will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically/pathologically confirmed Stage IIIA or Stage IIIB colon adenocarcinoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 1918A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of lymphoma · Participants must be 75 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell LymphomaThis phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL. Who Can Participate?
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Principal Investigator, Study ID, Keywords |
Arm and leg cycling for accelerated recovery from SCIThe purpose of our study is to understand the effects of combined arm and leg cycling on an individual’s walking ability following an incomplete spinal cord injury (iSCI). During the study, participants will complete 5 training sessions (~1.5hrs per session) per week with cycling for 12 consecutive weeks. During a training session, you will cycle with your arms and legs for 60 minutes. The cycling machine can be set to provide motorized assistance to help you cycle. Additionally, we will complete several assessments at baseline, at 3-week intervals during the training period, after the training period, and 6 months after the training period. The assessments include tests for sense, strength, balance, stability, spasticity/stiffness, walking speed, walking distance, muscle strength, gait analysis, muscle responses due to transcranial magnetic stimulation (TMS) of your brain, and brain-muscle connectivity via electro-encephalography (EEG). The assessments (~7hrs per timepoint) may be split across several days. Who Can Participate?Inclusion Criteria
Exclusion Criteria
Principal Investigator, Study ID, Keywords STU00216731 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB NCI CIRB) NRG GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or CarcinosarcomaThis phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial serous carcinoma or endometrial carcinosarcoma · Participants must be 18 or older · Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) ETCTN 10486: Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and may have spread to other parts of the body. Another aim of this study is to determine if and how patients' genes influence their response to this specific drug combination. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer. Who Can Participate?• Participants must have a diagnosis of metastatic or unresectable cancer • Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
PERSEVERETo assess the safety and effectiveness of AMDS to treat patients with acute DeBakey type I dissection with evidence of radiographic and/or clinical malperfusion, through open surgical repair. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 22I05Colon and rectal cancer are cancers that involve the lowest part of the digestive system: the large intestine and the rectum. A colorectal cancer that has already spread to distant sites by the time it is diagnosed is referred to as metastatic (stage IV) colorectal cancer (CRC). In colorectal cancer, mutations in the BRAF gene are present in approximately 10% of patients with metastatic disease. Outcomes in these patients are poor relative to patients with non-BRAF mutated colon cancer. Encorafenib and cetuximab are standard of care therapy for metastatic colorectal cancer (CRC) patients who have disease progression (worsening of disease) after a previous line of therapy. Addition of hydroxychloroquine (HCQ) with encorafenib has shown to overcome the tumor’s resistance to encorafenib in laboratory studies. This study examines adding hydroxychloroquine to encorafenib and cetuximab in patients with worsening metastatic colon cancer on previous therapy. HCQ is an oral drug which is approved by the Food and Drug Administration (FDA) for other indications such as for treatment of uncomplicated malaria, preventive against malaria in select geographic regions, and for treatment of rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus in adults. It is not currently FDA approved for the indication to be investigated in this study. As such, hydroxychloroquine will be the drug to be investigated (investigational drug) in this study in combination with encorafenib and cetuximab. Another drug named Panitumumab is also FDA approved for treatment of metastatic CRC in combination with other standard therapy. Panitumumab may also be used instead of Cetuximab in the above-mentioned treatment combination, depending on the choice of your doctor. Who Can Participate?Stage IV colon cancer with progression (disease worsening) on a prior line of therapy Principal Investigator, Study ID, Keywords |
DEFINE-HTDevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation (DEFINE-HT) Who Can Participate?Undergoing transplant evaluation or currently on the heart transplant waiting list and expected to receive a heart transplant. Principal Investigator, Study ID, Keywords |
DREAM StudyThe United States is currently facing a maternal health crisis. Pregnant and birthing people experience more maternal deaths in this country compared to other wealthy countries, but not everyone is impacted in the same way. Black women and birthing people are unequally burdened and are 2-3 times more likely to die during or following pregnancy than White birthing people. The majority of these deaths are preventable. Racism is believed to be the main reason why maternal deaths are impacting Black women and birthing people the most. However, we don’t know how to fully describe the complex ways racism impacts health outcomes. We are working to change that. The goal of the DREAM study is to develop an action plan that will identify resources and support that can improve Black maternal and infant health by building community relationships and uplifting the voices, perspectives, and knowledge of the communities who are being the most impacted. Who Can Participate?To be eligible for this study you must meet the following criteria:
Principal Investigator, Study ID, Keywords STU00217902 Click to Copy URL to Clipboard |
LeAAPS TrialLeft Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Study for Desensitization of Chronic Kidney Disease Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte AntigenBrief Summary: The primary objective of the study is to assess the safety and tolerability of REGN5459 (Part A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and are highly sensitized to human leukocyte antigen (HLA). The secondary objectives of the study are to determine/assess the following for REGN5459 (Part A) or REGN5458 (Part B):
Who Can Participate?Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
REHAB-HFpEFPhysical Rehabilitation for Older Patients with Acute Heart Failure with Preserved Ejection Fraction (REHAB-HFpEF) Who Can Participate?
Principal Investigator, Study ID, Keywords STU00218196 Click to Copy URL to Clipboard For questions about this study, contact: |
(PEAK) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486 + Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable or Metastsatic Gastrointestinal Stromal TumorsThe purpose of this research study is to evaluate how CGT9486 (also known as bezuclastinib) plus sunitinib affects gastrointestinal stromal tumor (GIST) compared to just treatment with sunitinib along. You may participate in this study if you have received prior therapy with imatinib only and no other anticancer drug for GIST, and no other tyrosine kinase inhibitors (TKIs). Participants will receive study treatment during 28-day study treatment cycles. The total number of study treatment cycles you may have will depend on how you respond to your study treatment. If you respond well, meaning your GIST does not progress or become worse, you may continue to receive treatment in 28-day cycles for a year, or longer. If your GIST progresses, meaning it grows, spreads, or gets worse, you will no longer receive treatment with the study drug and the study doctor will review other treatment options that may be available to you outside the study. Once you have stopped taking study drug, and all safety and imaging studies are completed, you will be contacted every 3-6 months to see how you are doing for up to 5 years, or until the study is over, whichever happens first. This follow-up can be done over the phone or by other electronic means. Who Can Participate?Participants must have confirmed locally advanced, metastatic and/ or unresectable gastrointestinal stromal tumor (GIST) and have documented disease progression on or intolerance to imatinib as determined by medical doctor. Principal Investigator, Study ID, Keywords |
NU 22MH03: Phase II open-label multi-cohort study evaluating CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancersThe primary objective is to estimate the Overall Response Rate (ORR) of treatment with CPI-613 plus HCQ and, depending on the cohort and indication, either 5-FU or gemcitabine.
Under this protocol, patients in cohorts 1 and 2 will be treated with combination of 2000 mg/m2 CPI-613 Day 1 and Day 15, plus 2400 mg/m2 Fluorouracil (5-FU) IV infusion over 46 hours Day 1 and Day 15, plus 400 mg hydroxychloroquine (HCQ) PO BID over 28-day cycles.
Patients in cohort 3 will be treated with combination of 2000 mg/m2 CPI-613 Day 1 and Day 15 plus 400 mg HCQ PO BID and, depending on indication, either 1000 mg/m2 gemcitabine or 2400 mg/m2 5-FU.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older · Patients in cohort 1 must have colorectal cancer. Patients in cohort 2 must have pancreatic cancer. Patients in cohort 3 may have any of the following cancers:o Biliary o Gastroesophageal o Urothelial o Ovarian o Non-small cell lung (adenocarcinoma only)
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients with Lung Tumors, The RADiotherapy Augmented Intelligence Trial (RAD-AI)The study is being done to obtain evidence of effectiveness and safety for an imaging and computer technology intended to assist your physician in prescribing the radiation dose for your lung Stereotactic Body Radiotherapy (SBRT) treatment. The duration of radiotherapy is 1-2 weeks after you have been registered. You will be followed for up to 5 years to check if your cancer has come back after the radiotherapy. Who Can Participate?· Participants must have a diagnosis of Lung cancer solitary or oligometastatic (spread a little) · Participants must be 18 or older · Who has not had prior radiotherapy Principal Investigator, Study ID, Keywords |
High vs. Standard Dose Influenza Vaccine in Lung Allograft RecipientsLung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls. Induction and early maintenance immunosuppression is thought to impair immunogenicity to standard dose inactivated influenza vaccine. This early post-transplant period is when immunity is most desirable, since influenza disease during this time frame is associated with adverse consequences. Thus, strategies to reduce severe influenza disease in this highly susceptible population are critical. No trials in lung transplant recipients have evaluated two doses of HD-IIV within the same influenza season as a strategy to improve immunogenicity and durability of influenza prevention. Furthermore, no influenza vaccine trials have focused on enrollment of subjects at early post-transplant timepoints. Very few studies have been performed in solely lung allograft recipients. Immunosuppression intensity is highest in lung patients, thereby limiting comparisons to recipients of heart, liver, and kidney transplants. Therefore, studies to assess both HD-IIV and two-dose strategies in the same influenza season in post-lung transplant recipients are greatly needed. The central hypothesis of our proposal is that lung allograft recipients who are 1-35 months post-transplant and receiving two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have higher HAI geometric mean titers (GMT) to influenza antigens compared to those receiving two doses of SD-QIV. To test this hypothesis and address the above critical knowledge gaps, we propose to conduct a phase II, multi-center, randomized, double-blind, controlled immunogenicity and safety trial comparing the administration of two doses of HD-QIV to two doses of SD-QIV in lung allograft recipients 1-35 months post-transplant. The results of this clinical trial will address significant knowledge gaps regarding influenza vaccine strategies (e.g., one vs. two doses and HD-QIV vs. SD-QIV) and immune responses in lung transplant recipients and will guide vaccine recommendations during the post-transplant period. Who Can Participate?Inclusion Criteria: Exclusion Criteria: Principal Investigator, Study ID, Keywords Influenza Vaccination Immunization Lung Transplantation High Dose Fluzone Standard Dose Influenza Human Communicable Diseases
For questions about this study, contact: |
NRG BN012This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Radiographic confirmation of 1-4 brain metastases · Participants must be 18 or older · Known active or history of invasive non-central nervous system (CNS) primary cancer based on documented pathologic diagnosis within the past 3 years cancer based on documented pathologic diagnosis within the past 3 years
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG GS-US-592-6238The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 2200: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)This phase II trial tests whether cabozantinib with or without atezolizumab works to shrink tumors in patients with papillary kidney cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with atezolizumab may prevent papillary kidney cancer from growing or spreading compared to cabozantinib alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of metastatic papillary renal cell carcinoma (PRCC) · Participants must be 18 or older · All sexes eligible for study
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Characterizing dysfunction of cerebral arteries in neurodegenerative diseases using high resolution MRIHealthy volunteers are invited to participate in a brain research study at Northwestern University. Our research group uses brain scans to develop and understand MRI techniques to help improve clinical diagnosis, treatment and follow-up assessment in patients with cerebrovascular disease.
This study includes questionaries and an MRI brain scan at the Center for Translational Imaging at Northwestern. The MRI scan takes approximately one hour. These procedures will be at no cost to you and will occur during one study visit lasting up to two hours. Participants will be compensated $30. Who Can Participate?Eligible volunteers will be: · At least 18 years of age · Able to have an MRI scan · No history of developmental, neurological, or psychiatric disorders Principal Investigator, Study ID, Keywords STU00217550 Click to Copy URL to Clipboard For questions about this study, contact: |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung CancerThis phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely deliver radiation to tumors with fewer doses over a shorter period and may cause less damage to normal tissue than conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, pemetrexed, paclitaxel and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of stage IV NSCLC · Participants must be 18 or older · No prior systemic chemotherapy or immunotherapy for advanced NSCLC No prior treatment with checkpoint inhibitors for metastatic lung cancer Principal Investigator, Study ID, Keywords |
Heart-Brain MRI EvaluationThe purpose of our study is to test experimental imaging methods (MRI) used to evaluate the structure and function of the heart and brain. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00217447 Click to Copy URL to Clipboard For questions about this study, contact: |
Metabolomic Signatures associated with Adverse Pregnancy Outcomes and Social Determinants of Health (MASH)This is a prospective, longitudinal, observational cohort study evaluating plasma metabolomic signatures associated with social determinants of health (SDOH) with adverse pregnancy outcomes (hypertensive disorders of pregnancy, preterm birth, fetal growth restriction, intrauterine fetal demise). Who Can Participate?Inclusion Criteria: Pregnant Viable singleton pregnancy Nulliparous or multiparous with a history of sPTB, HDP, FGR, or abnormal GWG (e.g., insufficient or excessive) Publicly insured (Medicaid insurance plan) or uninsured with plan to apply for Medicaid Obtain prenatal care within Prentice Ambulatory Care, General Obstetrics and Gynecology, Maternal-Fetal Medicine, and/or the Northwestern Obstetric Infectious Diseases Clinic Plan to deliver at Northwestern Memorial Hospital English or Spanish-speaking Agree to participate and willing to provide signature of informed consent Exclusion criteria: Have a fetus with a major fetal structural anomaly or major fetal chromosomal abnormality known at the time of enrollment Under 18 years of age Prisoners Enrolled in other Maternal-Fetal Medicine Units (MFMU) network studies conducted within Northwestern Medicine’s obstetric practices (GoMOMS, PASC, SLEEP) Lack of other inclusion criteria as described above Principal Investigator, Study ID, Keywords STU00217870 Click to Copy URL to Clipboard |
ASL in Cerebrovascular DiseaseThe purpose of this study is to help radiologists and researchers put together a better MRI protocol for patients with cerebrovascular diseases. The long-term goal is to strengthen the ability of MRI to predict results for these patients. MRI techniques made during this project will be combined into routine clinical care and will ultimately help improve diagnosis of various brain diseases. What's Involved?
Who Can Participate?Study participants must be: · Ages 18-85 · Patients with cerebrovascular diseases, such as moyamoya disease/syndrome, complex aneurysm, carotid steno-occlusive disease, arteriovenous malformation, intracranial atherosclerosis, and stroke, who will undergo or have had cerebral revascularization · Undergoing routine DSA, CTA or MRI Principal Investigator, Study ID, Keywords STU00217399 Click to Copy URL to Clipboard For questions about this study, contact: |
RESET-RAThis study will evaluate the safety and effectiveness of the SetPoint Medical System (study device) for the treatment of patients with active, moderate-to-severe rheumatoid arthritis (RA), who have had an inadequate response or intolerance to biologic or targeted synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs). Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
ADVANTAGE-AFA Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation Who Can Participate?Subjects having symptomatic, documented, drug-resistant, Persistent AF Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine TumorsThis study is being done to answer the following question: Can we lower the chance of pNET coming back by giving chemotherapy after surgery? We are doing this study because we want to find out if this approach is better or worse than the usual approach for patients that have had surgery for pNET. The usual approach is defined as care most people get after surgery for pNET. If you decide to take part in this study, you will either get the study drugs capecitabine and temozolomide for up to four months or you will receive the usual approach of observation only. Observation means you will not receive treatment for pNET. After the first four months, your doctor will continue to follow your condition for 5 years, watch you for side effects, and see if your tumor comes back. During this time you will need to visit the clinic every 6 months for the first 3 years, then once every 12 months for 2 more years. Who Can Participate?Prior surgery for pancreatic neuroendocrine tumor (pNET) Principal Investigator, Study ID, Keywords Capecitabine Temozolomide High-Risk Pancreatic Neuroendocrine Tumors Pancreatic Neuroendocrine Pancreatic Neuroendocrine pancreatic neuroendocrine tumor pNET
For questions about this study, contact: |
NU 22S08: Northwestern Sarcoma Biorepository and Clinical DatabaseThe purpose of this study is to collect and store tumor tissue samples and clinical data from participants with any type of sarcoma, obtained when participants undergo routine biopsy and/or surgery, for use in future research. Participants will be asked to allow for blood, tissue and archival tissue samples, and clinical data, to be used for this biorepository. Samples will only be collected during standard of care procedures. Additional blood will be requested at the time of standard of care labs. Leftover tissue will be requested from patients’ standard of care biopsy or surgery. Information related to cancer and its response to therapy, including pathology and radiology results, will be collected. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of any type of known or suspected neoplasm arising from cells of mesenchymal origin. This may be a confirmed malignancy (a sarcoma) or simply an aggressive benign tumor such as a desmoid tumor. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords STU00218245 Click to Copy URL to Clipboard |
Multi-center, Noninterventional Study Evaluating Variability, Reliability, and Compliance for the Parkinson’s Disease DiaryThe primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms. Who Can Participate?1.≥39 to ≤70 years of age at signing of informed consent 2. Diagnosis of clinically established PD 3. Marked levodopa responsiveness at screening per investigator’s judgment 4. A minimum of 3 years and a maximum of 18 years from time of PD diagnosis to the date of screening 5. Receiving optimized and stable PD medical therapy for ≥1 month prior to screening or demonstrated intolerance to PD medications per investigator’s judgment in agreement with the medical monitor 6. ≥3 hours of average daily OFF-time assessed within 3 months of screening by PD diary or per investigator’s judgment Principal Investigator, Study ID, Keywords STU00217962 Click to Copy URL to Clipboard |
ACR-368-201: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® StatusThis is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with low dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG GS-US-592-6173The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to pembrolizumab in combination with chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC. • Sacituzumab govitecan (Trodelvy®) is currently approved by the United States (U.S.) Food and Drug Administration (FDA) and other regulatory agencies for previously treated advanced TNBC. It is also approved by the U.S. FDA for the treatment of patients with bladder cancer and cancers of the urinary tract. • Pembrolizumab, is approved by the U.S. FDA and other regulatory agencies for the treatment of certain types of TNBC. It is also approved for the treatment of several different types of other cancers. The combination of sacituzumab govitecan and pembrolizumab has not been approved by any health authorities for previously untreated advanced TNBC. This is a randomized, open-label study. Participants will be randomly assigned to receive either the experimental treatment, sacituzumab govitecan in combination with pembrolizumab, OR 1 of the following 3 standard chemotherapy treatment regimens chosen by the doctor: • Pembrolizumab in combination with paclitaxel • Pembrolizumab in combination with nab-paclitaxel • Pembrolizumab in combination with gemcitabine with carboplatin Who Can Participate?· Participants must have a diagnosis of locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or FusionsThis study will evaluate erdafitinib administered via an intravesical delivery system for both NMIBC and MIBC. The TAR-210 intravesical delivery system has been developed to provide continuous intravesical drug delivery for prolonged periods over multiple voiding cycles, thereby minimizing the number of intravesical instillations required and providing sustained drug exposure at the tumor site while minimizing systemic exposure and improving tolerability. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
ETCTN 10492This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with stage III-IVB head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin which is a chemotherapy used in this trial is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of confirmed HNSCC (including tumors of the oropharynx, hypopharynx, larynx, oral cavity, nasal cavity, maxillary and other paranasal sinuses, and unknown primary of the head and neck), with measurable disease
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
(xIRB) DRUG BDTX-1535-101: A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung CancerThis is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Glioblastoma or Non-Small Cell Lung Cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Quantitative Cerebral Blood Vessel Imaging Biomarkers for AD (Alzheimer's Disease) and VCID (Vascular Cognitive Impairment and Dementia)This study will determine structural and functional changes of the brain blood vessels associated with one's risk for cognitive impairment (decline of memory and thinking capabilities) by using completely non-invasive high-resolution MRI. Your participation is important to identify early imaging markers of brain health, which help us understand, measure, and follow vascular changes over time, and potentially even prevent their progression. What's Involved?
Who Can Participate?
Principal Investigator, Study ID, Keywords STU00218160 Click to Copy URL to Clipboard MRI Alzheimer's disease Vascular Cognitive Impairment and Dementia Radiology Neuroimaging Brain Imaging
For questions about this study, contact: |
RESPONDER-HFRe-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
THE CHICAGO PERINATAL ORIGINS OF DISEASE COHORT AND THE FOUNDER'S 400Under the Chicago Perinatal Origins of Disease and Founders' 400 research initiative, we are conducting a longitudinal prospective cohort study of 500 mother-child dyads, including 400 Black and Brown participant dyads, in which we will collect comprehensive longitudinal social, environmental, and medical data alongside environmental and biological samples from early pregnancy through two years of life to assess the association of the following exposures with maternal, neonatal, and early childhood health outcomes: 1) early life antimicrobial exposures and microbiome evolution; 2) e nvironmental exposures, including lead, dust, water quality; 3) early childhood adversity and maternal psychosocial stress, specifically via epigenetic changes; 4) metabolome alterations in pregnancy, within the context of social vulnerability; 5) placental pathology and the proteome, with respect to fetal growth and neurobehavioral outcomes. Who Can Participate?Eligible participants should meet all the inclusion criteria: Adult Inclusion Criteria: 1. Singleton pregnancy, between 8-20 weeks of gestation at the time of enrollment 2. At least 18 years old 3. English- or Spanish-speaking 4. Plan to deliver at Northwestern Memorial Hospital 5. Able and willing to provide written informed consent
Child (0-2) Inclusion Criteria: 1. Delivered at Prentice Women's Hospital to a person who enrolled in this CPOD study during the current pregnancy. 2. Birth parent willing to provide parental permission consent for the child Adult Exclusion criteria: 1. Cognitively unable to provide consent. 2. Persons who are incarcerated 3. Persons living with HIV Child (0-2) Exclusion criteria: 1. Delivered by pregnant person who met the adult exclusion criteria Parental permission consent not obtained
Principal Investigator, Study ID, Keywords STU00218599 Click to Copy URL to Clipboard |
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsThis study is being done to answer the following question: Which standard therapy is better for controlling your cancer for a longer period of time? We are doing this study because we want to find out which approach is better or worse for your advanced pancreatic neuroendocrine cancer. The usual approach is defined as care most people get for advanced pancreatic neuroendocrine cancer. If you decide to take part in this study, you will either get lutetium Lu 177 dotatate, a radioactive drug given through your vein, for up to 8 months, or you will get the drugs temozolomide and capecitabine, as tablets you take by mouth, for up to 12 months. After you finish your treatment, your doctor will continue to follow your condition at clinic visits and watch you for side effects. If you finish or choose to stop your treatment before your cancer gets worse, they will check on you every 3 months at clinic visits until your cancer gets worse or you start a different treatment. If your cancer gets worse or you start a different cancer treatment, they will check on you every 6 months by phone or medical record for a maximum of 8 years starting from the day you enrolled on the study. Who Can Participate?Participants must have a diagnosis of advanced pancreatic neuroendocrine tumor. Principal Investigator, Study ID, Keywords |
DRUG CL1-95032-005: A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant AstrocytomasThe study is divided into 2 phases, a Safety Lead-In phase and a randomized perioperative phase. In the Safety Lead-In Phase, the recommended combination dose (RCD) of vorasidenib will be determined. In the Randomized Perioperative Phase, the Lymphocytes infiltration in tumors will be evaluated following pre-surgical treatment with vorasidenib and pembrolizumab combination, compared to untreated control tumors. Prior to surgery, participants will be randomized to receive vorasidenib at the RCD in combination with pembrolizumab, or vorasidenib only, or no treatment (untreated control group). Following surgery, participants will have the option to receive treatment with vorasidenib in combination with pembrolizumab in 21-day cycles. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met. Who Can Participate?Inclusion Criteria: Exclusion Criteria: Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
CVL 231-2003The primary goal of the study is assessing the study medication oral emraclidine to possibly treat schizophrenia in adult participants with schizophrenia when taken over a year. Emraclidine is a brain penetrant muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). Emraclidine is being developed for treatment of psychosis in schizophrenia. Who Can Participate?This study is for individuals who have been diagnosed with schizophrenia. 18-65years Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG GLSI-21-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)DRUG GLSI-21-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically confirmed HER2/neu positive primary breast cancer · Participants must have completed both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy · Participants must present with pathological evidence of residual invasive carcinoma at Stage I, II, or III in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy · Participants must be 18 years or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) ETCTN 10495: Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 AlterationsThis phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene. Who Can Participate?· Participants must have a diagnosis of confirmed malignancy that is metastatic or unresectable · Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancerYou are being asked to voluntarily take part in this clinical research study to test an oral drug, darolutamide, in addition to androgen deprivation therapy (ADT), because you have hormone sensitive high-risk biochemical recurrence (BCR) of prostate cancer (a type of cancer that is dependent on androgen hormones, such as testosterone). Testosterone helps prostate cancer to grow. So the most common way to control testosterone levels in the body is to block the gland that stimulates the testosterone production. High risk BCR refers to a stage of prostate cancer where the rise in Prostate Specific Antigen (PSA) levels to a certain threshold and within a specified period of time, during or following prostate cancer local therapies. This means that after local therapies with curative intent (surgery or radiotherapy) of prostate cancer, some cancer cells may have survived and are producing PSA. PSA is a protein that is produced by both cancerous and noncancerous prostate cells.
ADT is a systemic therapy called hormone therapy which reduces the androgen hormone (testosterone) levels to prevent prostate cancer cells from growing. ADT is frequently given with radiation therapy.
This study is being done to learn more about a new drug called darolutamide given in combination with ADT for your disease stage. Who Can Participate?Inclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
ETCTN 10496This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may be more effective than pembrolizumab alone in improving some outcomes in patients with recurrent/metastatic squamous cell cancer of the head and neck. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of head and neck squamous cell cancer (HNSCC) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Alliance A092104A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy Who Can Participate?Some of the eligibility criteria include: • Participants must have a diagnosis of advanced uterine leiomyosarcoma. • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDThe purpose of this study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Who Can Participate?- The subject is ≥35 and ≤80 years of age at the time of informed consent. - The subject has a clinical diagnosis of PD for at least 1 year and for no longer than 7 years before initiation of screening - The subject has a modified Hoehn and Yahr score ≤2.5. - The subject is receiving symptomatic treatment for PD. - The subject has a known GBA-PD risk-associated variant Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Biceps muscle properties in healthy and tendon repair populationsThe focus of this research it to examine muscle-tendon adaptation to orthopedic surgical repairs of biceps tendon lesions (or tears) and to determine the corresponding effect on function at the elbow and forearm. Specifically, we are interested in understanding how muscle architecture (a muscle’s fascicle length, sarcomere length, volume, and a tendon’s length) adapts following injury and repair, and whether this adaptation affects active and passive function of upper limb joints involved in daily activities. Who Can Participate?
Principal Investigator, Study ID, Keywords STU00217915 Click to Copy URL to Clipboard For questions about this study, contact: |
DRUG ARV-766-mCRPC-101A Phase 1/2 study to assess the safety and tolerability and how prostate cancer responds to two different doses of investigational study drug ARV-766 given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved systemic therapies Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of prostate cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
CT-155-R-001This is a digital mental health application study involving digital therapeutic CT-155 as an added treatment to standard antipsychotic therapy in adult participants with negative symptoms of schizophrenia The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an additional treatment to the regular care in patients diagnosed with experiential negative symptoms of schizophrenia. Who Can Participate?Eligibility: 18 years of age or older , Diagnosed with Schizophrenia Study duration=16 weeks Principal Investigator, Study ID, Keywords |
A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid TumorsThis is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability and preliminary efficacy of WTX-124, a conditionally activated IL-2 prodrug, when administered as monotherapy and in combination with pembrolizumab, for the treatment of patients with advanced solid tumors. Part 1 of the study is dose escalation of WTX-124, both as monotherapy and in combination with pembrolizumab. Part 2 is comprised of four arms in which WTX-124 will be administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic cutaneous malignant melanoma or advanced or metastatic renal cell carcinoma.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced stage or metastatic solid tumor for which anti-PD(L)-1 is indicated. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG QRNT-009: A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 DoseMulticenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG XMAB808-01: A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of · Part A:Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SOUND Pivotal Trial– Sonomotion stOne comminUtion resoNance ultrasounD Pivotal TrialTo evaluate the safety and effectiveness of the SonoMotion Break Wave System for the comminution of urinary tract stones. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords |
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL MF)As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with CTCL. Who Can Participate?Patient who has a diagnosis of mycosis fungoides (MF). Patient who is between 2-89 years of age. Patient who is willing and able to provide new skin samples via superficial scraping at least one affected and non-affected body site. Principal Investigator, Study ID, Keywords STU00217977 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) DRUG 213304: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 AntibodyCompassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Multiple Myeloma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Fit4TreatmentThis trial tests how well patient tailored physical activity interventions work to improve health and survival among older women with gynecologic cancers undergoing chemotherapy and other systemic therapies. Cancer therapy, as well as underlying cancer, cause accelerated aging and toxicity, leaving women vulnerable to functional decline, increased frailty, decreased health related quality of life, and ultimately, less systemic therapy completion and inferior cancer survival. Physical activity has been shown to improve functional health, improve quality of life, slow aging, and decrease rates of frailty. Engaging in patient tailored physical activity may safely and gradually increase physical activity in gynecologic cancer patients and lead to improved health and survival among older women with gynecologic cancers who are undergoing systemic treatment. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 2302: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy. Who Can Participate?
Principal Investigator, Study ID, Keywords
|
Treatment for Pruitis in Primary Biliary Cholangitis (PBC).Volixibat is an experimental treatment, meaning that it has not been approved by the US Food and Drug Administration (FDA) or any worldwide regulatory body. Volixibat is a medicine that lowers circulating bile acid levels (the amount of certain chemicals that are produced by the liver and are present in the blood) that are believed to lead to the itching in patients with PBC. There are no other medicines approved to treat itching in patients with PBC. Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
REACT-AFRhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG D8410C00001: A Modular Phase I/IIa, Open-Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed. Who Can Participate?Some of the eligibility criteria include:
· ALL MODULES: Participants must be 18 or older · MODULE 1 PART A: Participants must have a diagnosis of advanced/relapsed ovarian, breast, pancreatic, or prostate cancer who are deemed suitable for a PARPi will receive AZD9574 monotherapy at escalating cohorts. · MODULE 1 PART b: Participants must have a diagnosis of breast cancer who are PARPi naive at a dose determined in dose-escalation. · MODULE 1 PART b: Participants must have a diagnosis of IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Testing the addition of an anti-cancer drug, irinotecan, to the standard chemotherapy treatment (FOLFOX) after long-course radiation therapy for advanced-stage rectal cancers to improve the rate of complete response and long-term rates of organ preservationThis study is being done to answer the following question: Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard regimen of FOLFOX or CAPOX given following long-course chemoradiation for patients with locally advanced rectal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your rectal cancer. The usual approach is defined as care most people get for locally advanced rectal cancer. Who Can Participate?You must have advanced rectal cancer to participate in this study. Principal Investigator, Study ID, Keywords |
DRUG OM-GRPR1-02: A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Subjects with Recurrent or Metastatic GRPR-expressing TumorsA Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of: Cervical Cancer Prostate Cancer Metastatic Breast Cancer Colon Cancer NSCLC Cutaneous Melanoma
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Alliance A051902A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of T-cell lymphoma cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG NX-5948-301: A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesThere are 2 parts to this study. The phase 1a portion (dose escalation) evaluates the safety and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or Waldenströms macroglobulinemia (WM), who have received at least 2 prior systemic therapies (or at least 1 prior therapy for WM), and for whom no other therapies are known to provide clinical benefit. The phase 1b portion (cohort expansion) investigates the efficacy of NX-5948 at the dose selected in Phase 1a in up to 5 cohorts of patients with R/R B-cell malignancies, who have received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM, primary central nervous system lymphoma (PCNSL), or secondary central nervous system involvement.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or Waldenströms macroglobulinemia (WM), · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid TumorsOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. There are 7 parts to this study. In Parts A, B, C, and E, we’re testing different doses of tisotumab vedotin to see how it works to treat solid tumor cancers. Parts A, B, and C are no longer enrolling patients. In Parts D, F, and G of the study, we want to learn more about how tisotumab vedotin works with some types of anti-cancer drugs. We’re testing tisotumab vedotin with pembrolizumab and carboplatin. In Part D of the study, some patients with head and neck cancer could get tisotumab vedotin with pembrolizumab and cisplatin. Part D of the study is no longer enrolling patients. In Part F of the study, we’re testing tisotumab vedotin with pembrolizumab to see if it works for head and neck cancers. In Part G of the study, we will use the information we learn in Part F to keep studying tisotumab vedotin with carboplatin and pembrolizumab to see if it works for head and neck cancers. In Part E of this study, we’re testing tisotumab vedotin in patients with head and neck cancer that came back or got worse after their last treatment. Patients assigned to Group E will receive tisotumab vedotin once every 2 weeks for 4 weeks (28 day cycle) If you’re in Part F, we’ll give you tisotumab vedotin once every 2 weeks and pembrolizumab once every 6 weeks. If you’re in Part G, we’ll give you tisotumab vedotin and carboplatin once every 2 weeks and pembrolizumab every 6 weeks.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: • Participants must have a diagnosis of non-small cell lung cancer (NSCLC) – Squamous cell histology only, or Squamous cell carcinoma of the head and neck (SCCHN) • Participants with inoperable, locally advanced or metastatic cancer • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
DRUG M20-638: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)The purpose of this randomized Phase 3 study is to evaluate the efficacy, safety, and tolerability of epcoritamab 48 mg in combination with R 2 compared to R 2 alone in subjects with R/R FL. Who Can Participate?Subject must have histologically confirmed classic FL (previously Grade 1 to 3a FL) stage II, III, or IV with no evidence of histologic transformation to an aggressive lymphoma and CD20+ on a representative tumor biopsy. Principal Investigator, Study ID, Keywords |
(xIRB) A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) / NEPTUNE-17This research study is being done to test if the study drug GSK3858279 can improve the pain caused by damaged nerves due to diabetes, known as diabetic peripheral neuropathic pain (DPNP). The study is designed to collect information on the safety of the study drug, the possible effect of the study drug may have on your pain sensation, and what amount (or dose) of the study drug is best. The study has 3 periods that follow each other: a screening period (up to 5 weeks to assess your suitability for the study), a study treatment period (12 weeks of once weekly dosing with the study drug in clinic), and a follow-up period (15 weeks). You will come to the clinic approximately 21 times over a total period of up to 32 weeks. Who Can Participate?18-75 years of age with a pain condition caused by diabetes. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG 19-12021154The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of thyroid cancer that expresses ICAM-1 and that meets one of the following diagnoses: · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG CDRB436J12301150 adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy will enter in the trial. Patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will be stratified by number of prior VEGFR targeted therapy (1versus2) and prior lenvatinib treatment (yes versus no)
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of BRAFV600E mutation-positive Differentiated Thyroid Cancer · Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
NU MSK22H05: Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)This is a single-stage, phase 2 study of the combination of zanubrutinib, obinutuzumab, and venetoclax in previously untreated patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), the latter including patients with evidence of TP53 mutation as well as transplant ineligible patients. The primary aim of this study is to establish the rate of minimum residual disease (MRD) undetectable response in patients with CLL, to establish the 2-year progression free survival (PFS) in patients with TP53 mutated MCL, and to establish the 3-year PFS in transplant ineligible patients. Time to completion of study is estimated at 5 years. The secondary objectives are to establish the recommended phase 2/3 duration of therapy, to determine the proportion of patients who successfully discontinue therapy after achieving an MRD undetectable response. Also, to determine the durability of clinical benefit after treatment discontinuation as measured by duration of peripheral blood MRD response and treatment-free survival. In addition, to determine whether induction therapy with 2 cycles of zanubrutinib and obinutuzumab prior to venetoclax reduces TLS risk assignment, and to assess safety and tolerability of the of zanubrutinib, obinutuzumab, and venetoclax regimen in the first-line setting. Finally, to assess safety and tolerability of the of zanubrutinib, obinutuzumab, and venetoclax regimen in the first-line setting. The exploratory objectives are to cross validate MRD testing using multiparameter flow cytometry with DNA sequencing-based MRD assays in peripheral blood and bone marrow. To evaluate clonal evolution of CLL and MCL in serial patient samples on therapy with zanubrutinib, obinutuzumab, and venetoclax, during post-treatment surveillance, and at progression. To investigate the effects of zanubrutinib, obinutuzumab, and venetoclax on immune responses. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of mantle cell lymphoma (MCL) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
CCTG HN11This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck? This study will allow us to determine if this approach is better or worse in controlling cancer and has fewer side effects and better quality of life. The usual practice is the care most people get for your type of oropharyngeal cancer. Participants will either get 1) radiotherapy to cancer and both sides of the neck or 2) radiotherapy to cancer and neck based on Single Photon Emission Computed Tomography (SPECT/CT). The radiotherapy will be given in the usual way. Chemotherapy may be given in addition to radiotherapy as standard care. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: • Participants must have a diagnosis of oropharyngeal cancer • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Northwestern Myositis Registry and BiorepositoryThe purpose of this study is to provide a foundation for the collection of patient-reported outcomes and biospecimens to support future studies in myositis and to support existing studies by serving as a resource for patient recruitment and clinical data to supplement existing myositis studies. Participants will be asked to complete a screening and demographic form and give two tubes of blood for research purposes at or near the time of study enrollment. Participants will be asked to complete research questionnaires every 6 months near the time of regularly scheduled standard of care clinic visits at Northwestern. If participants undergo a standard of care bronchoscopy, they will be given the option to provide additional fluid for the study at the time of the procedure. If participants undergo a standard of care endoscopy, they will be given the option to add a research bronchoscopy for the collection of lung fluid. They will also be given the option to undergo collection of esophageal biopsies during the endoscopy. Additionally, if participants have a standard of care muscle biopsy performed at Northwestern, they will be given the option to donate an additional 4 mm of muscle tissue at the time of the procedure. Who Can Participate?Participants must be current patients at Northwestern who are 18 years or older and have a diagnosis of inflammatory myositis. They must be able to provide informed consent in English and cannot have a diagnosis of viral myositis. Principal Investigator, Study ID, Keywords STU00218058 Click to Copy URL to Clipboard |
Join the ADNI-4 StudyThe overall goal of ADNI-4 study is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. This is a non-randomized natural history non-treatment study. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts: (1) cognitively normal control participants, (2) individuals with mild cognitive impairment and (3) individuals with dementia. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (amyloid and tau) and MRI scans and optional cerebral spinal fluid (CSF) collection for up to 5 years. ADNI-4 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, ADNI-2 and ADNI-3), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD. ADNI is an observational research study, which means it has no study drug or intervention. The ADNI study is designed to look at the relationship between clinical, cognitive, imaging, genetic and biomarker tests to learn more about brain health and the full spectrum of Alzheimer’s disease (AD) from its earliest stages. The ADNI study will enroll participants from three groups: • Cognitively Normal (CN) group: individuals with no apparent memory problems • Mild Cognitive Impairment (MCI) group: individuals diagnosed with early or late stages of mild memory problems • Dementia (DEM) group: individuals diagnosed with a mild stage dementia https://www.adni4.org/ Who Can Participate?Age 55-90 (inclusive) Must have a study partner that is willing to participate as a source of information and who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, or caregiver) No history of major psychiatric disorders such as major depression, bipolar disorder, or schizophrenia. Must have visual and auditory acuity adequate for neuropsychological testing. Must be in good general health with no diseases expected to interfere with the study. Must be willing and able to participate in a longitudinal imaging study lasting up to 5 years. Must speak English fluently. Must be willing to undergo repeated MRIs (3Tesla) and at least two PET scans - must not have any MRI contraindications (i.e. pacemaker, claustrophobia) Must agree to collection of blood for genomic analysis (including GWAS (genome-wide association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and biospecimen banking. Must agree to collection of blood for biomarker testing. Must agree to share genomic data and biomarker samples. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
SWOG 2010This study is being done to answer the following question: Will monitoring side effects in between clinic visits help women keep taking their hormone therapy medicine as prescribed for early-stage breast cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for helping women take their hormone therapy medicine. The usual approach is the follow-up care most people get after they are diagnosed with breast cancer and start hormone therapy.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Breast Cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(XIRB) DRUG SGNBB228-001: A phase 1 study of SGN-BB228 in advanced melanoma and solid tumorsThis study will test the safety of a drug called SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe and if it works to treat solid tumor cancers.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG R3767-ONC-2055: A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk MelanomaThe primary objective of the study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS). Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: All patients must be either stage IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
uTRACT Jelmyto® RegistryThe primary objective of the registry is to study the use and impact of Jelmyto in patients with Upper Tract Urothelial Carcinoma in clinical practice in the U.S. Who Can Participate?Inclusion Criteria
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG CA-4948-102: A phase 1/2a, open-label dose escalation and cohort expansion study of orally administered ca-4948 (irak4i) as a monotherapy in patients with acute myelogenous leukemia or myelodysplastic syndrome and in combination with azacitidine or venetoclaxThis study is being done to test the orally administered study drug, CA-4948, either alone (monotherapy) or in combination (combination therapy) with an approved drug (azacitidine (AZA) or venetoclax (VEN)) in adult patients ages 18 and over diagnosed with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS). The study drug is thought to work by blocking a protein in your body called interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays an essential role in some of the signaling pathways that are frequently not controlled in AML/MDS. When these signals are not working properly, they can trigger cancer growth. By blocking IRAK4, the study drug may stop or reduce these signals and help fight your cancer Principal Investigator, Study ID, Keywords ca-4948 irak4i acute myelogenous leukemia myelodysplastic syndrome leukemia azacitidine venetoclax does escalation dose expansion AML MDS
For questions about this study, contact: |
DRUG 68284528MMY4006: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple MyelomaThe purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Multiple Myeloma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid MesotheliomaThis phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone. This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of stage I-IIIa sarcomatoid mesothelioma · Participants must be 18 or older This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Combing topical imiquimod with local radiotherapy treatment of mycosis fungoidesThe primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8. Who Can Participate?Patients must have confirmed stage IA-IIB mycosis fungoides, have failed at least one standard therapy for MF, have active, but stable disease for at least 6 months with 4 or more discrete lesions (with at least 2 lesions >50cm2 in area combined). Patients of child bearing potential must have a negative pregnancy test before enrolling on the study. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosisInventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of a non-cirrhotic liver disease called non-alcoholic steatohepatitis (NASH) fibrosis (stage 2 or 3 indicating the amount of scarring), and how safe it is to use in people. You are being asked if you would like to take part in this research study because you have been diagnosed with NASH and F2/F3 stage liver fibrosis or because you are at high risk of having this disease. Who Can Participate?NASH and fibrosis of the liver (scarring) Principal Investigator, Study ID, Keywords |
(xIRB) A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1) Who Can Participate?-18 years or older -BMI 35 or higher -diagnosed knee osteoarthritis Principal Investigator, Study ID, Keywords |
(XIRB) DRUG 001: A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor by pathology report with oncogenically activated receptor tyrosine kinase (RTK) confirmed by a historical report or local testing and have received, or been intolerant to, all available treatment known to confer clinical benefit
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3) This study is focused on understanding the efficacy and safety of a potential new treatment for severe obesity and established cardiovascular disease (e.g., diseases associated with your heart and blood vessels). Who Can Participate?-18 years or older -a history of a past cardiovascular event -unsuccessful weight loss attempt Principal Investigator, Study ID, Keywords clinical trials clinical research physical medicine and rehabilitation Weight loss cardiovascular research stroke heart attack
For questions about this study, contact: |
Molecular Biomarkers to Guide Therapy in the Systemic Sclerosis-Associated Interstitial Lung DiseaseThe purpose of this study is to better understand the development and progression of scleroderma-related lung fibrosis (SSc-ILD). We would like to find indicators (biomarkers) that can help us predict which patients will develop SSc-ILD and who might benefit from receiving certain treatments. To do this, we will collect and study your clinical and imaging data and samples (blood, lung fluid, and skin) if you agree to participate in this research. Who Can Participate?SSc Patients Inclusion Criteria:
Exclusion Criteria:
Healthy Controls Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords STU00218939 Click to Copy URL to Clipboard For questions about this study, contact: |
A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TDThis study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life. Who Can Participate?Patients diagnosed with Tardive dyskinesia, above 18 years of age Principal Investigator, Study ID, Keywords STU00219451 Click to Copy URL to Clipboard For questions about this study, contact: |
CY 6032A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO METOPROLOL IN ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Who Can Participate?Diagnosed with oHCM per study criteria by cardiac magnetic resonance imaging (CMR) or echocardiography Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG STML-ELA-0222: A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Histopathologically or cytologically confirmed ER+, HER2-, breast cancer · At least one measurable lesion as per RECIST version 1.1 or a mainly lytic bone lesion. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete Principal Investigator, Study ID, Keywords |
ECOG-ACRIN Y191: Molecular Analysis for Combination Therapy Choice (ComboMATCH)This ComboMATCH patient registration trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have been deemed potentially eligible for a ComboMATCH Treatment Trial · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xirb) DRUG Ph2 INBRX-109 SA CS: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional ChondrosarcomaRandomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer. Who Can Participate?Some of the eligibility criteria include: · Participants must have a diagnosis of Recurrent Lung Non-Small Cell Carcinoma or Stage IV Lung Cancer AJCC v8 . · Participants must be 18 or older Principal Investigator, Study ID, Keywords
|
ECOG-ACRIN EAY191-N2This study is being done to answer the following question: If you have never received fulvestrant (fulvestrant-naïve), can your breast cancer be stabilized and the time that you live with your breast cancer be lengthened by adding binimetinib to the usual drug fulvestrant? If you have received fulvestrant (fulvestrant exposed), has your breast cancer shrunk within 4 months of starting treatment with binimetinib added to the usual drug fulvestrant? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your breast cancer that is hormone receptor-positive and has metastasized. The usual approach is defined as care most people get for hormone receptor-positive metastatic breast cancer. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Breast Cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Alliance A042001, A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaThis phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a drug called CalichDMH. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers CalichDMH to kill them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them, stopping them from dividing, or spreading. Giving inotuzumab ozogamicin with chemotherapy may help shrink cancer and stop it from returning. The study subjects will either receive inotuzumab with lower doses of usual chemotherapy or get the usual chemotherapy treatment. In either treatment arm, study participants will receive two or more months (cycles) of more intensive chemotherapy. Both groups will continue with lower doses of chemotherapy for up to two years. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: • Participants must have a diagnosis of Philadelphia-Chromosome-Negative B-cell Acute Lymphoblastic Leukemia • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Investigational drug for NASH cirrhosisTreatment for subjects with NASH and cirrhosis Who Can Participate?adults 18-75 year old with NASH and cirrhosis Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 22H08This is a phase 1 trial with dose escalation. Phase 1 of the study will open first with a (Bayesian optimal interval BOIN) dose finding design. The starting dose of tomivosertib is 100mgdaily (doses 24 ± 2 hours apart), PO, self-administered with meals. The dose finding follows a BOIN design, with the 100mg BID dose level with a meal being the highest dose. There is one dose level below (dose level -1 = 100mg QD without a meal) that will be given if the de-escalation condition is met during dose finding. Upon completion of the phase 1 dose finding portion of the study, the recommended starting dose of tomivosertib for the subsequent combination with the other agents will be determined, as described in Section 4.3 and Section 8.0. Tomivosertib will be dosed continuously on days 1-28 of each 28-day cycle at the dose level assigned for that cohort. OBJECTIVES Primary Objective To determine the dose of maximum pharmacologic activity (MPA) of tomivosertib in relapsed/refractory AML based on the safety, tolerability, PK and PD in each dose cohort. Secondary Objectives 1. To assess the adverse event profile of tomivosertib 2. To estimate the rate of complete remission (CR) 3. To estimate the rate of overall response 4. To estimate the duration of response (DOR) 5. To estimate progression free survival (PFS) 6. To estimate overall survival (OS) 7. To assess the outcomes for patients who undergo allogeneic hematopoietic stem cell transplant (HSCT) 8. To assess the pharmacodynamics of tomivosertib by eIF4E phosphorylation before, during, and after cycle 1 treatment 9. To measure MCL1 expression before and after cycle 1 treatment 10. To assess the steady-state pharmacokinetics of tomivosertib Principal Investigator, Study ID, Keywords |
(xIRB NCI IRB) ETCTN 10522: A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal CarcinomaThis phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Who Can Participate?
Principal Investigator, Study ID, Keywords |
FAST StudyEndometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
LCRF Leader Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung CancerThe primary purpose of this testing is to determine the presence of 11 oncogenic drivers that can serve as targets for neoadjuvant therapies to be administered before surgery. The goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate but harmonized neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no driver is detected. Who Can Participate?· Participants must be 18 or older . Participants must have a diagnosis at early -stage Lung cancer Principal Investigator, Study ID, Keywords STU00218793 Click to Copy URL to Clipboard |
(xIRB NCI CIRB) ETCTN 10487: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine DifferentiationThis phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation (formed from cells that release hormones into the blood in response to a signal from the nervous system) that has spread to other places in the body (metastatic). Radioactive drugs, such as lutetium Lu 177, may carry radiation directly to tumor cells and not harm normal cells. The study aims to determine if this approach is better or worse than the usual approach for prostate cancer. Who Can Participate?• Participants must have a diagnosis of prostate cancer with neuroendocrine differentiation. • Participants must be 18 or older Principal Investigator, Study ID, Keywords |
Measuring copper parameters in Wilson's Disease using a novel assayThe purpose of this study is to find out if a new test for patients with Wilson’s disease can accurately and reliably measure so-called free copper, also known as non-ceruloplasmin copper (NCC). Ceruloplasmin is a protein that helps transport copper from the liver and deliver copper to the rest of your body to maintain your health. In Wilson’s disease, ceruloplasmin levels are low and free copper levels are higher than normal, which can be controlled by taking your Wilson’s disease medications regularly. There is currently no approved test to measure NCC. Your doctor may use a combination of tests including a blood test to measure ceruloplasmin in order to calculate the NCC, but this is not accurate or reliable. Having a more reliable and accurate measurement of NCC may help your doctor, in the future, make better informed decisions about your treatment, including the dose of your medicine. Who Can Participate?Inclusion: 1. Willing and able to give informed consent for participation in the study 2. Male or female patients, aged 18 years or older as of signing the Informed Consent Form (ICF) 3. Able and willing to comply with study procedures and requirements, as judged by the treating physician 4. Established diagnosis of Wilson’s Disease (Leipzig score >4) 5. Either newly diagnosed or with elevated liver enzymes (defined as ALT, AST ≥1.5xULN) or 24-hour urinary copper excretion outside of recommended ranges [chelation range 200-500mcg/24 hr; zinc < 100mcg/24 hr] 6. Adequate venous access to allow collection of blood samples Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG 1454-0001: A first-in-human Phase I, non-randomized, open-label, multicenter dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines may help the immune system fight cancer. The purpose of this study is to find out the highest dose of BI 765049 alone and in combination with ezabenlimab the participants can tolerate. In this study, BI 765049 is given to people for the first time. Participants can stay in the study for up to 3 years, if they benefit from treatment and can tolerate it. During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. The doctors also regularly monitor the size of the tumor
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
ETCTN 10538: Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 TrialThis phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia, myelodysplastic syndrome /myeloproliferative neoplasm with excess blasts. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The combination of ASTX727 and venetoclax may kill more cancer cells in patients with chronic myelomonocytic leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm with excess blasts.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of bone marrow cancer with chronic myelomonocytic leukemia, myelodysplastic syndrome /myeloproliferative neoplasm with excess blasts · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
A Pilot Study of rhPSMA -PET MRI Imaging For the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active SurveillanceThe overall goal of this pilot study is to evaluate whether rhPMSA-7.3-PET-MRI can detect higher grade or stage disease in a population of NCCN low and favorable intermediate risk men. Who Can Participate?Inclusion Criteria:
Exclusion Criteria
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG CTX-009-002: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy RegimenThe purpose of this study is to compare the effects of using study drug (CTX-009) along with the chemotherapy paclitaxel to using paclitaxel alone. This study will allow the researchers to know whether this different treatment is better, the same, or worse at shrinking your tumor(s). Who Can Participate?Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Blue Light Cystoscopy™ with Cysview® RegistryThe purpose of the registry is to study the use of BLC™ with Cysview® in clinical practice in the United States. Who Can Participate?Inclusion Criteria
Exclusion Criteria
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG SOLTI-2101HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of HR-positive and HER2-negative breast cancer · Participants must be 18 or older
·
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
(xIRB) DRUG EP0031-101: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered MalignanciesThe aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial Who Can Participate?Some of the eligibility criteria include: Participants must have a diagnosis of RET-altered malignancy Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
SEISMIC-HF INon-invasive Seismocardiogram In Cardiovascular monitoring for Heart Failure I Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
MA-GVHD-401: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial Who Can Participate?
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB) DRUG BA3182-001: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BA3182, A BISPECIFIC EPITHELIAL CELL ADHESION MOLECULE (EPCAM)/CD3 ANTIBODY, IN PATIENTS WITH ADVANCED ADENOCARCINOMAThe objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced adenocarcinoma · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) ECOG-ACRIN EA1211: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT TrialThis phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of HER2-positive stage IIa-IIIc breast cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Testing the effectiveness of an anti-cancer drug, triapine, when used with targeted radiation-based treatment (Lutetium Lu 177 Dotatate), compared to Lutetium Lu 177 Dotatate alone for metastatic neuroendocrine tumorsThis phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radio-conjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. Study participants will be assigned to receive lutetium Lu 177 dotatate alone or lutetium Lu 177 dotatate and triapine. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: • Participants must have a diagnosis of metastatic neuroendocrine tumor • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Hair Disorder RegistryThe purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys.
The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for them by adding to our understanding of normal hair physiology, causes and mechanisms of disease, clinical and molecular features, natural history, and treatment outcomes. Who Can Participate?12 years and older with primary or secondary involvement of hair follicle disease Principal Investigator, Study ID, Keywords STU00219310 Click to Copy URL to Clipboard |
IMVT-1401-3201Brief Summary: To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24. Who Can Participate?Participants must meet all the following criteria to be eligible for inclusion in the study: -Are ≥ 18 years of age at screening -Have a clinical diagnosis of TED associated with onset of active TED within 12 months prior to screening active - Moderate to severe TED. -Are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
PREDICT: Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee OsteoarthritisThis study aims to add scientific knowledge and gain insight on personalized treatments in medicine by identifying specific biomarkers (a combination of patient-reported symptoms, brain and joint imaging, demographics, etc.) in patients with osteoarthritis (OA) knee pain. Who Can Participate?-40 years or older -diagnosed knee osteoarthritis Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) CCTG NE1: NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NETThis phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets cancer cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some cancer cells. The radioactive peptide builds up in these cells and helps kill the cancer cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until the midgut NET worsens compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping cancer cells from reproducing and by decreasing the blood supply to the cancer cells. Retreating with 177Lu-DOTATATE may work better than everolimus in shrinking or stabilizing tumor in patients with metastatic and unresectable NET who were previously treated with 177Lu-DOTATATE.
Who Can Participate?· Participants must have a diagnosis of metastatic midgut neuroendocrine tumor · Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG POLARIS2022-001This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Leiomyosarcoma (LMS) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in =2nd Line Small Cell Lung Cancer (SCLC) TreatmentThis trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1 Have a life expectancy of at least 3 months
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial Principal Investigator, Study ID, Keywords |
ECOG-ACRIN 7211This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of RetroPeritoneal Sarcoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
CY 6033 ACACIATRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 23H06: A Phase II multi-center open-label trial of six doses of pembrolizumab monotherapy prior to limited chemotherapy as front-line therapy for patients with classical Hodgkin lymphoma, including elderly patientsThis purpose of this trial is to shift the paradigm from chemotherapy to immunotherapy-based regimens and thereby reduce chemotherapy- related toxicities and improve clinical outcomes. We propose a phase II trial to assess the efficacy and safety of PET-directed PEM monotherapy for 6 cycles followed by abbreviated AVD therapy in newly diagnosed cHL, early unfavorable and advanced stages. We anticipate that six cycles of PEM upfront (three more cycles than in the NU 16H08 study) will increase the rate of complete metabolic response (CMR) to PEM monotherapy and allow the majority of patients to receive an abbreviated course of AVD chemotherapy with clinical outcomes similar to those seen in NU 16H08. We thereby anticipate shifting from chemotherapy-based strategies for cHL to predominantly immunotherapy, with the ultimate goal of eliminating chemotherapy altogether. Who Can Participate?Patients must have confirmed diagnosis of Ann Arbor Stage III or IV classic Hodgkin lymphoma or Ann Arbor Stage I and Stage II classic Hodgkin lymphoma with at least one unfavorable risk factor by NCCN criteria. Principal Investigator, Study ID, Keywords |
RGN-NK-302To compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK) Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
XIRB Eli Lilly J2P-MC-LXBDThe main purpose of this study is to learn more about LY3556050, which is an investigational treatment for diabetic peripheral neuropathic pain (DPNP). The study aims to learn: • Whether it can reduce the DPNP severity. • Whether it can work better than fake medicine (placebo). • What are the possible side effects. Who Can Participate?-18 years or older -Type 1 or Type 2 Diabetes -Diabetic painful neuropathy Principal Investigator, Study ID, Keywords diabetes diabetes pain diabetic neuropathy clinical trials physical medicine and rehabiliation type 1 diabetic type 2 diabetic
For questions about this study, contact: |
(XIRB) DRUG TOS-358-001: A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid TumorsThe goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG J2J-MC-JZLH: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of RecurrenceThe main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
NU 23S01In this study, a standard dose of radiation will be given to the majority of the tumor, while a simultaneously integrated boost of additional radiation will be given to certain areas of the tumor identified as higher risk. This means that a higher radiation dose will be given to the higher risk areas of the tumor.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of primary soft tissue sarcoma of the retroperitoneum · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB) DRUG MER-XMT-1660-1: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid TumorsThis first-in-human (FIH) study will test the safety and side effects of a drug called XMT-1660. A side effect is anything a drug does to the body besides treating the disease. Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started(advanced) or spread through the body (metastatic). The study will have two parts. The first part called Dose Escalation will find out how much XMT-1660 should be given toparticipants. The second part called Dose Expansion will use the dose found in the first part to find out how safe XMT-1660 is and if it works to treat solid tumor cancers. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Complion Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: -Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti-cancer therapies known to confer benefit or is intolerant to treatment. -Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
SWOG 2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III StudyThis phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of early-stage triple negative breast cancer. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB NCI IRB) SWOG 2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer and interfere with tumor cells' ability to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping, or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone. The study has three arms to which you could be randomly assigned: 1) atezolizumab, platinum drug, etoposide; 2) atezolizumab, platinum drug, etoposide, observation; 3) platinum drug, etoposide, observation. Who Can Participate?· Participants must have a diagnosis with poorly differentiated extrapulmonary neuroendocrine tumor · Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung CancerThis phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of non-small cell lung cancer that has spread to lymph nodes in chest and is not able to be treated by surgery. · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
NU 23B05 - Randomized phase II study of elacestrant vs elacestrant plus a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) in patients with ER+/HER2- advanced or metastatic breast cancer with prior exposure to a CKD4/6 inhibitorBreast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically or cytologically confirmed ER-positive and HER2- negative breast cancer as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Equity in Modifying Plaque Of WomEn with UndeRtreated Calcified Coronary Artery Disease (EMPOWER CAD)The purpose of the study is to further assess the safety and effectiveness of the Shockwave Coronary IVL system (“Study Device”) in the arteries of your heart. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG CYP-GVHD-P2-01: A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host DiseaseThis study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of acute Graft vs Host Disease (GvHD) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
NU 23U08: A Randomized Phase II study of ADT + Abiraterone versus ADT + Docetaxel + Abiraterone in Patients with Low Volume Metastatic Hormone Sensitive Prostate CancerThis is a phase II, randomized, open label study comparing first line therapy with AThis is a phase II, randomized, open label study comparing first line therapy with ADT + abiraterone (doublet arm) or ADT + abiraterone + docetaxel (triplet arm) in low volume, metastatic hormone sensitive prostate cancer (mHSPC). This is a phase II, randomized, open label study comparing first line therapy with Androgen Deprivation Therapy (ADT) + abiraterone (doublet arm) or ADT + abiraterone + docetaxel (triplet arm) in low volume, metastatic hormone sensitive prostate cancer (mHSPC). The hypothesis being asked in this trial is whether first line treatment with ADT plus an androgen receptor pathway inhibitor (abiraterone) as a doublet regimen compared to ADT plus an androgen receptor pathway inhibitor (abiraterone) and docetaxel, as a triplet regimen results in superior outcomes for patients with low volume mHSPC. We plan to enroll patients with mHPSC that meet the CHAARTED criteria for low disease volume. Patients will be randomized 1:1 to either treatment arm:
All subjects must receive ADT of the Investigator's choice (LHRH agonist/antagonists or orchiectomy) as standard therapy, started = 12 weeks before randomization. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, Keywords |
SOAR - Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal CarcinomaThis study is being done to answer the following question: For kidney cancer patients with limited (2-5) number of metastases like yourself, 1) is radiation therapy equal or better when compared to systemic therapy and 2) can stereotactic ablative radiation have less side effects when compared to systemic therapy. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your kidney cancer. The usual approach is defined as care most people get for metastatic kidney cancer. If you decide to take part in this clinical trial, you will be randomly assigned to one of the two groups: group 1 or group 2. If you are assigned to group 1, you will receive standard systemic therapy (including Immunotherapy and small molecular inhibitor therapies listed above either by themselves or in combination). If you are assigned to group 2, you will first receive stereotactic ablative radiation to metastatic sites and repeated stereotactic ablative radiation to additional sites until additional radiation is not possible, at which time you will receive standard systemic therapy. Stereotactic ablative” radiotherapy is a standard, non-experimental, way of giving radiotherapy that is very precisely localized and delivered and is given with larger daily doses of radiation than is given using non stereotactic approaches. Given this way radiotherapy treatments are usually more powerful and effective at shrinking and/or ablating (killing) individual spots of cancer. radiation for patients in group 2 may not be possible due to many reasons such as the development of multiple new sites of metastasis or the development of a metastasis at a location not treatable by focused radiation. After you finish your study treatment, your doctor will continue to follow your condition for up to 10 years with a phone call every three months. Who Can Participate?Participants must have metastatic kidney cancer with a limited number of metastatic lesions. Principal Investigator, Study ID, Keywords |
Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor TherapyThe phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) Alliance A092107: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated LiposarcomaThis phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of dedifferentiated liposarcoma that cannot be removed by surgery · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
An Open-Label Study of Dupilumab in Adolescent and Adult Skin-of-Color Patients with Moderate-to-Severe Atopic DermatitisThe study is focused on skin-of-color participants who have moderate-to-severe atopic dermatitis. For the purposes of this research study, “skin-of-color” refers to participants with Fitzpatrick types 4, 5, and 6. Fitzpatrick skin type is a commonly used system to describe a person’s skin response to ultraviolet radiation (UVR) exposure. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
EXTENDThoraflex Hybrid and Relay Extension Post-Approval Study Who Can Participate?Patient will undergo treatment with a Thoraflex Hybrid device Principal Investigator, Study ID, Keywords STU00219308 Click to Copy URL to Clipboard For questions about this study, contact: |
(xIRB) DRUG IMSA101-103: Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor MalignanciesPhase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior PD-L1or PD-1-targeted ICI immunotherapy. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of oligoprogressive disease · Participants must be 18 or older Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG ALE.C04.01: A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti- PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell CarcinomaThe purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with pembrolizumab in patients with Head and Neck Cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) that has not responded to treatment. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
DRUG SBI-BSF-001: Collection of Plasma Samples Using Sodium Heparin from Subjects Undergoing Intravenous Busulfan TreatmentBusulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG SC291-101A Phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, in relapsed and/or refractory B-cell malignancies (ARDENT) Who Can Participate?Must be 18 Diagnosis of NHL (WHO 2016 criteria) or CLL (iwCLL criteria) Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) SWOG 1905: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/TCell Lymphoblastic Lymphoma (T-LBL)This phase I/II trial studies the side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). The study doctors hope to learn if the study drug, OBI-3424, will reduce the amount of leukemia cells or lymphoma in the body.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of leukemia or lymphoma that has come back or did not go away after treatment. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
(xIRB) DRUG COVALENT-103: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemiaA Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
ARISE-IIEvaluation of the GORE® Ascending Stent Graft (ASG device) in the Treatment of Lesions of the Ascending Aorta Who Can Participate?
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB) DRUG 20210004: Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line ChemotherapyThe main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS). Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include: Participants must have a diagnosis of Histologically or cytologically confirmed relapsed/refractory SCLC. Participants who progressed or recurred following 1 platinum-based regimen. Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG CP-MVC-101-01A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer Who Can Participate?· Participants must have a diagnosis of head, neck, or lung cancer. · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) Alliance A092105: Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and ImmunotherapyThis phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced dedifferentiated liposarcoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG KT-US-472-0141The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Mantle Cell Lymphona or Acute Lymphoblastic Leukemia · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB) DRUG TAK-500-1001: An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid TumorsThis study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are:
Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
Participants must have a diagnosis of Gastroesophageal (esophageal, gastroesophageal junction, and gastric) adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma (HCC), nonsquamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), mesothelioma, triple-negative breast cancer (TNBC), renal clear cell carcinoma (RCC) and nasopharyngeal carcinoma (NPC). Participants who are intolerant to all standard therapies are those who have developed clinical or laboratory abnormalities that prevent continued drug administration as evaluated by the principal investigator at the time of screening.
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
NRG GU013: The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate CancerThis phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of high-risk prostate cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG EDGE-Lung: A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung CancerThe purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLC
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous CancersThis phase I/II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone are immunosuppressants that are given to keep the body from rejecting the transplanted kidney. Giving nivolumab and ipilimumab in combination with sirolimus and prednisone may kill more cancer cells, while also keeping the transplanted kidney healthy, in patients with unresectable or metastatic cutaneous cancer who have received a kidney transplant. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of skin cancer after a kidney transplantation. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
(xIRB NCI CIRB) ETCTN 10347: A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in patients with mycosis fungoides and Sezary syndrome. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced mycosis fungoides or Sézary syndrome that has not responded to at least one type of treatment. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
Preserve Heart StudyStudy of Hearts Transplanted after Non-Ischemic Heart PRESERVation from Extended Donors Who Can Participate?Listed for heart transplantation Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG IMM1104-101: A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid TumorsThis is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti- tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof- of-concept cohorts in malignancies of interest. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate? Participants must have a diagnosis of Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or metastatic solid tumor malignancy that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation. 2. Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC) 3. Combination therapy (both phases): A locally advanced unresectable or metastatic PDAC Participants must be treatment naive or received prior systemic standard-of-care treatment as follows: 1. Monotherapy Phase 1: received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease 2. Monotherapy Phase 2a: 1. First-line PDAC participants will have received no previous systemic anti-cancer therapy. Second-line PDAC participants will have received no more than one prior Public Recruitment Abstract Version Date: v.02.23.2023 emic anti-cancer therapy. 2. First-line melanoma participants will have received no previous systemic anti-cancer therapy. Second- and third-line participants will have received and failed one or two prior systemic anti-cancer therapies, respectively. 3. NSCLC participants will have received at least one and no more than two previous lines of systemic therapy. 3. Combination therapy (both phases): PDAC participants will have received no previous systemic anti- cancer therapy for their advanced or metastatic disease. Principal Investigator, Study ID, Keywords |
NRG BR009This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of early-stage breast cancer that is sensitive to hormones and is HER2-negative, be premenopausal, and have an Oncotype DX Recurrence Score® equal to or less than 25. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
DRUG M24-311: A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal CancerCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer. ABBV-400 is an investigational drug being developed for the treatment of unresectable metastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizumab is an drug approved for the treatment of unresectable metastatic colorectal cancer. Study doctors put the participants in groups called treatment arms. Each treatment arm receives a different dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab (FFB) in escalating doses on two different schedules (safety lead in), followed by low or high doses of ABBV-400 in combination with FFB or fluorouracil, folinic acid, irinotecan, and bevacizumab (standard of care [SOC]) [dose optimization] on its own. Approximately 206 adult participants with unresectable metastatic colorectal cancer will be enrolled in the study in 65 sites worldwide. In the safety lead in, participants will receive escalating intravenous (IV) ABBV-400 in combination with IV FFB on two different schedules. During the dose optimization participants will receive IV ABBV-400 in combination with FFB at low or high doses determined in the safety lead in on two different dosing schedules. The dose optimization arm will also include a comparator cohort in which participants will receive SOC. The study will run for a duration of approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
DRUG 1403-0019This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check participants' health and take note of any unwanted effects. The doctors also regularly check tumour size. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of Liposarcoma · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)Participants in this study will be randomized to receive TAR-200 with intravenous (IV) cetrelimab (Group A), TAR-200 alone (Group C), or intravesical BCG therapy alone (Group B), which is the current standard of care (SOC) for high-risk non-muscle invasive bladder cancer. Who Can Participate?Inclusion Criteria:
Exclusion Criteria:
Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
Study to understand the safety and efficacy of an experimental oral drug for HSThis research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of HS patients. Upadacitinib has been approved for specific medical conditions, but not approved for HS. The use of the study drug is investigational (experimental) for the purposes of this study. Who Can Participate?Eligible subjects will be individuals who are at least 12 years of age at screening with a diagnosis of HS for at least 6 months and failed to respond to or are intolerant to anti-TNF alpha therapy or one approved non-anti-TNF biologic therapy for HS. Subjects will have moderate to severe HS. Principal Investigator, Study ID, KeywordsFor questions about this study, contact: |
DRUG M24-427: A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor IndicationsCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up period. Approximately 220 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive [HR+]/HER2-breast cancer [BC]), head and neck squamous-cell-carcinoma (HNSCC), or advanced solid tumors, will be enrolled in the study in approximately 60 sites worldwide. In the each cohorts, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, and HNSCC will receive intravenous (IV) ABBV-400 monotherapy for up to 2 years during and up to the treatment period with an additional safety follow-up period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a documented diagnosis of locally advanced or metastatic hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), squamous cell carcinoma of the esophagus, (ESCC), triple negative breast cancer (TNBC), hormone receptor+/HER2-breast cancer (HR+/HER2-BC), or head and neck squamous-cell-carcinoma (HNSCC) (by World Health Organization [WHO] criteria).
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords |
ALT-FLOW IIClinical trial for evaluation of the Edwards APTURE transcatheter shunt system (ALT-FLOW II) Who Can Participate?
Principal Investigator, Study ID, Keywords |
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.This phase II/III trial tests the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy (nivolumab alone or with relatlimab) after surgical removal of the bladder for bladder cancer treatment. DNA is material found inside all of our cells that acts as a blueprint for how cells function. Tumor cells often have abnormal DNA that looks different than DNA in normal cells. A new test called Signatera has been developed that can detect bladder cancer DNA in the blood which might indicate the presence of bladder tumor cells somewhere in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if the Signatera test can better identify which patients need an additional treatment with immunotherapy to help prevent bladder cancer from coming back after surgery.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of bladder cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
ETCTN 10601This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Giving mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients with relapsed/refractory DLBCL. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of diffuse large B-cell lymphoma. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB) NCI CIRB COG ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia TherapyThis phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Who Can Participate?· Participants must have a diagnosis of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated AnorexiaThis phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced cancer and their cancer and treatments for cancer can cause side effects such as loss of appetite. · Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
DRUG TP-CA-002Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance. Who Can Participate?· Participants must have a diagnosis of Non-Small Cell Lung Cancer · Participants must be 18 or older Principal Investigator, Study ID, Keywords STU00221108 Click to Copy URL to Clipboard |
A Randomized Open label Phase II Trial of FDG-PETguided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY trial: PET- Guided RadioTherapY consolidationThis study aims to examine the use of radiotherapy and its ability to keep cancer controlled for longer than with just standard medications on their own. Patients will undergo standard systemic therapy (treatment that is widely used by healthcare professionals for your cancer), and then imaging (fluorodeoxyglucose (FDG)-positron emission tomography or FDG-PET) to identify cancer sites that remain active despite the treatment. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of prostate cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords |
(xIRB NCI CIRB) NRG HN011: A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood cells from the participants body that are collected intravenously. This EBV immunotherapy product may stop cancer cells from growing abnormally. EBV immunotherapy products have been used in several research studies for NPC. Information from these studies suggests the EBV immunotherapy products may stop the growth of NPC in some subjects. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Principal Investigator, Study ID, Keywords |
A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX TrialThis phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of pathologically confirmed locally advanced/unresectable Merkel cell carcinoma or metastatic Merkel cell carcinoma. · Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Principal Investigator, Study ID, Keywords ATR inhibition Merkel Cell Carcinoma Phase II Tuvusertib Avelumab Refractory ATR Kinase Inhibitor Advanced/Unresectable Metastatic
For questions about this study, contact: |
(xIRB NCI CIRB) NRG CC011: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled TrialThis Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors. Who Can Participate?Some of the eligibility criteria include:
· Participants must have a diagnosis of breast cancer survivor with cancer-related cognitive impairment (CRCI). · Participants must be 18 or older Principal Investigator, Study ID, Keywords |
CATCH-USThis is an observational research study to provide data to better understand what characteristics and treatment approaches predict an optimal outcome (i.e., remission and no joint damage) in real world patients with new onset RA. We want to learn more about the factors that predict how patients’ disease might progress over time and what their response to treatment might be. Participation involves approximately 10 study visits: every 3 months for the first year, every 6 months until the end of year 2, and at year 3, year 4 and year 5. These visits will be at the time of routinely scheduled visits with the participant's Northwestern rheumatologist. Research procedures include collection of questionnaires and clinical information collected from the patient's rheumatologist at each visit. If participating in the optional biological specimen and genetic testing study component, participants may be asked to give research blood (during standard of care blood draws) and leftover joint fluid collected at the time of standard of care joint aspirations. Who Can Participate?• Age > 18 years at time of referral, AND • Joint symptoms for ≤12 months, AND • At least one of the following (summarized in checklist below): o two (2) or more swollen joints OR o one (1) swollen metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint and any one (or more) of the following:
Principal Investigator, Study ID, Keywords STU00220995 Click to Copy URL to Clipboard For questions about this study, contact: |